[
  {
    "question": "A 68-year-old male with a history of hypertension and type 2 diabetes presents with a 3-day history of cough, fever, and shortness of breath. He is diagnosed with community-acquired pneumonia (CAP). According to the guidelines, which of the following should be used, in addition to clinical judgment, to determine the need for hospitalization?",
    "options": [
      "CURB-65 score only",
      "Pneumonia Severity Index (PSI) preferentially over CURB-65",
      "Serum procalcitonin levels only",
      "Influenza virus testing only"
    ],
    "correct_answer_text": "Pneumonia Severity Index (PSI) preferentially over CURB-65",
    "correct_answer_idx": 1.0,
    "model_answer": "A",
    "model_answer_idx": 0,
    "model_reasoning": "The context mentions that the guidelines include urea level, respiratory rate, blood pressure, and age (>=65) as factors to determine the need for hospitalization in adults diagnosed with CAP. This aligns with the CURB-65 score, which incorporates these elements. The other options do not align with the specific criteria mentioned in the context for determining hospitalization.",
    "reasoning_ground_truth": "The guidelines for CAP recommend using a validated clinical prediction rule for prognosis, **preferentially the Pneumonia Severity Index (PSI) over the CURB-65**, in addition to clinical judgment to determine the need for hospitalization [1]. Serum procalcitonin levels are used to determine initiation of antibiotics, and influenza testing is for identifying the presence of influenza virus but not for determining hospitalization [1, 2].",
    "context": "urea level, respiratory rate, blood pressure, and age &gt;=65) (conditional recommendation, low quality of evidence), to determine the need for hospitalization in adults diagnosed with CAP.\nThis document provides evidence-based clinical practice guidelines on the management of adult patients with community-acquired pneumonia.\nGiven the expansion in information related to the diagnostic, therapeutic, and management decisions for the care of patients with CAP, we have purposely narrowed the scope of this guideline to address decisions from the time of clinical diagnosis of pneumonia (i.e., signs and symptoms of pneumonia\nThe panel formulated and provided the rationale for recommendations on selected diagnostic and treatment strategies for adult patients with community-acquired pneumonia.\nIn Adults with CAP, Should a Respiratory Sample Be Tested for In\ufb02uenza Virus at the Time of Diagnosis?",
    "ground_truth_context": "In addition to clinical judgement, we recommend that clinicians use a validated clinical prediction rule for prognosis, preferentially the Pneumonia Severity Index (PSI) (strong recommendation, moderate quality of evidence) over the CURB-65 (tool based on confusion, urea level, respiratory rate, blood pressure, and age >65) (conditional recommendation, low quality of evidence), to determine the need for hospitalization in adults diagnosed with CAP. [1]",
    "is_correct": false
  },
  {
    "question": "A 55-year-old female with a history of chronic kidney disease (CKD) and hypertension presents for a routine follow-up. Her eGFRcr is 40 mL/min/1.73 m2. Which of the following is the most appropriate next step in evaluating her kidney function?",
    "options": [
      "Measure cystatin C to calculate eGFRcr-cys",
      "Proceed directly to measuring GFR using an exogenous filtration marker",
      "Repeat eGFRcr in 3 months",
      "No additional testing is needed"
    ],
    "correct_answer_text": "Measure cystatin C to calculate eGFRcr-cys",
    "correct_answer_idx": 0.0,
    "model_answer": "A",
    "model_answer_idx": 0,
    "model_reasoning": "The context emphasizes the importance of assessing kidney function in individuals with chronic kidney disease (CKD) by measuring both urine albumin and glomerular filtration rate (GFR). It specifically mentions that for people with CKD, a change in eGFR of >20% warrants evaluation. While the context does not explicitly state the need for cystatin C measurement, it implies that further evaluation is necessary when there are concerns about kidney function. Therefore, measuring cystatin C to calculate eGFRcr-cys is a reasonable next step in evaluating her kidney function, as it provides additional information about her renal status.",
    "reasoning_ground_truth": "According to the CKD guidelines, the initial test for GFR evaluation is eGFRcr. If the eGFRcr is thought to be inaccurate, a more accurate assessment of GFR is needed. In such cases, cystatin C should be measured to estimate eGFRcr-cys.  If eGFRcr-cys is inaccurate, then mGFR can be considered [3, 4].",
    "context": "Practice Point 1.1.1.1: Test people at risk for and with chronic kidney disease (CKD) using both urine albumin measurement and assessment of glomerular filtration rate (GFR).\nPractice Point 1.1.1.1: Test people at risk for and with chronic kidney disease (CKD) using both urine albumin measurement and assessment of glomerular filtration rate (GFR).\nFor people with CKD, a change in eGFR of >20% on a subsequent test exceeds the expected variability and warrants evaluation.\nPractice Point 2.1.3: For people with CKD, a change in eGFR of >20% on a subsequent test exceeds the expected variability and warrants evaluation.\nFollowing incidental detection of elevated urinary albumin-to-creatinine ratio (ACR), hematuria, or low estimated GFR (eGFR), repeat tests to confirm presence of CKD.",
    "ground_truth_context": "The initial test for the evaluation of GFR is creatinine-based estimated GFR (eGFRcr), which will be available for most people because creatinine is measured routinely as part of the basic metabolic panel. If eGFRcr is expected to be inaccurate, or if a more accurate assessment of GFR is needed for clinical decision-making, such as diagnosis or staging of chronic kidney disease or drug dosing, then, if available, cystatin C should be measured, and creatinine and cystatin C\u2013based estimated GFR (eGFRcr-cys) should be estimated. [3] eGFRcr-cys provides the most accurate estimate and is recommended as the primary supportive test for people in whom there are concerns about eGFRcr accuracy [4] ",
    "is_correct": true
  },
  {
    "question": "A 70-year-old male with a history of a recent acute coronary syndrome (ACS) is currently on dual antiplatelet therapy (DAPT). He is now 18 months post-ACS and has had no recurrent events. What is the recommended approach for his DAPT?",
    "options": [
      "Continue DAPT for another 12 months.",
      "Transition to single antiplatelet therapy.",
      "Discontinue all antiplatelet therapy",
      "Add a third antiplatelet agent"
    ],
    "correct_answer_text": "Transition to single antiplatelet therapy.",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context indicates that for patients with acute coronary syndrome (ACS) who have tolerated dual antiplatelet therapy (DAPT) without bleeding complications and are not at high bleeding risk, continuation of DAPT for longer than 12 months may be reasonable. However, since the patient is now 18 months post-ACS and has had no recurrent events, transitioning to single antiplatelet therapy is the most appropriate recommendation based on the guidelines. The context does not support continuing DAPT for another 12 months (A), discontinuing all antiplatelet therapy (C), or adding a third antiplatelet agent (D).",
    "reasoning_ground_truth": "According to the guidelines, patients with a history of ACS >1 year prior who have remained free of recurrent ACS are considered to have transitioned to stable ischemic heart disease (SIHD). The document focuses on the duration of DAPT and suggests that the relevant sections in the guidelines be updated to reflect a transition to single antiplatelet therapy for these patients after one year, [5].",
    "context": "The scope of this focused update is limited to addressing recommendations on duration of dual antiplatelet therapy (DAPT) (aspirin plus a P2Y12 inhibitor) in patients with coronary artery disease (CAD). Recommendations considered are those in 6 guidelines: \u201c2011 ACCF/AHA/SCAI Guideline for\n|I|C-LD|In patients with ACS (NSTE-ACS or STEMI) being treated with DAPT who undergo CABG, P2Y12 inhibitor therapy should be resumed after CABG to complete 12 months of DAPT therapy after ACS (52\u201354,118\u2013120).| |\n|IIb|ASR|In patients with ACS treated with coronary stent implantation who have tolerated DAPT without bleeding complication and who are not at high bleeding risk (e.g., prior bleeding on DAPT, coagulopathy, oral anticoagulant use) continuation of DAPT for longer than 12 months may be reasonable\n|IIb|ASR|In patients with ACS treated with medical therapy alone (without revascularization or fibrinolytic therapy) who have tolerated DAPT without bleeding complication and who are not at high bleeding risk (e.g., prior bleeding on DAPT, coagulopathy, oral anticoagulant use), continuation of DAPT\n|COR|LOE|RECOMMENDATION|\n|---|---|---|\n|I|C-LD|In patients with ACS being treated with DAPT who undergo CABG, P2Y12 inhibitor therapy should be resumed after CABG to complete 12 months of DAPT therapy after ACS (52\u201354,118\u2013120).|",
    "ground_truth_context": "patients with a history of acute coronary syndrome (ACS) >1 year prior who have since remained free of recurrent ACS are considered to have transitioned to stable ischemic heart disease (SIHD) and are addressed in the section on SIHD.  This focused update is designed to function both as a standalone document and to serve as an update to the relevant sections on duration of DAPT in the 6 clinical practice guidelines, replacing relevant text, figures, and recommendations. [5]",
    "is_correct": true
  },
  {
    "question": "A 35-year-old female presents with a 5-day history of nasal congestion, facial pain, and purulent nasal discharge. She reports no improvement with over-the-counter decongestants. According to the guidelines, what is the appropriate initial management strategy?",
    "options": [
      "Immediate antibiotic therapy",
      "Watchful waiting without antibiotics",
      "Intranasal corticosteroids",
      "Referral to an otolaryngologist"
    ],
    "correct_answer_text": "Watchful waiting without antibiotics",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context discusses the management of nasal drainage, obstruction, and associated symptoms, indicating that if symptoms persist for 5 days, one should avoid immediate antibiotic therapy to prevent complications like rebound congestion. It suggests that watchful waiting is appropriate, especially since the patient has not shown improvement with over-the-counter decongestants. There is no mention of the need for immediate antibiotics or referral to a specialist at this stage, making \"watchful waiting without antibiotics\" the most suitable initial management strategy.",
    "reasoning_ground_truth": "The guidelines recommend that the initial management strategy for uncomplicated acute bacterial rhinosinusitis (ABRS) is **watchful waiting without antibiotic therapy**, regardless of severity [6]. Supportive therapies for symptom relief can also be considered [7].",
    "context": "nasal drainage accompanied by nasal obstruction, facial pain-pressure-fullness, or both) persist without\n5 days, as recommended by the manufacturers, to avoid rebound congestion and rhinitis medicamentosa. Clinical experience suggests oral antihistamines may provide symptomatic relief of excessive secretions and sneezing, although there are no clinical studies supporting the use of antihistamines in\nAnalgesics or antipyretic drugs (acetaminophen, ibuprofen, or other nonsteroidal anti-inflammatory agents) may be given for pain or fever. Nasal saline may be palliative and cleansing with low risk of adverse reactions. A Cochrane review reported minor improvements in nasal symptom scores with the\nagents, nasal saline, decongestants, antihistamines, mucolytics, cough suppressants, and topical or oral corticosteroids\u2014may be used alone or in varying combinations for symptom relief.\nOral decongestants may provide symptomatic relief and should be considered barring any medical contraindications, such as hypertension or anxiety. The use of topical decongestant is likely to be palliative, but continuous duration of use should not exceed 3 to 5 days, as recommended by the",
    "ground_truth_context": "Extension of watchful waiting (without antibiotic therapy) as an initial management strategy to all patients with uncomplicated acute bacterial rhi-nosinusitis (ABRS) regardless of severity, not just patients with \u201cmild\u201d illness (prior guideline) [6]. The purpose of this statement is to encourage consideration of supportive therapies that may improve quality of life for indi-viduals with viral rhinosinusitis (VRS) and to avoid unneces-sary prescribing of antibiotics for viral disease. [7]",
    "is_correct": true
  },
  {
    "question": "A 40-year-old male presents to the emergency department with a witnessed seizure lasting 7 minutes. He has no known history of epilepsy. According to the guidelines, what is the recommended initial therapy?",
    "options": [
      "Intravenous phenytoin",
      "Intramuscular midazolam",
      "Intravenous lorazepam",
      "Intravenous phenobarbital"
    ],
    "correct_answer_text": "Intramuscular midazolam",
    "correct_answer_idx": 1.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context specifies that for the treatment of convulsive status epilepticus, studies considered only those with a seizure duration of at least 5 minutes. The initial therapy for seizures lasting longer than 5 minutes includes lorazepam, as indicated by the mention of randomized controlled trials involving lorazepam. Therefore, for a seizure lasting 7 minutes, the recommended initial therapy is intravenous lorazepam (option C).",
    "reasoning_ground_truth": "For convulsive status epilepticus, the guidelines recommend that a benzodiazepine (specifically IM midazolam, IV lorazepam, or IV diazepam) is the initial therapy of choice. IM midazolam has superior effectiveness in adults when intravenous access is not established. IV Phenobarbital is an alternative, not first line [8, 9].",
    "context": "This guideline will address the evidence regarding the treatment of convulsive status epilepticus. For the purposes of this guideline, only studies that enrolled subjects having a seizure duration of at least 5 minutes were considered. The guideline\u2019s analysis is presented by subject age (adult\nor longer, or two or more GTC seizures without full recovery of consciousness. A treatment was successful if the status epilepticus stopped within 20 minutes after infusion started with no recurrence prior to 60 minutes. Overall, 570 patients were randomized to either lorazepam (n = 146), diazepam\nRandomized controlled trials of anticonvulsant treatment for seizures lasting longer than 5 minutes.\nThe third therapy phase should begin when the seizure duration reaches 40 minutes. There is no clear evidence to guide therapy in this phase (level U). Compared with initial therapy, second therapy is often less effective (adults\u2014level A, one class I RCT; children\u2014level C, two class III RCTs), and\nThe second-therapy phase should begin when the seizure duration reaches 20 minutes and should conclude by the 40-minute mark when response (or lack of response) to the second therapy should be apparent. Reasonable options include fosphenytoin (level U), valproic acid (level B, one class II study)",
    "ground_truth_context": "In adults with convulsive status epilepticus, intramuscular midazolam, intravenous lorazepam, intravenous diazepam and intravenous phenobarbital are established as efficacious as initial therapy (Level A). Intra-muscular midazolam has superior effectiveness compared to intravenous lorazepam in adults with convulsive status epilepticus without established intravenous access (Level A). A benzodiazepine (specifically IM mid-azolam, IV lorazepam, or IV diazepam) is recommended as the initial therapy of choice [8, 9]",
    "is_correct": false
  },
  {
    "question": "A 60-year-old female presents with a 6-month history of persistent nasal congestion and facial pressure. She has tried over-the-counter remedies with no relief. To confirm a diagnosis of chronic rhinosinusitis (CRS), which of the following is required?",
    "options": [
      "Self-reported symptoms alone",
      "Objective documentation of sinonasal inflammation",
      "Positive allergy testing",
      "CT scan of the sinuses only"
    ],
    "correct_answer_text": "Objective documentation of sinonasal inflammation",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context specifies that diagnosing chronic rhinosinusitis (CRS) requires \"objective documentation of sinonasal inflammation\" in addition to persistent symptoms. This indicates that self-reported symptoms alone (Option A) are insufficient, and while a CT scan may be part of the documentation process, it is not the only requirement (Option D). Positive allergy testing (Option C) is not mentioned as a requirement for diagnosing CRS. Therefore, the correct answer is B, as it directly aligns with the context's emphasis on the need for objective evidence of inflammation.",
    "reasoning_ground_truth": "The guidelines state that a diagnosis of CRS cannot be based on signs and symptoms alone, but also requires **objective evidence of sinonasal inflammation**, which can be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography [10, 11].",
    "context": "Symptoms of CRS vary in severity and prevalence. Nasal obstruction is most common (81%-95%) followed by facial congestion-pressure-fullness (70%-85%), discolored nasal discharge (51%-83%) and hyposmia (61%-69%). The presence of 2 or more signs or symptoms persisting beyond 12 weeks is highly\nAcute rhinosinusitis is diagnosed when a patient presents with up to 4 weeks of purulent (not clear) nasal drainage accompanied by nasal obstruction, facial pain-pressure-fullness, or both (Table 4). Nasal obstruction without purulent nasal drainage is not consistent with ARS and is beyond the scope\n|Chronic rhinosinusitis|Twelve weeks or longer of two or more of the following signs and symptoms: \u2022 mucopurulent drainage (anterior, posterior, or both), \u2022 nasal obstruction (congestion), \u2022 facial pain-pressure-fullness, or \u2022 decreased sense of smell. AND inflammation is documented by one or more\nbeyond 12 weeks is highly sensitive for diagnosing CRS, but symptom-based criteria alone are relatively nonspecific. Diagnosing CRS requires that inflammation be documented (polyps, edema, or purulent mucus) in addition to persistent symptoms. Examination of the nasal cavity can be performed using\nThe clinician should confirm a clinical diagnosis of CRS with objective documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. Strong recommendation based on cross-sectional studies with a preponderance of benefit over",
    "ground_truth_context": "The clinician should confirm a clinical diagnosis of CRS with objective documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed  tomography. [10] The purpose of this statement is to strongly emphasize that a diagnosis of CRS cannot be based on signs and symptoms alone but also requires objective evidence of sinonasal inflammation [11]",
    "is_correct": true
  },
  {
    "question": "A 45-year-old male with a new diagnosis of primary open-angle glaucoma is being educated about his condition. According to the guidelines, which of the following is most important to ensure effective patient education?",
    "options": [
      "Providing lengthy written educational material",
      "Using complex medical terminology to explain the disease",
      "Ensuring the information is clear, relevant, and accessible",
      "Relying solely on verbal explanations"
    ],
    "correct_answer_text": "Ensuring the information is clear, relevant, and accessible",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context emphasizes the importance of patient education through various means, highlighting that \"techniques such as asking patients to explain what they understand about glaucoma may be helpful for patients with limited literacy skills.\" This indicates that ensuring the information is \"clear, relevant, and accessible\" is crucial for effective education, particularly for patients with varying literacy levels. The other options do not align with the context's focus on clarity and accessibility in patient education.",
    "reasoning_ground_truth": "The guidelines emphasize that ophthalmologists should strive to provide education that is **clear, relevant, and accessible** to the patient and their caregivers. Limiting dense text and using techniques such as asking patients to explain what they understand can be helpful [12].",
    "context": "When deciding to treat a patient with glaucoma, it is important to remember that the goal of treatment is to maintain the IOP within a range at which visual field loss is unlikely to substantially reduce a patient\u2019s health-related quality of life over his or her lifetime.322\nPatient education through oral, written, and online information and informed participation in treatment decisions may improve adherence357 and overall effectiveness of glaucoma management. Adherence to medical therapy may be handicapped when patients run out of medication, due to inadvertent drop\nmedications and to barriers to self-management. Ophthalmologists should remain mindful that the diagnosis of glaucoma can itself lead to negative psychological effects and to fear of blindness.691-695\ntechniques such as asking patients to explain what they understand about glaucoma may be helpful for patients with limited literacy skills. Patients with higher levels of literacy may ask questions that lead to a more complex discussion, but patients who do not understand the information provided\nGuidelines for follow-up of patients with POAG are summarized in Table 7. These recommendations apply to ongoing glaucoma management and not to visits for other purposes. The purpose of follow-up examination is to evaluate IOP level, visual field status, and optic disc appearance as well as ONH,",
    "ground_truth_context": "Ophthalmologists should strive to provide education that is clear, relevant, and accessible to the patient and their caregiver(s). Patients with poor health literacy skills may be especially vulnerable to worse visual outcomes.696 Limiting dense text and using \u201cteach-back\u201d techniques such as asking patients to explain what they understand about glaucoma may be helpful for patients with limited literacy skills. [12]",
    "is_correct": true
  },
  {
    "question": "A 50-year-old female with rheumatoid arthritis (RA) has moderate-to-high disease activity despite being treated with methotrexate. Which of the following is conditionally recommended according to the guidelines?",
    "options": [
      "Adding a biologic DMARD to methotrexate",
      "Switching to a different conventional synthetic DMARD",
      "Continuing methotrexate monotherapy",
      "Adding a targeted synthetic DMARD to methotrexate"
    ],
    "correct_answer_text": "Continuing methotrexate monotherapy",
    "correct_answer_idx": 2.0,
    "model_answer": "A",
    "model_answer_idx": 0,
    "model_reasoning": "The context indicates that methotrexate is conditionally recommended for patients with moderate-to-high disease activity, but it does not specify that continuing methotrexate monotherapy is sufficient if the patient is not responding adequately. Therefore, adding a biologic DMARD to methotrexate is a reasonable approach for managing moderate-to-high disease activity in a patient who is not adequately controlled on methotrexate alone, aligning with common clinical practices. Options B and D are not explicitly supported by the context, and option C does not address the need for additional treatment given the patient's ongoing moderate-to-high disease activity.",
    "reasoning_ground_truth": "For patients with moderate to high disease activity, despite being treated with methotrexate, the guidelines conditionally recommend continuing methotrexate monotherapy over combining methotrexate with a biologic (bDMARD) or targeted synthetic DMARD (tsDMARD) [13].",
    "context": "Methotrexate is conditionally recommended over alternative DMARDs for the treatment of inflammatory arthritis for patients with clinically diagnosed mild and stable airway or parenchymal lung disease, or incidental disease detected on imaging, who have moderate-to-high disease activity.\nMethotrexate is strongly recommended over hydroxychloroquine or sulfasalazine for DMARD-naive patients with moderate-to-high disease activity. This recommendation is strongly in favor of methotrexate despite very low-certainty evidence for hydroxychloroquine and low-certainty evidence for\nMethotrexate is conditionally recommended over leflunomide for DMARD-naive patients with moderate-to-high disease activity. Despite low-certainty evidence of comparable efficacy, methotrexate is preferred over leflunomide because of the evidence supporting its value as an anchor DMARD in\n|Methotrexate is conditionally recommended over alternative DMARDs for DMARD-naive patients with nonalcoholic fatty liver disease, normal liver enzymes and liver function tests, and no evidence of advanced liver fibrosis who have moderate-to high disease activity.|Very low|PICO 87|p. 489|\nmonotherapy, preferably with methotrexate, for patients with both low and moderate/high disease activity, whereas this update recommends an initial trial of hydroxychloroquine or sulfasalazine for those with low disease activity. Second, the 2015 guidelines recommended DMARD tapering for patients",
    "ground_truth_context": "Methotrexate monotherapy is conditionally recommended over the combination of methotrexate plus a bDMARD or tsDMARD [13]",
    "is_correct": false
  },
  {
    "question": "A 25-year-old male is diagnosed with gonococcal urethritis.  The guidelines for treating gonorrhoea emphasize the importance of using the GRADE approach to assess the certainty of evidence. What is one way this is achieved?",
    "options": [
      "By relying solely on expert opinions.",
      "By conducting a narrative review of the literature.",
      "By assessing the quality of evidence based on risk of bias and inconsistency.",
      "By only including data from randomized controlled trials"
    ],
    "correct_answer_text": "By assessing the quality of evidence based on risk of bias and inconsistency.",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context mentions that the guidelines provide evidence-based recommendations and that the quality of evidence is assessed, specifically noting that the quality of evidence for treatments is evaluated based on factors such as risk of bias and inconsistency. This aligns with the GRADE approach, which emphasizes assessing the quality of evidence in a systematic manner. Options A, B, and D do not reflect the evidence-based approach described in the context.",
    "reasoning_ground_truth": "The GRADE approach assesses the quality of evidence for treatment interventions using criteria for design, risk of bias, inconsistency, indirectness, imprecision, effect size, and other factors [14].",
    "context": "The objectives of these guidelines are:  \n- to provide evidence-based guidance on treatment of infection with N. gonorrhoeae; and\n- to support countries to update their national guidelines for treatment of gonococcal infection.\nThese guidelines provide evidence-based recommendations for the treatment of specific clinical conditions caused by N. gonorrhoeae. These guidelines provide direction for countries as they develop national treatment recommendations; however, national guidelines should also take into account the\nThese guidelines provide recommendations for treatment of gonorrhoea based on the best global evidence available at the time of compilation. However, the epidemiology and AMR of STIs vary by geographical location and are constantly changing, sometimes rapidly. It is recommended that countries\n8. Annex C: Lists of references for reviewed evidence\n9. Recommendation 1\n10. Recommendation 2\n11. Recommendation 3\n12. Recommendation 4\n13. Recommendations 5 and 6  \nWeb annexes available at: www.who.int/reproductivehealth/publications/rtis/gonorrhoea-treatment-guidelines/en/\nThe quality of the evidence for the effects of different treatments for oropharyngeal gonococcal infections is low and very low, and therefore, overall, the evidence for this recommendation is very low. Evidence from 28 studies was identified: eight randomized and 20 non-randomized studies",
    "ground_truth_context": "Briefly, the GRADE approach assesses the quality of evidence for treatment interventions using well-established criteria for the design, risk of bias, inconsistency, indirectness, imprecision, effect size, dose\u2013response curve and other considerations that may affect the quality of the evidence. [14]",
    "is_correct": true
  },
  {
    "question": "A 65-year-old male is admitted to the hospital with an acute medical illness. According to guidelines, what is the primary purpose of using a parenteral anticoagulant in this setting?",
    "options": [
      "To treat an existing deep vein thrombosis",
      "To prevent the development of venous thromboembolism (VTE)",
      "To reduce the risk of arterial thrombosis",
      "To manage acute bleeding events"
    ],
    "correct_answer_text": "To prevent the development of venous thromboembolism (VTE)",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context indicates that the American Society of Hematology (ASH) guideline panel suggests using parenteral anticoagulants in acutely ill medical patients to prevent the development of venous thromboembolism (VTE). This is supported by the statement that guidelines advocate assessing the risk of VTE in admitted medical patients, which implies that the primary purpose of using these anticoagulants is for prevention rather than treatment or management of existing conditions.",
    "reasoning_ground_truth": "The primary purpose of parenteral anticoagulation in acutely ill medical patients is to **prevent the development of VTE**, which includes deep vein thrombosis (DVT) and pulmonary embolism (PE) [15].",
    "context": "Recommendations 1, 2, and 3. In acutely ill medical patients, the American Society of Hematology (ASH) guideline panel suggests using UFH, LMWH, or fondaparinux rather than no parenteral anticoagulant (conditional recommendation, low certainty in the evidence of effects). Among these anticoagulants,\nConclusions and research needs for this recommendation. The panel determined that there is low certainty in the evidence for a net health benefit from using any parenteral anticoagulant in acutely ill medical patients. Other EtD criteria were generally in favor of using any parenteral anticoagulant\nIn acutely ill medical patients, the ASH guideline panel suggests using UFH, LMWH, or fondaparinux rather than no parenteral anticoagulant (conditional recommendation, low certainty in the evidence of effects \u00c5\u00c5\u25ef\u25ef). Among these anticoagulants, the panel suggests using LMWH (low certainty in the\nAll guidelines advocated assessing the risk of VTE and bleeding in admitted medical patients. The American College of Physicians issued 2 additional recommendations: for the use of heparin or a related drug, unless patients were at high bleeding risk, and against use of graduated compression\ncharacteristics of acutely or critically ill medical inpatients over the past 2 decades (eg, length of stay, illness severity, duration of administered VTE prophylaxis). We did not address whether twice or thrice daily unfractionated heparin should be used when unfractionated heparin is chosen,",
    "ground_truth_context": "The panel also considered the randomized controlled trial (RCT) by Cohen et al28 that compared fondaparinux against no parenteral anticoagulation and felt that the results were similar enough to include fondaparinux with UFH and LMWH. The EtD framework is shown online at https://dbep.gradepro.org/profile/ 54B577E9-7F80-3A78-B3EA-3850E9A1D432.[15]",
    "is_correct": true
  },
  {
    "question": "A 60-year-old male with a history of smoking and hypertension presents with a persistent cough, fever, and shortness of breath. A chest X-ray reveals a right lower lobe infiltrate. Initial blood cultures are negative. What is the most appropriate next step in his management?",
    "options": [
      "Start empiric antibiotic therapy for community-acquired pneumonia (CAP)",
      "Prescribe cough suppressants and monitor symptoms",
      "Perform a bronchoscopy to obtain lower respiratory secretions for culture",
      "Order a CT scan of the chest with contrast to rule out pulmonary embolism"
    ],
    "correct_answer_text": "Start empiric antibiotic therapy for community-acquired pneumonia (CAP)",
    "correct_answer_idx": 0.0,
    "model_answer": "A",
    "model_answer_idx": 0,
    "model_reasoning": "The context discusses the management of community-acquired pneumonia (CAP) and emphasizes the importance of starting empiric antibiotic therapy, particularly in cases where pneumonia is suspected, as indicated by the patient's symptoms and chest X-ray findings. The recommendation for a b-lactam plus a respiratory fluoroquinolone supports the initiation of antibiotic therapy for CAP. Other options, such as cough suppressants, bronchoscopy, or a CT scan, are not indicated as immediate next steps based on the context provided.",
    "reasoning_ground_truth": "The patient's symptoms and chest X-ray findings are consistent with CAP. The guidelines recommend initiating **empiric antibiotic therapy** for possible bacterial infection or coinfection. Although blood cultures are recommended, they should not delay the start of antibiotic treatment. The other options are not the first-line steps for a typical CAP case.",
    "context": "deterioration, aspiration and poor compliance. Regular chest physiotherapy should be carried out and ventilator associated pneumonia avoided (evidence level III, grade of recommendation 1).\n- A b-lactam plus a respiratory fluoroquinolone (strong recommendation, low quality of evidence).\nIn adults with CAP whose symptoms have resolved within 5 to 7 days, we suggest not routinely obtaining follow-up chest imaging (conditional recommendation, low quality of evidence).\nswab is positive, coverage for MRSA pneumonia should generally be initiated, but blood and sputum cultures should be sent and therapy deescalated if cultures are negative.\nand symptoms of pneumonia with radiographic confirmation) to completion of antimicrobial therapy and follow-up chest imaging.",
    "ground_truth_context": "our recommendations are to initially treat empirically for possible bacterial infection or coinfection. Routinely obtaining blood cultures may generate false-positive results that lead to unnecessary antibiotic use and increased length of stay.",
    "is_correct": true
  },
  {
    "question": "A 72-year-old female with known chronic kidney disease (CKD) and type 2 diabetes is admitted for a urinary tract infection. Her estimated glomerular filtration rate (eGFR) based on serum creatinine (SCr) is 35 mL/min/1.73 m\u00b2. What is the most appropriate approach for medication dosing?",
    "options": [
      "Use eGFR based solely on serum creatinine for drug dosing.",
      "Use equations that combine both creatinine and cystatin C for drug dosing.",
      "Immediately initiate dialysis",
      "Discontinue all medications until the patient's kidney function improves."
    ],
    "correct_answer_text": "Use equations that combine both creatinine and cystatin C for drug dosing.",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context emphasizes the importance of using a combination of creatinine and cystatin C for estimating GFR in adults at risk for CKD. It specifically states that if cystatin C is available, the GFR category should be estimated from both creatinine and cystatin C. This approach is crucial for making informed decisions regarding medication dosing, especially in patients with CKD. Therefore, option B is the most appropriate approach for medication dosing in this scenario.",
    "reasoning_ground_truth": "For most people, validated eGFR equations using SCr are appropriate for drug dosing. However, when **more accuracy** is needed, such as with a narrow therapeutic range, drug toxicity, or when eGFR estimates may be unreliable, equations that combine both creatinine and cystatin C, or measured GFR may be indicated.",
    "context": "Implications for aging adults with CKD are important in both diagnosis and treatment. The interpretation of laboratory results (specifically SCr) used in the staging system should factor in an older adult\u2019s habitus given the frequency of sarcopenia. A creatinine-based eGFR (eGFRcr) will\nRecommendation 1.1.2.1: In adults at risk for CKD, we recommend using creatinine-based estimated glomerular filtration rate (eGFRcr). If cystatin C is available, the GFR category should be estimated from the combination of creatinine and cystatin C (creatinine and cystatin C\u2013based estimated\nRecommendation 1.1.2.1: In adults at risk for CKD, we recommend using creatinine-based estimated glomerular filtration rate (eGFRcr). If cystatin C is available, the GFR category should be estimated from the combination of creatinine and cystatin C (creatinine and cystatin C\u2013based estimated\ndecisions as an assessment of excretory kidney function (Table 4) to detect and stage AKD and CKD, determine CKD progression, dose medications, determine appropriate use of diagnostic tests, and guide treatment decisions around KRT therapies. Equations are available that estimate GFR using SCr and\nTable S3. Adults and children with or without CKD, estimated GFR (eGFR) based on measurements of cystatin C (eGFRcys); creatinine (eGFRcr); cystatin C and creatinine (eGFRcr-cys) versus measured GFR (mGFR; using urinary or plasma clearance of exogenous filtration marker)Table S4. Adults and children",
    "ground_truth_context": "Where more accuracy is required for drug-related decision-making (e.g., dosing due to narrow therapeutic or toxic range), drug toxicity, or clinical situations where eGFRcr estimates may be unreliable, use of equations that combine both creatinine and cystatin C, or measured GFR may be indicated.",
    "is_correct": true
  },
  {
    "question": "A 55-year-old male presents with a first-time seizure lasting 7 minutes. He has no history of epilepsy. Intravenous (IV) access is difficult to obtain. What is the preferred initial pharmacologic treatment?",
    "options": [
      "Intramuscular midazolam",
      "IV lorazepam",
      "IV phenytoin",
      "Rectal diazepam"
    ],
    "correct_answer_text": "Intramuscular midazolam",
    "correct_answer_idx": 0.0,
    "model_answer": "A",
    "model_answer_idx": 0,
    "model_reasoning": "The context states that in adults, intramuscular (IM) midazolam is established as efficacious at stopping seizures lasting at least 5 minutes, particularly when intravenous access is difficult to obtain. Since the patient in the scenario has a seizure lasting 7 minutes and IV access is difficult, IM midazolam is the preferred initial pharmacologic treatment. Other options like IV lorazepam and IV phenytoin are not suitable due to the difficulty in obtaining IV access.",
    "reasoning_ground_truth": "For patients with convulsive status epilepticus where **IV access is difficult**, intramuscular midazolam is superior to intravenous lorazepam. IV lorazepam is a first line treatment for status epilepticus, but if an IV line cannot be established, IM midazolam is prefered. Rectal diazepam is a reasonable alternative, but midazolam has better effectiveness when IV access is not established.",
    "context": "or longer, or two or more GTC seizures without full recovery of consciousness. A treatment was successful if the status epilepticus stopped within 20 minutes after infusion started with no recurrence prior to 60 minutes. Overall, 570 patients were randomized to either lorazepam (n = 146), diazepam\nlorazepam in adults with convulsive status epilepticus without established intravenous access (Level A). In children, intravenous lorazepam and intravenous diazepam are established as efficacious at stopping seizures lasting at least 5 minutes (Level A) while rectal diazepam, intramuscular\nThe following conclusions were drawn. In adults, IM midazolam, IV lorazepam, IV diazepam (with or without phenytoin), and IV phenobarbital are established as efficacious at stopping seizures lasting at least 5 minutes (level A). Intramuscular midazolam has superior effectiveness compared with IV\nold whose seizures did not respond to IV diazepam (0.2 mg/kg) within 5 minutes. No significant difference was noted in efficacy between valproic acid and phenobarbital for terminating seizures within 20 minutes, but the valproic acid group experienced significantly fewer clinically significant\nmg/kg), diazepam (0.15 mg/kg) followed by phenytoin (18 mg/kg), phenobarbital (18 mg/kg), and phenytoin alone (18 mg/kg) in adults with either overt or subtle status epilepticus (22). Overt status epilepticus was defined as a continuous GTC seizure lasting 10 minutes or longer, or two or more GTC",
    "ground_truth_context": "In adults with convulsive status epilepticus, intramuscular midazolam, intravenous lorazepam, intravenous diazepam and intravenous phenobarbital are established as efficacious as initial therapy (Level A). Intra-muscular midazolam has superior effectiveness compared to intravenous lorazepam in adults with convulsive status epilepticus without established intravenous access (Level A).",
    "is_correct": true
  },
  {
    "question": "A 48-year-old woman with a history of heavy alcohol use presents with jaundice, ascites, and confusion. She has been diagnosed with alcoholic hepatitis. What is the initial nutritional recommendation?",
    "options": [
      "Restrict fluid intake to manage ascites",
      "Initiate a high-protein, low-carbohydrate diet",
      "Start enteral nutrition with a standard formula",
      "Delay nutritional support until her liver function stabilizes"
    ],
    "correct_answer_text": "Start enteral nutrition with a standard formula",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context discusses nutritional support in patients with alcoholic liver disease, specifically highlighting the importance of adequate calorie and protein intake through supplementation. The mention of \"protein energy malnutrition in severe alcoholic hepatitis\" and the need for nutritional support indicates that starting enteral nutrition is a recommended approach. There is no indication in the context that suggests delaying nutritional support or restricting fluid intake as the initial recommendation.",
    "reasoning_ground_truth": "The patient has signs of liver disease, which requires nutritional management. Based on the liver disease guideline, enteral nutrition should be started and is a safe route for delivery of nutritional support for patients with liver disease. Restricting fluids and or delaying nutrition may cause significant harm.",
    "context": "51. Galambos JT, Hersh T, Fulenwider JT, Ansley JD, Rudman D. Hyperalimentation in alcoholic hepatitis. Am J Gastroenterol 1979;72(5):535e41.\n19. Bunout D, Aicardi V, Hirsch S, Petermann M, Kelly M, Silva G, et al. Nutritional support in hospitalized patients with alcoholic liver disease. Eur J Clin Nutr 1989;43(9):615e21.\n21. Mendenhall CL, Tosch T, Weesner RE, Garcia-Pont P, Goldberg SJ, Kiernan T, et al. VA cooperative study on alcoholic hepatitis. II: prognostic significance of protein-calorie malnutrition. Am J Clin Nutr 1986;43(2):213e8.\nadequate calorie and protein intake by supplementation. Whether alcoholic hepatitis is a state of accelerated starvation akin to cirrhosis has not been directly reported, metabolomic studies and metabolic cart studies suggest hyper-metabolism, accelerated lipolysis and accelerated starvation\n20. Mendenhall CL, Moritz TE, Roselle GA, Morgan TR, Nemchausky BA, Tamburro CH, et al. Protein energy malnutrition in severe alcoholic hepatitis: diagnosis and response to treatment. The VA cooperative study group #275. J Parenter Enteral Nutr 1995;19(4):258e65.",
    "ground_truth_context": "A total of 85 recommendations were made for the nutritional and metabolic management of patients with acute liver failure, severe alcoholic steatohepatitis, non-alcoholic fatty liver disease, liver cirrhosis, liver surgery and transplantation as well as nutrition associated liver injury",
    "is_correct": true
  },
  {
    "question": "A 50-year-old patient with a history of coronary artery disease underwent percutaneous coronary intervention (PCI) with drug-eluting stent placement. How long should dual antiplatelet therapy (DAPT) be continued?",
    "options": [
      "3 months",
      "6 months",
      "12 months",
      "24 months"
    ],
    "correct_answer_text": "12 months",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context states that patients with NSTE-ACS treated with coronary stent implantation should be treated with DAPT for at least 12 months, based on evidence from the CURE trial and other studies. This recommendation applies to patients who have undergone PCI, which includes the 50-year-old patient in the question. Therefore, the correct duration for continuing DAPT is 12 months.",
    "reasoning_ground_truth": "For most patients, 12 months of DAPT is the recommended or minimal duration of therapy following PCI with drug-eluting stent placement. The duration can vary based on the patient profile, but 12 months is the standard recommendation.",
    "context": "monotherapy (Data Supplement 4). Based primarily on the CURE trial and PCI-CURE analyses, the prior recommendation that patients with NSTE-ACS treated with coronary stent implantation be treated with DAPT for at least 12 months is continued in this update and has been extrapolated to patients with\nboth in those treated with revascularization (PCI or CABG) and in those treated with medical therapy alone (51,52). Available evidence from this trial, as well as from PLATO (53,71,72) and TRITON-TIMI 38 (54,55), supports DAPT duration of at least 12 months for patients with NSTE-ACS.\nIn studies of drug-eluting bioabsorbable polymer stents and bioabsorbable stents (third- and fourth-generation stents), by study protocol, DAPT was continued for at least 6 to 12 months (110\u2013116). In a study of a novel polymer-free and carrier-free drug-coated stent in patients at high risk of\n|IIb|ASR|In patients with ACS treated with coronary stent implantation who have tolerated DAPT without bleeding complication and who are not at high bleeding risk (e.g., prior bleeding on DAPT, coagulopathy, oral anticoagulant use) continuation of DAPT for longer than 12 months may be reasonable\n|---|---|---|---|\n|In patients treated with DAPT after coronary stent implantation who subsequently undergo CABG, P2Y12 inhibitor therapy should be resumed postoperatively so that DAPT continues until the recommended duration of therapy is completed.|I|C-EO| |",
    "ground_truth_context": "Most contemporary studies of DAPT have compared either shorter (3 to 6 months) (17\u201321) or longer (18 to 48 months) (16,22\u201326) duration of therapy with 12 months of DAPT, which is the recom-mended or minimal duration of therapy for most patients in ACC/AHA (9,13,14) and European Society of Cardiology (31\u201333) guidelines published between 2011 and 2014.",
    "is_correct": true
  },
  {
    "question": "A 68-year-old male with a history of benign prostatic hyperplasia (BPH) and hypertension presents with new-onset fatigue, constipation, and dry skin. His TSH level is elevated, and free T4 level is low. What is the appropriate initial treatment?",
    "options": [
      "Liothyronine (T3) monotherapy",
      "Combination of levothyroxine (T4) and liothyronine (T3)",
      "Levothyroxine (T4) monotherapy",
      "Thyroid-stimulating hormone (TSH) injection therapy"
    ],
    "correct_answer_text": "Levothyroxine (T4) monotherapy",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context specifies that for patients older than 50-60 years with overt hypothyroidism, an initial L-thyroxine (levothyroxine) dose of 50 \u00b5g daily should be considered. The patient in the question is 68 years old and presents with symptoms consistent with hypothyroidism, along with elevated TSH and low free T4 levels. Therefore, the appropriate initial treatment for this patient is levothyroxine (T4) monotherapy, as indicated in the context.",
    "reasoning_ground_truth": "The patient's symptoms and lab results are consistent with primary hypothyroidism. The standard treatment is replacement with L-thyroxine (T4). Combination therapy with T3 is not recommended in the majority of cases.",
    "context": "When initiating therapy in patients older than 50-60 years with overt hypothyroidism, without evidence of coronary heart disease, an L-thyroxine dose of 50 \u00b5g daily should be considered. Grade D, BEL 4  \nSee: L-thyroxine treatment of hypothyroidism\nTreatment based on individual factors for patients with TSH levels between the upper limit of a given laboratory\u2019s reference range and 10 mIU/L should be considered particularly if patients have symptoms suggestive of hypothyroidism, positive TPOAb or evidence of atherosclerotic cardiovascular\nwith L-thyroxine. This has been reported in 20% of those treated with thyroid hormone (12). The principal adverse consequences of subtle or frank overtreatment are cardiovascular (187-190), skeletal (191-194), and possibly affective disturbances (195-197). The elderly are particularly susceptible to\ntherapy (54,55) (see L-thyroxine treatment of hypothyroidism).\nSee: L-thyroxine treatment of hypothyroidism",
    "ground_truth_context": "The standard treatment is replacement with L-thyroxine which must be tailored to the individual patient.",
    "is_correct": true
  },
  {
    "question": "A 35-year-old pregnant woman, at 20 weeks gestation, presents with a new diagnosis of gonococcal infection. What is the recommended treatment?",
    "options": [
      "Oral azithromycin 1 g single dose",
      "Intramuscular ceftriaxone 500 mg single dose",
      "Oral doxycycline 100 mg twice daily for 7 days",
      "Topical erythromycin ointment"
    ],
    "correct_answer_text": "Intramuscular ceftriaxone 500 mg single dose",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context specifies that for pregnant women with uncomplicated gonococcal infections, the recommended treatment includes \"Ceftriaxone \u2265 250 mg IM x 1.\" Since option B states \"Intramuscular ceftriaxone 500 mg single dose,\" it aligns with the guideline provided in the context for treating gonococcal infections in pregnant women. Other options do not match the recommended treatment for this specific case.",
    "reasoning_ground_truth": "The current recommended treatment for gonococcal infection, including in pregnant women, is ceftriaxone 500mg single dose. Doxycycline is contraindicated in pregnancy, azithromycin may not provide adequate coverage, and topical erythromycin is not an adequate treatment for systemic gonococcal infection.",
    "context": "Remarks: Treatment failures have been observed after single therapy for gonococcal oropharyngeal infections and therefore dual therapy is suggested over single therapy. This recommendation applies to pregnant women, who should be closely monitored for complications.\nRemarks: Treatment failures have been observed after single therapy for gonococcal oropharyngeal infections and therefore dual therapy is suggested over single therapy. This recommendation applies to pregnant women, who should be closely monitored for complications.\n|Pregnant women with uncomplicated genital (cervix, urethra) and anorectal gonococcal infections|Ceftriaxone \u2265 250 mg IM x 1 Cefixime 800 mg orally x 1 Cefixime 400 mg orally x 2 Azithromycin 1\u20132 g orally x 1 Cefixime 400 mg orally x 1|Single therapy: Cefixime 800 mg orally x 1 Cefixime 400 mg\nIn people with gonococcal infections who have failed treatment, the WHO STI guideline suggests the following options.  \n- If reinfection is suspected, re-treat with a WHO-recommended regimen, reinforce sexual abstinence or condom use, and provide partner treatment.\nGonococcal treatment guidelines need to be updated in response to the changing antimicrobial susceptibility patterns of N. gonorrhoeae. Increased resistance to most antibiotics used to treat gonococcal infections has been reported worldwide, raising concerns about the eventual development of",
    "ground_truth_context": "Six PICO questions were identified for the update on the treatment of genital, anorectal and oropharyngeal gonococcal infections, management of treatment failure, and prevention and treatment of neonatal ophthalmia (see Annex B). These questions pertained to adults and other special populations,  namely adolescents, pregnant women, people living  with HIV, and populations at high risk of acquiring  and transmitting STIs, such as men who have sex with men (MSM) and sex workers.",
    "is_correct": true
  },
  {
    "question": "A 50-year-old patient with rheumatoid arthritis (RA) is currently on methotrexate. The patient's disease activity remains moderate, as indicated by a DAS28 score. What is the next appropriate step in managing RA?",
    "options": [
      "Increase the dose of methotrexate",
      "Add a biologic or targeted synthetic DMARD to methotrexate",
      "Switch to sulfasalazine monotherapy",
      "Prescribe a short course of oral prednisone"
    ],
    "correct_answer_text": "Add a biologic or targeted synthetic DMARD to methotrexate",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context indicates that for patients with moderate-to-high disease activity who are already on methotrexate, the recommendation is to consider adding a biologic or targeted synthetic DMARD for better management. This aligns with the need for a more effective treatment strategy when disease activity remains moderate despite current therapy. Options A, C, and D do not align with the recommendations provided for managing moderate disease activity in patients already on methotrexate.",
    "reasoning_ground_truth": "If a patient's RA remains moderately active despite methotrexate therapy, it's recommended to add a biologic or targeted synthetic DMARD. Increasing the dose of methotrexate may be considered in some cases but adding a second DMARD is more appropriate for moderate disease activity.",
    "context": "Methotrexate is conditionally recommended over alternative DMARDs for the treatment of inflammatory arthritis for patients with clinically diagnosed mild and stable airway or parenchymal lung disease, or incidental disease detected on imaging, who have moderate-to-high disease activity.\nThe recommendation is conditional because the voting panel thought that some patients who have already had persistent disease activity despite use of \u22651 csDMARD will prefer combination treatment for a more rapid response.  \nRecommendations for administration of methotrexate (Table 3)\nMethotrexate is strongly recommended over hydroxychloroquine or sulfasalazine for DMARD-naive patients with moderate-to-high disease activity. This recommendation is strongly in favor of methotrexate despite very low-certainty evidence for hydroxychloroquine and low-certainty evidence for\nin csDMARD-treated, but methotrexate-naive, patients with moderate-to-high disease activity#|Initiation of treatment in csDMARD-treated, but methotrexate-naive, patients with moderate-to-high disease activity#|\nmonotherapy, preferably with methotrexate, for patients with both low and moderate/high disease activity, whereas this update recommends an initial trial of hydroxychloroquine or sulfasalazine for those with low disease activity. Second, the 2015 guidelines recommended DMARD tapering for patients",
    "ground_truth_context": "Methotrexate monotherapy is conditionally recommended over the combination of methotrexate plus a bDMARD or tsDMARD.",
    "is_correct": true
  },
  {
    "question": "A 62-year-old male with a history of primary open-angle glaucoma (POAG) is being treated with prostaglandin eye drops. He mentions having trouble consistently using his medication due to forgetfulness. What is the most appropriate next step?",
    "options": [
      "Switch to a beta-blocker eye drop",
      "Recommend laser trabeculoplasty",
      "Encourage the use of a medication reminder system",
      "Discontinue treatment, since adherence is low"
    ],
    "correct_answer_text": "Encourage the use of a medication reminder system",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context mentions that fixed combination therapy may improve patient adherence, indicating that adherence is a significant concern in glaucoma treatment. Since the patient is experiencing forgetfulness and has trouble consistently using his medication, the most appropriate next step would be to encourage the use of a medication reminder system to help improve adherence, rather than switching medications or discontinuing treatment.",
    "reasoning_ground_truth": "For patients with glaucoma, particularly those with poor adherence, the first step is to implement strategies to improve adherence, including medication reminders, simplify treatment regimens, or encourage caregiver involvement. Switching to a different class of medication or laser trabeculoplasty is not the best initial step and should be considered if adherence remains an issue.",
    "context": "If the diagnosis or management of POAG is in question, or if the condition is refractory to treatment, consultation with or referral to an ophthalmologist with special training or experience in managing glaucoma should be considered. Patients with substantial visual impairment or blindness can be\n|Advanced Glaucoma Intervention Study, 2000|POAG after medical therapy failure with no previous surgery: laser trabeculoplasty first vs. trabeculectomy first|591|10\u201313|\n|United Kingdom Glaucoma Treatment Study, 2014|Newly diagnosed OAG: latanoprost 0.005% vs. placebo|516|2|\nMedical therapy is presently the most common initial intervention to lower IOP (see Table 4 for an overview of options available). Prostaglandin analogs are the most frequently prescribed eye drops for lowering IOP in patients with glaucoma because they are most efficacious and well tolerated, and\nglaucoma. The use of generic prostaglandin analogs was found to be the more cost-effective treatment option compared with laser trabeculoplasty when assuming optimal medication adherence. However, when assuming more realistic estimates of medication adherence, laser trabeculoplasty was found to\nto glaucoma treatment,347, 348 fixed combination therapy may improve patient adherence, and reduce exposure to preservatives, although it is not recommended for initial treatment in most circumstances. However, when the necessary reduction of IOP exceeds the expected efficacy of a single drug,",
    "ground_truth_context": "Ophthalmologists should strive to provide education that is clear, relevant, and accessible to the patient and their caregiver(s).",
    "is_correct": true
  },
  {
    "question": "A 68-year-old male is admitted to the hospital with an acute illness. He has a high risk of venous thromboembolism (VTE) based on the Padua risk score. What is the recommended approach for VTE prophylaxis?",
    "options": [
      "No prophylaxis, just early ambulation",
      "Mechanical prophylaxis with compression stockings",
      "Pharmacological prophylaxis with parenteral anticoagulation",
      "Combined pharmacological and mechanical prophylaxis"
    ],
    "correct_answer_text": "Pharmacological prophylaxis with parenteral anticoagulation",
    "correct_answer_idx": 2.0,
    "model_answer": "D",
    "model_answer_idx": 3,
    "model_reasoning": "The context indicates that for patients with a Padua score of 4 or higher, which signifies high risk for VTE, prophylaxis is indicated. The American College of Physicians recommends the use of heparin or a related drug unless patients are at high bleeding risk, and it is implied that mechanical prophylaxis (such as compression stockings) can also be beneficial. Therefore, the combined approach of pharmacological and mechanical prophylaxis (option D) is the most appropriate recommendation for a patient with a high risk of VTE.",
    "reasoning_ground_truth": "The guidelines recommend using parenteral anticoagulation for VTE prophylaxis in acutely ill patients at high risk. Mechanical prophylaxis may be considered when anticoagulation is contraindicated or as an adjunct therapy, but not as the first line strategy.",
    "context": "*A total of 60.3% of patients in this study were low risk (Padua score 0-3). VTE prophylaxis was administered by provider choice from among several medications and with or without concomitant compression stockings.  \nVTE incidence without VTE prophylaxis:  \n- Padua score 0 to 3: 0.3%\nAll guidelines advocated assessing the risk of VTE and bleeding in admitted medical patients. The American College of Physicians issued 2 additional recommendations: for the use of heparin or a related drug, unless patients were at high bleeding risk, and against use of graduated compression\n\u2020Risk level: score of 0 or 1 5 low risk, score of 2 or 3 5 moderate risk; score $ 4 5 high risk. For scores $ 2, VTE prophylaxis is indicated.  \nA total of 69% of patients in this study were low risk for VTE (score 0 or 1).  \nThree-month rate of symptomatic VTE:  \n- IMPROVE VTE score 0 or 1: 0.5%\n- Padua score 0 to 3: 0.3%\n- Padua score $ 4: 11%  \nAmong at-risk patients (Padua score $ 4):  \n- Overall VTE hazard ratio (HR), 32 (95% CI, 4.1-251)\n- Incidence of VTE\n- - No prophylaxis: 11%\n- With prophylaxis: 2.2%\n- VTE HR with prophylaxis, 0.13 (95% CI, 0.04-0.4)\nStudies on identification of high-risk subgroups of chronically ill medical patients who could benefit from VTE prophylaxis, with consideration given to those who are immobilized.",
    "ground_truth_context": "We found 17 systematic reviews that addressed this question,51-67 with 25 studies29,30,68-89 (H. Vissinger and S. Husted, unpublished data, 1995) in these reviews evaluating outcomes relevant to this question.",
    "is_correct": false
  },
  {
    "question": "A 58-year-old male with a history of chronic kidney disease (CKD) is being evaluated for kidney function. His eGFR based on creatinine is 40 mL/min/1.73m^2. What additional test should be considered?",
    "options": [
      "Repeat creatinine-based eGFR in 3 months",
      "Measure cystatin C to estimate eGFR",
      "Perform a kidney biopsy",
      "Start renal replacement therapy"
    ],
    "correct_answer_text": "Measure cystatin C to estimate eGFR",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context emphasizes the importance of assessing kidney function in individuals with chronic kidney disease (CKD) using both urine albumin measurement and glomerular filtration rate (GFR) assessments. While the eGFR based on creatinine is already provided, measuring cystatin C is a relevant additional test that can provide a more accurate estimate of kidney function, especially in cases where creatinine levels may be influenced by factors such as muscle mass. This aligns with the context's focus on comprehensive evaluation in CKD management.",
    "reasoning_ground_truth": "The initial test for evaluating GFR is eGFRcr. If eGFRcr is suspected to be inaccurate, then cystatin C should be measured and eGFRcr-cys should be estimated. A kidney biopsy would be indicated if the cause of CKD is uncertain, not for the evaluation of GFR. Renal replacement therapy is not indicated unless the eGFR is much lower.",
    "context": "Practice Point 1.1.1.1: Test people at risk for and with chronic kidney disease (CKD) using both urine albumin measurement and assessment of glomerular filtration rate (GFR).\nPractice Point 1.1.1.1: Test people at risk for and with chronic kidney disease (CKD) using both urine albumin measurement and assessment of glomerular filtration rate (GFR).\nImplications for aging adults with CKD are important in both diagnosis and treatment. The interpretation of laboratory results (specifically SCr) used in the staging system should factor in an older adult\u2019s habitus given the frequency of sarcopenia. A creatinine-based eGFR (eGFRcr) will\nPractice Point 2.1.3: For people with CKD, a change in eGFR of >20% on a subsequent test exceeds the expected variability and warrants evaluation.\nFor people with CKD, a change in eGFR of >20% on a subsequent test exceeds the expected variability and warrants evaluation.",
    "ground_truth_context": "If eGFRcr is expected to be inaccurate, or if a more accurate assessment of GFR is needed for clinical decision-making, such as diagnosis or staging of chronic kidney disease or drug dosing, then, if available, cystatin C should be measured, and creatinine and cystatin C\u2013based estimated GFR (eGFRcr-cys) should be estimated.",
    "is_correct": true
  },
  {
    "question": "A 42-year-old female with a history of migraine presents with frequent, severe headaches. She has tried several abortive therapies with limited success. What is the next step in her management?",
    "options": [
      "Initiate a preventative migraine therapy",
      "Refer her for neurosurgery",
      "Prescribe a higher dose of her current abortive medication",
      "Recommend lifestyle modifications only"
    ],
    "correct_answer_text": "Initiate a preventative migraine therapy",
    "correct_answer_idx": 0.0,
    "model_answer": "A",
    "model_answer_idx": 0,
    "model_reasoning": "The context discusses the need for updated evidence-based recommendations for the preventive treatment of migraine headaches, particularly for patients who have not had success with abortive therapies. Since the patient has a history of migraines and has tried several abortive therapies with limited success, initiating a preventative migraine therapy is the logical next step in her management, as supported by the context's focus on pharmacologic therapies for migraine prevention.",
    "reasoning_ground_truth": "For patients with frequent, severe migraines or if abortive therapies are not effective, preventative therapy should be considered. Other options are not appropriate at this stage.",
    "context": "are present. Because migraine is frequent in women of childbearing age, the potential for adverse fetal effects related to migraine prevention strategies is particularly concerning.\n- Assessed the efficacy of therapeutic agents for headache other than episodic migraine in adults\n- Assessed acute migraine treatment, migraine aura treatment/prevention, or nonpharmacologic treatments (e.g., behavioral approaches)\nObjective: To provide updated evidence-based recommendations for the preventive treatment of migraine headache. The clinical question addressed was: What pharmacologic therapies are proven effective for migraine prevention?\non the efficacy and safety of migraine preventive therapies. This guideline seeks to assess this new evidence to answer the following clinical question: For patients with migraine, which pharmacologic therapies are proven effective for prevention, as measured by reduced migraine attack frequency,\n23. Brandes JL, Poole A, Kallela M, et al. Short-term frovatriptan for the prevention of difficult-to-treat menstrual migraine attacks. Cephalalgia 2009;29:1133\u20131148.",
    "ground_truth_context": "Evidence to support pharmacologic treatment strategies for migraine prevention indicates which treatments might be effective but is insufficient to establish how to choose an optimal therapy.",
    "is_correct": true
  },
  {
    "question": "A 30-year-old male presents with a 3-day history of nasal congestion, facial pain, and purulent nasal discharge. He reports no improvement after using over-the-counter decongestants. What is the most appropriate initial management strategy?",
    "options": [
      "Start antibiotic therapy immediately",
      "Prescribe nasal corticosteroids",
      "Recommend watchful waiting for 7 days",
      "Order a sinus CT scan"
    ],
    "correct_answer_text": "Recommend watchful waiting for 7 days",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context indicates that for cases of nasal drainage with nasal obstruction and facial pain, clinicians should either offer watchful waiting (without antibiotics) or prescribe initial antibiotic therapy. Given that the patient has had symptoms for only 3 days and has not shown improvement with over-the-counter decongestants, the most appropriate initial management strategy is to recommend watchful waiting for 7 days, as this aligns with the recommendations provided in the context.",
    "reasoning_ground_truth": "The guideline recommends watchful waiting as an initial management strategy for uncomplicated acute bacterial rhinosinusitis, regardless of severity. Antibiotics should not be used right away unless symptoms fail to improve. A CT scan is not required at this stage.",
    "context": "nasal drainage accompanied by nasal obstruction, facial pain-pressure-fullness, or both) persist without\nagents, nasal saline, decongestants, antihistamines, mucolytics, cough suppressants, and topical or oral corticosteroids\u2014may be used alone or in varying combinations for symptom relief.\nOral decongestants may provide symptomatic relief and should be considered barring any medical contraindications, such as hypertension or anxiety. The use of topical decongestant is likely to be palliative, but continuous duration of use should not exceed 3 to 5 days, as recommended by the\ndocumentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. The update group made recommendations that clinicians (1) should either offer watchful waiting (without antibiotics) or prescribe initial antibiotic therapy for\nimprove diagnostic accuracy for adult rhinosinusitis, promote judicious use of systemic and topical therapy, and promote appropriate use of ancillary tests to confirm diagnosis and guide management, which include radiography, nasal endoscopy, computed tomography, and testing for allergy and immune",
    "ground_truth_context": "Extension of watchful waiting (without antibiotic therapy) as an initial management strategy to all patients with uncomplicated acute bacterial rhi-nosinusitis (ABRS) regardless of severity, not just patients with \u201cmild\u201d illness (prior guideline).",
    "is_correct": true
  },
  {
    "question": "A 55-year-old male with a long history of sun exposure presents with several rough, scaly lesions on his scalp and face. He is diagnosed with actinic keratoses (AKs). What is the recommended initial treatment?",
    "options": [
      "Surgical excision of the lesions",
      "Cryotherapy of the lesions",
      "Topical application of a medication approved for AKs",
      "Observation only"
    ],
    "correct_answer_text": "Topical application of a medication approved for AKs",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context indicates that actinic keratosis (AK) is a common condition treated by dermatologists, and it mentions guidelines addressing the management of AK. While it does not specify the exact initial treatment, the presence of \"topical application of a medication approved for AKs\" aligns with standard treatment practices for AKs, which typically include topical therapies. Options A (surgical excision) and B (cryotherapy) are treatments but not necessarily the initial recommendation, and D (observation only) is not appropriate given the diagnosis of AKs.",
    "reasoning_ground_truth": "The clinical question asks if topically applied agents should be used for the treatment of AKs. Topical therapy is a standard first line treatment option for AK's.",
    "context": "AKs are typically absent in the first decades of life unless genetic or environmental factors predispose an individual to increased skin damage from UV exposure. AKs typically present in areas of highest solar damage in fair-skinned individuals and have a propensity for the head, ears, neck, dorsal\nActinic keratoses are keratinocyte neoplasms occurring on skin that has had long-term exposure to ultraviolet radiation.\nAlthough they often persist as chronic skin lesions, AKs can spontaneously involute or, most importantly, evolve into keratinocyte carcinoma if left untreated.26-32 This is particularly concerning in patients with a previous history of skin cancer, advanced age, or other factors that predispose\nA single study examined whether field treatment of AKs with 10% alpha hydroxy acid and ALA-blue light PDT resulted in fewer subsequent invasive skin cancers on the face of individuals with previous facial cutaneous malignancy.130 Patients were\nActinic keratosis (AK) is one of the most common conditions diagnosed and treated by dermatologists in the United States (US). These guidelines address the management of AK from the perspective of US dermatologists, other practitioners who treat AK, and patients. Premalignant neoplasia on",
    "ground_truth_context": "Clinical question (CQ) 1 asks: Should topically applied agents be used for the treatment of AKs?.",
    "is_correct": true
  },
  {
    "question": "A 45-year-old patient with chronic kidney disease (CKD) and type 2 diabetes is starting on a new antihypertensive medication. What is the most important information to consider regarding drug dosing?",
    "options": [
      "Whether the medication is metabolized by the liver",
      "Whether the medication requires a loading dose",
      "The patient's estimated glomerular filtration rate (eGFR)",
      "The patient's blood pressure reading at the time of medication initiation"
    ],
    "correct_answer_text": "The patient's estimated glomerular filtration rate (eGFR)",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context emphasizes the importance of considering the patient's chronic kidney disease (CKD) when starting antihypertensive medications. Specifically, it mentions that knowledge of altered risks and benefits of medications in CKD is crucial, which implies that the patient's estimated glomerular filtration rate (eGFR) is a key factor in determining appropriate drug dosing. There is no mention of liver metabolism, loading doses, or blood pressure readings being the most critical factors in this context.",
    "reasoning_ground_truth": "The eGFR is important for guiding decisions related to the choice and dosing of medications in patients with CKD, particularly those medications that are renally cleared.",
    "context": "We recommend avoiding any combination of ACEi, ARB, and direct renin inhibitor (DRI) therapy in people with CKD, with or without diabetes (1B).  \nS158 Kidney International (2024) 105 (Suppl 4S), S117\u2013S314\nConsider starting people with CKD with normal to mildly increased albuminuria (A1) on RASi (ACEi or ARB) for specific indications (e.g., to treat hypertension or heart failure with low ejection fraction).\nPractice Point 3.6.6: Consider starting people with CKD with normal to mildly increased albuminuria (A1) on RASi (ACEi or ARB) for specific indications (e.g., to treat hypertension or heart failure with low ejection fraction).\nrecommended for younger people with CKD, as they may not necessarily be transferable to older adults. Strict BP-lowering, for example, may come with the risk of dizziness, falls, and fractures in older adults, many of whom are on anticoagulants risking severe hemorrhage.\nmedications in people with CKD. This guidance is based on knowledge of pharmacology that has universal relevance. In many cases, knowledge of altered risks/benefits of medications comes, however, from observational studies and case reports from routine care.",
    "ground_truth_context": "An assessment of GFR is important for guiding decisions related to the choice and dosing of medications. Section 1.2 addresses the accuracy of validated eGFR equations, as well as indications for the use of eGFRcr-cys or mGFR.",
    "is_correct": true
  },
  {
    "question": "A 68-year-old woman with a recent diagnosis of community acquired pneumonia (CAP) is being discharged from the hospital. She has multiple comorbidities. Which of the following is the most appropriate antibiotic regimen for outpatient therapy?",
    "options": [
      "Amoxicillin monotherapy",
      "Azithromycin monotherapy",
      "A fluoroquinolone",
      "Doxycycline monotherapy"
    ],
    "correct_answer_text": "A fluoroquinolone",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context indicates that patients with community-acquired pneumonia (CAP) who have significant comorbidities may require specific antibiotic regimens. While the context does not explicitly list the recommended outpatient regimens for patients with comorbidities, it implies that more robust treatment is necessary for these patients. Among the options provided, a fluoroquinolone is typically considered a stronger option for patients with multiple comorbidities, making it the most appropriate choice for outpatient therapy in this case.",
    "reasoning_ground_truth": "For outpatients with comorbidities, a respiratory fluoroquinolone or a combination of a beta-lactam and a macrolide is appropriate. Monotherapy with amoxicillin, azithromycin or doxycycline are options for patients without comorbidities and may not provide adequate coverage for all CAP pathogens in a patient with comorbidities.",
    "context": "For adults with community-acquired pneumonia (CAP) at risk for MRSA or P. aeruginosa (see Recommendation 11), we recommend the following empiric treatment regimens (in no order of preference) (Table 4):\nDespite substantial concern over the rise of antibiotic-resistant pathogens, most patients with CAP can be adequately treated with regimens that have been used for multiple decades. It is also true that the subset of patients with CAP who have significant comorbidities and frequent contact with\nill. As observational data suggest that inpatient and outpatient CAP are due to the same pathogens (69, 71\u201373, 82), except for Legionella and gram-negative bacilli, which are rarely documented in outpatient settings, it seems reasonable that an antibiotic regimen that was effective for inpatients\nIn the Inpatient Setting, Which Antibiotic Regimens Are Recommended for Empiric Treatment of CAP in Adults without Risk Factors for MRSA and P. aeruginosa?\nIn the Outpatient Setting, Which Antibiotics Are Recommended for Empiric Treatment of CAP in Adults?",
    "ground_truth_context": "the panel believed that fluoroquinolone therapy was justified for adults with comorbidities and CAP managed in the outpatient setting.",
    "is_correct": true
  },
  {
    "question": "A 70-year-old man with a history of heart failure is hospitalized for an acute exacerbation. He develops acute kidney injury. What is the most appropriate initial test for evaluating GFR in this patient?",
    "options": [
      "Measured GFR using exogenous filtration markers",
      "eGFR based on serum cystatin C (eGFRcys)",
      "eGFR based on serum creatinine (eGFRcr)",
      "A renal ultrasound"
    ],
    "correct_answer_text": "eGFR based on serum creatinine (eGFRcr)",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context emphasizes the importance of assessing glomerular filtration rate (GFR) in patients with chronic kidney disease (CKD) and mentions that most people with CKD and their healthcare providers prefer the more accurate assessment of kidney function using GFR estimating equations compared to serum creatinine (SCr) alone. Since the patient has developed acute kidney injury, the most appropriate initial test for evaluating GFR would be the eGFR based on serum creatinine (eGFRcr), as it is the standard method referenced in the context for initial GFR assessment.",
    "reasoning_ground_truth": "The initial test for evaluation of GFR is eGFRcr. Cystatin C is a supportive test to be used if eGFRcr is suspected of being inaccurate. mGFR is only needed when eGFR is not accurate enough for clinical decision making. A renal ultrasound may be indicated if the cause of AKI is uncertain, but not for GFR evaluation.",
    "context": "Practice Point 1.1.1.1: Test people at risk for and with chronic kidney disease (CKD) using both urine albumin measurement and assessment of glomerular filtration rate (GFR).\nPractice Point 1.1.1.1: Test people at risk for and with chronic kidney disease (CKD) using both urine albumin measurement and assessment of glomerular filtration rate (GFR).\nIdentify adults at risk for CKD  \nTest for GFR* and ACR \u00b1 other markers of kidney damage \u2020  \nGFR &lt;60 ml/min per 1.73 m2 or ACR \u226530 mg/g [3 mg/mmol]2 and/or other markers of kidney damage present  \nTest for GFR or ACR if not performed and exclude AKI/AKD\nMost people with CKD and their healthcare providers would prefer the more accurate assessment of kidney function resulting from the use of GFR estimating equations compared with SCr alone. Minimal cost or resources issues are expected because creatinine is available in healthcare settings globally,\nWe describe a framework for the evaluation of GFR beginning with an initial test and followed by additional supportive tests (Figure 11, Table 7). Cystatin C is an alternative endogenous filtration marker that is now increasingly available. Its assay can be put on autoanalyzers, and therefore its",
    "ground_truth_context": "As in the previous KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease,1 the first method to evaluate GFR should be eGFRcr. If necessary for greater accuracy, the approach then recommends subsequent supportive tests from either the more accurate eGFRcr-cys or measurement of GFR using urinary or plasma clearance of exogenous filtration markers.",
    "is_correct": true
  },
  {
    "question": "A 50-year-old female with a recent diagnosis of CKD is being educated about her condition. What is the most important aspect to address in her education?",
    "options": [
      "Detailed kidney anatomy",
      "The type of kidney failure and its treatment options",
      "Specific dietary restrictions",
      "The etiology of CKD, its management, and the available kidney failure management options"
    ],
    "correct_answer_text": "The etiology of CKD, its management, and the available kidney failure management options",
    "correct_answer_idx": 3.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context emphasizes the importance of educating people with CKD about dietary adaptations, specifically regarding sodium, phosphorus, potassium, and protein intake, tailored to their individual needs. This indicates that specific dietary restrictions are a critical aspect of education for someone with CKD, making option C the most relevant choice.",
    "reasoning_ground_truth": "Educational topics should cover knowledge about CKD, including the etiology, signs, and symptoms, treatment to slow progression, treatment of complications, and available kidney failure management options. Focusing on the etiology of CKD, its management, and the available kidney failure management options is essential for patient self-management.",
    "context": "Education programs that also involve care partners where indicated are important to promote informed, activated people with CKD.  \nAn effective patient education program is a critical success factor of self-care management support strategies. Education should address 3 main issues:\nTargeting education to people with CKD who are at high risk of CKD progression might yield a better outcome than routine care not only to the individual but also to the healthcare system.\n- Improving CKD awareness\n- Empower self-management\n- Management of CKD complications\nUse renal dietitians or accredited nutrition providers to educate people with CKD about dietary adaptations regarding sodium, phosphorus, potassium, and protein intake, tailored to their individual needs, and severity of CKD and other comorbid conditions.\nUse renal dietitians or accredited nutrition providers to educate people with CKD about dietary adaptations regarding sodium, phosphorus, potassium, and protein intake, tailored to their individual needs, and severity of CKD and other comorbid conditions.",
    "ground_truth_context": "Standardized educational topics should cover 3 main subject areas: knowledge about CKD, knowledge about treatment to slow progression and complications of CKD, and knowledge about the kidney failure management options.",
    "is_correct": false
  },
  {
    "question": "A 35-year-old male presents with a 2-day history of fever, cough, and shortness of breath. He is diagnosed with community-acquired pneumonia (CAP). He is admitted to the hospital.  What is the recommended approach to determine if he needs a higher level of care (ICU admission)?",
    "options": [
      "Use a clinical prediction tool plus clinical judgment.",
      "Rely solely on clinical judgment.",
      "Use a serum procalcitonin test to assess disease severity",
      "Obtain blood cultures and wait for results before deciding on level of care."
    ],
    "correct_answer_text": "Use a clinical prediction tool plus clinical judgment.",
    "correct_answer_idx": 0.0,
    "model_answer": "A",
    "model_answer_idx": 0,
    "model_reasoning": "The context mentions the use of specific clinical indicators (urea level, respiratory rate, blood pressure, and age) to determine the need for hospitalization in adults diagnosed with CAP. This implies that a structured approach, such as a clinical prediction tool combined with clinical judgment, is recommended to assess the need for a higher level of care, like ICU admission. Options B, C, and D do not align with the context's emphasis on a systematic approach for decision-making.",
    "reasoning_ground_truth": "For determining inpatient care, the guidelines recommends using a clinical severity tool like the IDSA/ATS minor criteria combined with clinical judgment to assess the need for higher intensity of treatment such as ICU admission. Other options do not use the best evidence based approach.",
    "context": "Given the expansion in information related to the diagnostic, therapeutic, and management decisions for the care of patients with CAP, we have purposely narrowed the scope of this guideline to address decisions from the time of clinical diagnosis of pneumonia (i.e., signs and symptoms of pneumonia\nIn Adults with CAP, Should a Respiratory Sample Be Tested for In\ufb02uenza Virus at the Time of Diagnosis?\nIn the Inpatient Setting, Should Patients with Suspected Aspiration Pneumonia Receive Additional Anaerobic Coverage beyond Standard Empiric Treatment for CAP?\nwith CAP has potential to decrease unnecessary variability in admission rates, the high cost of inpatient pneumonia treatment (53, 54), and the risk of hospital-acquired complications.\nurea level, respiratory rate, blood pressure, and age &gt;=65) (conditional recommendation, low quality of evidence), to determine the need for hospitalization in adults diagnosed with CAP.",
    "ground_truth_context": "We recommend the 2007 IDSA/ATS severe CAP criteria over other published scores, because they are composed of readily available severity parameters and are more accurate than the other scores described above.",
    "is_correct": true
  },
  {
    "question": "A 58-year-old patient with CKD is being evaluated for the cause of his condition. After initial evaluation, a kidney biopsy is being considered. When is it most appropriate to perform a kidney biopsy?",
    "options": [
      "When the eGFR is below 30 mL/min/1.73 m\u00b2.",
      "When it is thought that it can provide information for cause and treatment.",
      "If the CKD is suspected to be caused by diabetes.",
      "Only after all other tests have been exhausted."
    ],
    "correct_answer_text": "When it is thought that it can provide information for cause and treatment.",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context emphasizes that the Work Group values the kidney biopsy for its ability to establish the cause of CKD more accurately and potentially provide prognostic information. It indicates that the decision to perform a kidney biopsy should be based on whether it can provide useful information regarding the cause and treatment of the condition, aligning directly with option B. The other options do not reflect the specific criteria mentioned in the context for when a kidney biopsy is deemed appropriate.",
    "reasoning_ground_truth": "Kidney biopsy should be considered when it can provide information to identify the cause, facilitate prognostication and treatment strategies.. The eGFR value does not dictate the need for a biopsy. Other options are not the correct reason for performing a biopsy.",
    "context": "This recommendation places a high value on an acceptable safety profile of kidney biopsies when used to evaluate the cause of CKD and to plan appropriate treatment.\nValues and preferences. The Work Group judged that many people with CKD would choose to undergo a kidney biopsy to establish the cause of their CKD more accurately and potentially offer prognostic information. Thus, this recommendation puts a high value on the specificity of a kidney biopsy for the\nof a kidney biopsy for the evaluation of cause as well as the very low certainty evidence demonstrating a low risk of complications associated with kidney biopsy. Because the potential that the information gleaned from the biopsy may not directly or immediately benefit the person, the Work Group\ndepends on clinical judgment, with earlier evaluation for those suspected of having AKI and later evaluation for those suspected of having CKD.\nDetermine the additional value of genetic testing in people with CKD, both with and without kidney biopsy, for determination of cause, prognosis, and treatment choices.",
    "ground_truth_context": "Kidney biopsy is an important part of the investigations for the cause of CKD. It is often deferred because of the potential for harm or lack of recognition of potential utility. The evi-dence to support safety of biopsy is heterogeneous and therefore uncertain, but in the studies evaluated, appears to confer low risk of harm, supporting our suggestion that kidney biopsies should be considered when it is thought that they can provide information to identify cause, facilitate prognostication, and inform treatment strategies.",
    "is_correct": true
  },
  {
    "question": "A 65-year-old male with a history of atrial fibrillation and CKD is being started on anticoagulation. What is the most appropriate approach for selecting the medication?",
    "options": [
      "Start warfarin and monitor INR closely.",
      "Use a non-vitamin K antagonist oral anticoagulant (NOAC) without regard to kidney function.",
      "Use a NOAC, but monitor for bleeding risks.",
      "Avoid anticoagulation due to the risk of bleeding."
    ],
    "correct_answer_text": "Use a NOAC, but monitor for bleeding risks.",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context recommends the use of non\u2013vitamin K antagonist oral anticoagulants (NOACs) in preference to vitamin K antagonists (e.g., warfarin) for thromboprophylaxis in atrial fibrillation in people with CKD G1\u2013G4. It also notes the necessity of considering dose adjustments in people with chronic kidney disease. Therefore, using a NOAC while monitoring for bleeding risks aligns with the recommendations provided in the context.",
    "reasoning_ground_truth": "The guideline addresses the use of NOACs in CKD with atrial fibrillation, and recommends their use while being mindful of bleeding risks. Warfarin is not recommended due to challenges with monitoring and efficacy. Anticoagulation is not contraindicated, and a careful assessment of benefit and harm should be made. NOAC use in CKD requires assessment of dose and kidney function.",
    "context": "43. Su X, Yan B, Wang L, et al. Oral anticoagulant agents in patients with atrial fibrillation and CKD: a systematic review and pairwise network meta-analysis. Am J Kidney Dis. 2021;78:678\u2013689.e1.\nRecent cardiology guidelines recommend a risk factor\u2013based approach to stroke thromboprophylaxis decisions in atrial fibrillation using the Congestive heart failure, Hypertension, Age $75 (doubled), Diabetes, Stroke (doubled), Vascular disease, Age 65 to 74, and Sex category (female) (CHA 2DS -2\nWe recommend use of non\u2013vitamin K antagonist oral anticoagulants (NOACs) in preference to vitamin K antagonists (e.g., warfarin) for thromboprophylaxis in atrial \ufb01brillation in people with CKD G1\u2013G4 (1C).\nWe recommend use of non\u2013vitamin K antagonist oral anticoagulants (NOACs) in preference to vitamin K antagonists (e.g., warfarin) for thromboprophylaxis in atrial fibrillation in people with CKD G1\u2013G4 (1C).\nFigure 40 | Strategies for the diagnosis and management of atrial fibrillation. *Consider dose adjustments necessary in people with chronic kidney disease (CKD). \u2020The following has been recommended as a standard package for diagnostic evaluation of new atrial fibrillation: (i) a 12-lead",
    "ground_truth_context": "Figure S12. PRISMA diagram for the clinical question \u201cWhat are the effects of NOACs with or without warfarin compared to placebo or warfarin alone among people with CKD and atrial fibrillation in terms of stroke and bleeding risks?\u201d",
    "is_correct": true
  },
  {
    "question": "A 75 year old male is admitted to the hospital with decompensated heart failure. He is treated with IV furosemide but remains volume overloaded. What type of fluid should be used for volume resuscitation in this case?",
    "options": [
      "0.9% Normal Saline",
      "5% Dextrose in water",
      "Albumin",
      "Lactated Ringers Solution"
    ],
    "correct_answer_text": "Albumin",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context indicates that \"there is little evidence supporting the use of any specific fluid for volume loading in ALF,\" suggesting that the choice of fluid should be guided by the clinical situation. In the case of a patient with decompensated heart failure who is volume overloaded, the use of albumin is often considered in critical care settings for volume resuscitation, especially when managing fluid balance. The other options (0.9% Normal Saline, 5% Dextrose in water, and Lactated Ringers Solution) do not align with the context's emphasis on the need for careful fluid management in volume overload situations.",
    "reasoning_ground_truth": "While saline can be used for volume resuscitation, in patients with severe hypoalbuminemia from liver failure or heart failure, albumin can be used as a drug for volume resuscitation. Although this patient does not have liver failure, his use case is similar.",
    "context": "- Volume overload is as detrimental as underfilling (evidence level II-2, grade of recommendation 1).\n- Hypoxic hepatitis will require consideration of inotropic agents (evidence level II-3, grade of recommendation 1).\n- Most patients are volume depleted at presentation and require crystalloid volume resuscitation (evidence level II-1, grade of recommendation 1).\nor renal failure), then it is highly likely that they are volume depleted and will respond to an appropriate fluid challenge. There is little evidence supporting the use of any specific fluid for volume loading in ALF. However, general critical care literature [130\u2013133]. The choice should be guided\nin the normal range and avoid excessive fluid overload. Assessment of volume status in a ward environment may be challenging. In the initial phases of hyperacute and acute presentation, falls in lactate may allow assessment of volume responsiveness [114]. However, subsequent lactate reflects a\nFollowing adequate volume loading, persistent hypotension requires treatment with vasopressors. Given the usual clinical picture in ALF of an elevated cardiac output and decreased vascular tone, norepinephrine, at a starting dose of 0.05 lg/kg/min. Additional low dose vasopressin (1\u20132 units/hour),",
    "ground_truth_context": "If used in this context, albumin should be viewed more as a drug, than as a resuscitative solution.",
    "is_correct": true
  },
  {
    "question": "A 50 year old male is admitted for a planned coronary artery bypass graft (CABG) surgery. He is currently on dual antiplatelet therapy (DAPT).  What is the recommendation for continuation of DAPT?",
    "options": [
      "DAPT should be stopped at least 5 days prior to surgery.",
      "DAPT should be continued through the surgery",
      "DAPT should be stopped 7 days prior to surgery",
      "DAPT should be continued up to 3 days prior to surgery"
    ],
    "correct_answer_text": "DAPT should be stopped at least 5 days prior to surgery.",
    "correct_answer_idx": 0.0,
    "model_answer": "A",
    "model_answer_idx": 0,
    "model_reasoning": "The context indicates that issues related to the timing of discontinuation of DAPT before CABG are addressed in the 2011 CABG guideline, but it does not provide specific recommendations for the timing of stopping DAPT. However, the common clinical practice, supported by various guidelines, suggests that DAPT should typically be stopped at least 5 days prior to surgery to reduce the risk of bleeding. Therefore, option A aligns with standard recommendations, even though the context does not explicitly state this. Options B, C, and D do not reflect the typical recommendations for DAPT management before CABG.",
    "reasoning_ground_truth": "While the guidelines focus on duration of DAPT, the general consensus for elective surgeries including CABG is to stop DAPT at least 5 days prior to surgery, with some exceptions made for very high risk patients.",
    "context": "|COR|LOE|RECOMMENDATION|\n|---|---|---|\n|I|C-LD|In patients with ACS being treated with DAPT who undergo CABG, P2Y12 inhibitor therapy should be resumed after CABG to complete 12 months of DAPT therapy after ACS (52\u201354,118\u2013120).|\n|I|C-LD|In patients with ACS (NSTE-ACS or STEMI) being treated with DAPT who undergo CABG, P2Y12 inhibitor therapy should be resumed after CABG to complete 12 months of DAPT therapy after ACS (52\u201354,118\u2013120).| |\nThe scope of this focused update is limited to addressing recommendations on duration of dual antiplatelet therapy (DAPT) (aspirin plus a P2Y12 inhibitor) in patients with coronary artery disease (CAD). Recommendations considered are those in 6 guidelines: \u201c2011 ACCF/AHA/SCAI Guideline for\n|---|---|---|---|\n|In patients treated with DAPT after coronary stent implantation who subsequently undergo CABG, P2Y12 inhibitor therapy should be resumed postoperatively so that DAPT continues until the recommended duration of therapy is completed.|I|C-EO| |\nIssues related to the timing of discontinuation of DAPT before CABG are beyond the scope of this update but are addressed in the 2011 CABG guideline (10). Figure 3 summarizes recommendations for the management and duration of P2Y12 inhibitor therapy in patients undergoing CABG.",
    "ground_truth_context": "Issues and recommendations with regard to P2Y12 inhibitor \u201cpre-treatment,\u201d \u201cpreloading,\u201d and loading are beyond the scope of this document but are addressed in other guidelines.",
    "is_correct": true
  },
  {
    "question": "A 60-year-old male with a history of hypertension presents with a persistent cough, fever, and shortness of breath. A chest X-ray reveals a right lower lobe infiltrate. Initial blood cultures are negative. What is the most appropriate next step in his management?",
    "options": [
      "Start empiric antibiotic therapy for community-acquired pneumonia (CAP)",
      "Prescribe cough suppressants and monitor symptoms",
      "Perform a bronchoscopy to obtain lower respiratory secretions for culture",
      "Order a CT scan of the chest with contrast to rule out pulmonary embolism"
    ],
    "correct_answer_text": "Start empiric antibiotic therapy for community-acquired pneumonia (CAP)",
    "correct_answer_idx": 0.0,
    "model_answer": "A",
    "model_answer_idx": 0,
    "model_reasoning": "The context discusses management for adults with community-acquired pneumonia (CAP), indicating that if a patient presents with symptoms such as cough, fever, and shortness of breath, along with a chest X-ray showing infiltrates, the appropriate next step is to start empiric antibiotic therapy for CAP. The initial blood cultures being negative does not negate the need for antibiotic treatment, as the context suggests initiating therapy for pneumonia when indicated. Options B, C, and D do not align with the immediate management steps outlined for CAP in the context.",
    "reasoning_ground_truth": "The patient's symptoms and chest X-ray findings are consistent with CAP. The guidelines recommend initiating **empiric antibiotic therapy** for possible bacterial infection or coinfection. Although blood cultures are recommended, they should not delay the start of antibiotic treatment. The other options are not the first-line steps for a typical CAP case.",
    "context": "In adults with CAP whose symptoms have resolved within 5 to 7 days, we suggest not routinely obtaining follow-up chest imaging (conditional recommendation, low quality of evidence).\nswab is positive, coverage for MRSA pneumonia should generally be initiated, but blood and sputum cultures should be sent and therapy deescalated if cultures are negative.\nand symptoms of pneumonia with radiographic confirmation) to completion of antimicrobial therapy and follow-up chest imaging.\nWe suggest testing for Legionella urinary antigen and collecting lower respiratory tract secretions for Legionella culture on selective media or Legionella nucleic acid amplification testing in adults with severe CAP (conditional recommendation, low quality of evidence).\nGiven the variability of NTM lung disease severity and response to treatment, patients should be closely comanaged with an infectious disease or pulmonary specialist.",
    "ground_truth_context": "our recommendations are to initially treat empirically for possible bacterial infection or coinfection. Routinely obtaining blood cultures may generate false-positive results that lead to unnecessary antibiotic use and increased length of stay.",
    "is_correct": true
  },
  {
    "question": "A 72-year-old female with known chronic kidney disease (CKD) and type 2 diabetes is admitted for a urinary tract infection. Her estimated glomerular filtration rate (eGFR) based on serum creatinine (SCr) is 35 mL/min/1.73 m\u00b2. What is the most appropriate approach for medication dosing?",
    "options": [
      "Use eGFR based solely on serum creatinine for drug dosing.",
      "Use equations that combine both creatinine and cystatin C for drug dosing.",
      "Immediately initiate dialysis",
      "Discontinue all medications until the patient's kidney function improves."
    ],
    "correct_answer_text": "Use equations that combine both creatinine and cystatin C for drug dosing.",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context emphasizes the importance of using a combination of creatinine and cystatin C for estimating GFR in adults at risk for CKD. It specifically states that if cystatin C is available, the GFR category should be estimated from both creatinine and cystatin C. This approach is crucial for accurately assessing kidney function and guiding medication dosing, especially in older adults with CKD. Therefore, option B is the most appropriate approach for medication dosing in this scenario.",
    "reasoning_ground_truth": "For most people, validated eGFR equations using SCr are appropriate for drug dosing. However, when **more accuracy** is needed, such as with a narrow therapeutic range, drug toxicity, or when eGFR estimates may be unreliable, equations that combine both creatinine and cystatin C, or measured GFR may be indicated.",
    "context": "Implications for aging adults with CKD are important in both diagnosis and treatment. The interpretation of laboratory results (specifically SCr) used in the staging system should factor in an older adult\u2019s habitus given the frequency of sarcopenia. A creatinine-based eGFR (eGFRcr) will\nRecommendation 1.1.2.1: In adults at risk for CKD, we recommend using creatinine-based estimated glomerular filtration rate (eGFRcr). If cystatin C is available, the GFR category should be estimated from the combination of creatinine and cystatin C (creatinine and cystatin C\u2013based estimated\nRecommendation 1.1.2.1: In adults at risk for CKD, we recommend using creatinine-based estimated glomerular filtration rate (eGFRcr). If cystatin C is available, the GFR category should be estimated from the combination of creatinine and cystatin C (creatinine and cystatin C\u2013based estimated\ndecisions as an assessment of excretory kidney function (Table 4) to detect and stage AKD and CKD, determine CKD progression, dose medications, determine appropriate use of diagnostic tests, and guide treatment decisions around KRT therapies. Equations are available that estimate GFR using SCr and\nTable S3. Adults and children with or without CKD, estimated GFR (eGFR) based on measurements of cystatin C (eGFRcys); creatinine (eGFRcr); cystatin C and creatinine (eGFRcr-cys) versus measured GFR (mGFR; using urinary or plasma clearance of exogenous filtration marker)Table S4. Adults and children",
    "ground_truth_context": "Where more accuracy is required for drug-related decision-making (e.g., dosing due to narrow therapeutic or toxic range), drug toxicity, or clinical situations where eGFRcr estimates may be unreliable, use of equations that combine both creatinine and cystatin C, or measured GFR may be indicated.",
    "is_correct": true
  },
  {
    "question": "A 55-year-old male presents with a first-time seizure lasting 7 minutes. He has no history of epilepsy. Intravenous (IV) access is difficult to obtain. What is the preferred initial pharmacologic treatment?",
    "options": [
      "Intramuscular midazolam",
      "IV lorazepam",
      "IV phenytoin",
      "Rectal diazepam"
    ],
    "correct_answer_text": "Intramuscular midazolam",
    "correct_answer_idx": 0.0,
    "model_answer": "A",
    "model_answer_idx": 0,
    "model_reasoning": "The context states that in adults, intramuscular (IM) midazolam is established as efficacious at stopping seizures lasting at least 5 minutes, especially when intravenous access is difficult to obtain. Since the patient in the scenario has a seizure lasting 7 minutes and IV access is challenging, IM midazolam is the preferred initial pharmacologic treatment. Other options like IV lorazepam and IV phenytoin are not viable due to the difficulty in obtaining IV access.",
    "reasoning_ground_truth": "For patients with convulsive status epilepticus where **IV access is difficult**, intramuscular midazolam is superior to intravenous lorazepam. IV lorazepam is a first line treatment for status epilepticus, but if an IV line cannot be established, IM midazolam is prefered. Rectal diazepam is a reasonable alternative, but midazolam has better effectiveness when IV access is not established.",
    "context": "or longer, or two or more GTC seizures without full recovery of consciousness. A treatment was successful if the status epilepticus stopped within 20 minutes after infusion started with no recurrence prior to 60 minutes. Overall, 570 patients were randomized to either lorazepam (n = 146), diazepam\nlorazepam in adults with convulsive status epilepticus without established intravenous access (Level A). In children, intravenous lorazepam and intravenous diazepam are established as efficacious at stopping seizures lasting at least 5 minutes (Level A) while rectal diazepam, intramuscular\nThe following conclusions were drawn. In adults, IM midazolam, IV lorazepam, IV diazepam (with or without phenytoin), and IV phenobarbital are established as efficacious at stopping seizures lasting at least 5 minutes (level A). Intramuscular midazolam has superior effectiveness compared with IV\nold whose seizures did not respond to IV diazepam (0.2 mg/kg) within 5 minutes. No significant difference was noted in efficacy between valproic acid and phenobarbital for terminating seizures within 20 minutes, but the valproic acid group experienced significantly fewer clinically significant\nmg/kg), diazepam (0.15 mg/kg) followed by phenytoin (18 mg/kg), phenobarbital (18 mg/kg), and phenytoin alone (18 mg/kg) in adults with either overt or subtle status epilepticus (22). Overt status epilepticus was defined as a continuous GTC seizure lasting 10 minutes or longer, or two or more GTC",
    "ground_truth_context": "In adults with convulsive status epilepticus, intramuscular midazolam, intravenous lorazepam, intravenous diazepam and intravenous phenobarbital are established as efficacious as initial therapy (Level A). Intra-muscular midazolam has superior effectiveness compared to intravenous lorazepam in adults with convulsive status epilepticus without established intravenous access (Level A).",
    "is_correct": true
  },
  {
    "question": "A 48-year-old woman with a history of heavy alcohol use presents with jaundice, ascites, and confusion. She has been diagnosed with alcoholic hepatitis. What is the initial nutritional recommendation?",
    "options": [
      "Restrict fluid intake to manage ascites",
      "Initiate a high-protein, low-carbohydrate diet",
      "Start enteral nutrition with a standard formula",
      "Delay nutritional support until her liver function stabilizes"
    ],
    "correct_answer_text": "Start enteral nutrition with a standard formula",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context discusses the importance of adequate calorie and protein intake through supplementation in patients with alcoholic hepatitis. It emphasizes the need for nutritional support, particularly in cases of protein-energy malnutrition associated with severe alcoholic hepatitis. Starting enteral nutrition with a standard formula aligns with the recommendation for nutritional support in these patients, making option C the most appropriate choice. Options A, B, and D do not directly support the need for immediate nutritional intervention as indicated in the context.",
    "reasoning_ground_truth": "The patient has signs of liver disease, which requires nutritional management. Based on the liver disease guideline, enteral nutrition should be started and is a safe route for delivery of nutritional support for patients with liver disease. Restricting fluids and or delaying nutrition may cause significant harm.",
    "context": "51. Galambos JT, Hersh T, Fulenwider JT, Ansley JD, Rudman D. Hyperalimentation in alcoholic hepatitis. Am J Gastroenterol 1979;72(5):535e41.\n19. Bunout D, Aicardi V, Hirsch S, Petermann M, Kelly M, Silva G, et al. Nutritional support in hospitalized patients with alcoholic liver disease. Eur J Clin Nutr 1989;43(9):615e21.\n21. Mendenhall CL, Tosch T, Weesner RE, Garcia-Pont P, Goldberg SJ, Kiernan T, et al. VA cooperative study on alcoholic hepatitis. II: prognostic significance of protein-calorie malnutrition. Am J Clin Nutr 1986;43(2):213e8.\nadequate calorie and protein intake by supplementation. Whether alcoholic hepatitis is a state of accelerated starvation akin to cirrhosis has not been directly reported, metabolomic studies and metabolic cart studies suggest hyper-metabolism, accelerated lipolysis and accelerated starvation\n20. Mendenhall CL, Moritz TE, Roselle GA, Morgan TR, Nemchausky BA, Tamburro CH, et al. Protein energy malnutrition in severe alcoholic hepatitis: diagnosis and response to treatment. The VA cooperative study group #275. J Parenter Enteral Nutr 1995;19(4):258e65.",
    "ground_truth_context": "A total of 85 recommendations were made for the nutritional and metabolic management of patients with acute liver failure, severe alcoholic steatohepatitis, non-alcoholic fatty liver disease, liver cirrhosis, liver surgery and transplantation as well as nutrition associated liver injury",
    "is_correct": true
  },
  {
    "question": "A 50-year-old patient with a history of coronary artery disease underwent percutaneous coronary intervention (PCI) with drug-eluting stent placement. How long should dual antiplatelet therapy (DAPT) be continued?",
    "options": [
      "3 months",
      "6 months",
      "12 months",
      "24 months"
    ],
    "correct_answer_text": "12 months",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context states that patients with NSTE-ACS treated with coronary stent implantation should be treated with DAPT for at least 12 months, based on evidence from the CURE trial and other studies. This recommendation applies to patients undergoing PCI, which includes those with drug-eluting stents. Therefore, the correct duration for continuing DAPT in this scenario is 12 months.",
    "reasoning_ground_truth": "For most patients, 12 months of DAPT is the recommended or minimal duration of therapy following PCI with drug-eluting stent placement. The duration can vary based on the patient profile, but 12 months is the standard recommendation.",
    "context": "monotherapy (Data Supplement 4). Based primarily on the CURE trial and PCI-CURE analyses, the prior recommendation that patients with NSTE-ACS treated with coronary stent implantation be treated with DAPT for at least 12 months is continued in this update and has been extrapolated to patients with\nboth in those treated with revascularization (PCI or CABG) and in those treated with medical therapy alone (51,52). Available evidence from this trial, as well as from PLATO (53,71,72) and TRITON-TIMI 38 (54,55), supports DAPT duration of at least 12 months for patients with NSTE-ACS.\nIn studies of drug-eluting bioabsorbable polymer stents and bioabsorbable stents (third- and fourth-generation stents), by study protocol, DAPT was continued for at least 6 to 12 months (110\u2013116). In a study of a novel polymer-free and carrier-free drug-coated stent in patients at high risk of\n|IIb|ASR|In patients with ACS treated with coronary stent implantation who have tolerated DAPT without bleeding complication and who are not at high bleeding risk (e.g., prior bleeding on DAPT, coagulopathy, oral anticoagulant use) continuation of DAPT for longer than 12 months may be reasonable\n|---|---|---|---|\n|In patients treated with DAPT after coronary stent implantation who subsequently undergo CABG, P2Y12 inhibitor therapy should be resumed postoperatively so that DAPT continues until the recommended duration of therapy is completed.|I|C-EO| |",
    "ground_truth_context": "Most contemporary studies of DAPT have compared either shorter (3 to 6 months) (17\u201321) or longer (18 to 48 months) (16,22\u201326) duration of therapy with 12 months of DAPT, which is the recom-mended or minimal duration of therapy for most patients in ACC/AHA (9,13,14) and European Society of Cardiology (31\u201333) guidelines published between 2011 and 2014.",
    "is_correct": true
  },
  {
    "question": "A 68-year-old male with a history of benign prostatic hyperplasia (BPH) and hypertension presents with new-onset fatigue, constipation, and dry skin. His TSH level is elevated, and free T4 level is low. What is the appropriate initial treatment?",
    "options": [
      "Liothyronine (T3) monotherapy",
      "Combination of levothyroxine (T4) and liothyronine (T3)",
      "Levothyroxine (T4) monotherapy",
      "Thyroid-stimulating hormone (TSH) injection therapy"
    ],
    "correct_answer_text": "Levothyroxine (T4) monotherapy",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context specifies that for patients older than 50-60 years with overt hypothyroidism, an initial L-thyroxine (T4) dose of 50 \u00b5g daily should be considered. The patient in the question is 68 years old and presents with symptoms consistent with hypothyroidism, along with elevated TSH and low free T4 levels. Therefore, the appropriate initial treatment for this patient is Levothyroxine (T4) monotherapy, as indicated in the context.",
    "reasoning_ground_truth": "The patient's symptoms and lab results are consistent with primary hypothyroidism. The standard treatment is replacement with L-thyroxine (T4). Combination therapy with T3 is not recommended in the majority of cases.",
    "context": "When initiating therapy in patients older than 50-60 years with overt hypothyroidism, without evidence of coronary heart disease, an L-thyroxine dose of 50 \u00b5g daily should be considered. Grade D, BEL 4  \nSee: L-thyroxine treatment of hypothyroidism\nTreatment based on individual factors for patients with TSH levels between the upper limit of a given laboratory\u2019s reference range and 10 mIU/L should be considered particularly if patients have symptoms suggestive of hypothyroidism, positive TPOAb or evidence of atherosclerotic cardiovascular\nwith L-thyroxine. This has been reported in 20% of those treated with thyroid hormone (12). The principal adverse consequences of subtle or frank overtreatment are cardiovascular (187-190), skeletal (191-194), and possibly affective disturbances (195-197). The elderly are particularly susceptible to\ntherapy (54,55) (see L-thyroxine treatment of hypothyroidism).\nSee: L-thyroxine treatment of hypothyroidism",
    "ground_truth_context": "The standard treatment is replacement with L-thyroxine which must be tailored to the individual patient.",
    "is_correct": true
  },
  {
    "question": "A 68-year-old male with a history of hypertension and type 2 diabetes presents with a 7-day history of cough, fever, and purulent nasal discharge. He reports no improvement with over-the-counter cold medications. What is the most appropriate next step in management?",
    "options": [
      "Initiate oral azithromycin for presumed community-acquired pneumonia (CAP)",
      "Prescribe a short course of oral prednisone for symptomatic relief",
      "Begin a course of amoxicillin with or without clavulanate for possible acute bacterial rhinosinusitis (ABRS)",
      "Order a chest x-ray to evaluate for pneumonia"
    ],
    "correct_answer_text": "Begin a course of amoxicillin with or without clavulanate for possible acute bacterial rhinosinusitis (ABRS)",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context indicates that a patient presenting with severe symptoms such as high fever and purulent nasal discharge is likely experiencing acute bacterial rhinosinusitis (ABRS), which warrants antibiotic therapy. The guidelines recommend considering a diagnosis of ABRS in patients with severe symptoms, and since the patient has not improved with over-the-counter medications, initiating a course of amoxicillin with or without clavulanate is the appropriate next step in management. Options A, B, and D do not align with the context regarding the management of ABRS.",
    "reasoning_ground_truth": "The patient's symptoms of fever, purulent nasal discharge, and lack of improvement with over-the-counter medications suggest **acute bacterial rhinosinusitis (ABRS)**. The appropriate initial treatment is amoxicillin with or without clavulanate. While pneumonia is a differential, the primary presentation is consistent with ABRS.  Azithromycin is an alternative for penicillin allergies but is not the first-line treatment for ABRS.",
    "context": "high fever and purulent nasal discharge as a \u201csevere\u201d presentation of ABRS that warrants antibiotic therapy. Similarly, the Infectious Disease Society of America guideline on ABRS recommended that the clinician consider a diagnosis of ABRS if the patient presented with severe symptoms at the onset\nto symptomatic therapy, especially when nasal discharge is colored or purulent. Existing educational material from the Centers for Disease Control and Prevention (CDC) Get Smart Campaign can be used by clinicians to help clarify misconceptions about viral illness and nasal discharge.\ncorroborate the diagnosis. 163 Examination of the middle meatus for purulence in the decongested state may strongly suggest ABRS and allows endoscopically guided culture.164\nClinicians should assess the patient with chronic rhinosinusitis or recurrent acute rhinosinusitis for multiple chronic conditions that would modify management such as asthma, cystic fibrosis, immunocompromised state, and ciliary dyskinesia. Recommendation based on one systematic review and multiple\ndocumentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. The update group made recommendations that clinicians (1) should either offer watchful waiting (without antibiotics) or prescribe initial antibiotic therapy for",
    "ground_truth_context": "For acute bacterial rhinosinusitis (ABRS), amoxicillin with or without clavulanate is a recommended antibiotic. If a patient is allergic to penicillin, doxycycline or a respiratory quinolone can be used. Saline nasal irrigation and/or topical intranasal corticosteroids are recommended.",
    "is_correct": true
  },
  {
    "question": "A 55-year-old female with a history of chronic kidney disease (CKD) and hypertension is started on a new medication for her blood pressure. After two weeks she returns to the clinic for follow up reporting muscle weakness. Her labs show an increase in serum potassium. What is the most appropriate next step?",
    "options": [
      "Discontinue the new blood pressure medication immediately.",
      "Add a potassium-binding agent and continue the medication, with dietary modification",
      "Refer to nephrology for hemodialysis evaluation",
      "Prescribe an oral diuretic and schedule a follow-up in one week"
    ],
    "correct_answer_text": "Add a potassium-binding agent and continue the medication, with dietary modification",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context emphasizes the importance of an individualized approach for patients with CKD and emergent hyperkalemia, which includes dietary and pharmacologic interventions. Given the patient's increased serum potassium, adding a potassium-binding agent while continuing the blood pressure medication aligns with the recommended management strategies for hyperkalemia in CKD patients. Discontinuing the medication (Option A) may not be necessary without further assessment, and referring for hemodialysis (Option C) is not indicated at this stage. Prescribing an oral diuretic (Option D) does not directly address the hyperkalemia as effectively as a potassium-binding agent would.",
    "reasoning_ground_truth": "The patient's hyperkalemia, likely from her new blood pressure medication, can often be managed without stopping the medication. The appropriate step would be to add a potassium-binding agent, implement individualized dietary approaches, and monitor potassium levels.  Discontinuing the medication should be considered as a last resort,.",
    "context": "Practice Point 3.11.5.1: Implement an individualized approach in people with CKD G3\u2013G5 and emergent hyperkalemia that includes dietary and pharmacologic interventions and takes into consideration associated comorbidities and quality of life (QoL). Assessment and education through a renal dietitian\nPractice Point 3.11.5.1: Implement an individualized approach in people with CKD G3\u2013G5 and emergent hyperkalemia that includes dietary and pharmacologic interventions and takes into consideration associated comorbidities and quality of life (QoL). Assessment and education through a renal dietitian\nPractice Point 4.1.2: Monitor eGFR, electrolytes, and therapeutic medication levels, when indicated, in people with CKD receiving medications with narrow therapeutic windows, potential adverse effects, or nephrotoxicity, both in outpatient practice and in hospital settings.\n- Appropriate monitoring and treatment of laboratory abnormalities of CKD associated with implications for health (e.g., anemia, CKD-MBD, potassium disorders, acidosis)\nPerform thorough medication review periodically and at transitions of care to assess adherence, continued indication, and potential drug interactions because people with CKD often have complex medication regimens and are seen by multiple specialists.",
    "ground_truth_context": "Hyperkalemia associated with RASi use can often be managed without stopping RASi. Individualized dietary approaches should be implemented for those with hyperkalemia.",
    "is_correct": true
  },
  {
    "question": "A 72-year-old male with a history of stable ischemic heart disease (SIHD) is being discharged after a recent hospitalization for pneumonia, He has been on dual antiplatelet therapy (DAPT) for 12 months following a percutaneous coronary intervention (PCI). What is the most appropriate duration of DAPT at this point?",
    "options": [
      "Continue DAPT for an additional 12 months.",
      "Stop DAPT and continue on aspirin alone.",
      "Reduce DAPT to single antiplatelet therapy with clopidogrel",
      "Reduce DAPT to single antiplatelet therapy with aspirin"
    ],
    "correct_answer_text": "Reduce DAPT to single antiplatelet therapy with aspirin",
    "correct_answer_idx": 3.0,
    "model_answer": "A",
    "model_answer_idx": 0,
    "model_reasoning": "The context indicates that in patients with stable ischemic heart disease (SIHD) who have tolerated dual antiplatelet therapy (DAPT) without bleeding complications and are not at high bleeding risk, further continuation of DAPT may be appropriate. Since the patient has been on DAPT for 12 months following PCI and there is no indication of high bleeding risk, it supports the continuation of DAPT for an additional 12 months.",
    "reasoning_ground_truth": "For patients with a history of ACS greater than one year prior, and who have since been stable, their condition is considered SIHD. At this point the current recommendation is to continue treatment with Aspirin alone.",
    "context": "|IIb|A SR|In patients with SIHD being treated with DAPT for an MI that occurred 1 to 3 years earlier who have tolerated DAPT without a bleeding complication and who are not at high bleeding risk (e.g., prior bleeding on DAPT, coagulopathy, oral anticoagulant use), further continuation of DAPT may\n|I|B-RSR|In patients with SIHD treated with DAPT after DES implantation, P2Y12 inhibitor therapy (clopidogrel) should be given for at least 6 months (17,18,21,30,96,97).|\n|I|B-NR|In patients treated with DAPT, a daily aspirin dose of 81 mg (range, 75 mg to 100 mg) is recommended (56\u201360,75\u201378).|\n|I|B-RSR|In patients with SIHD treated with DAPT after DES implantation, P2Y12 inhibitor therapy (clopidogrel) should be given for at least 6 months (17,18,21,30,96,97).|\n|I|B-NR|In patients treated with DAPT, a daily aspirin dose of 81 mg (range, 75 mg to 100 mg) is recommended (56\u201360,75\u201378).|\nThe benefit/risk ratio of prolonged DAPT in patients treated with PCI may be more favorable for those with prior MI (or ACS) than for those with SIHD (28,41,43). Preliminary data suggest that in patients with a high DAPT score the benefit/risk ratio with prolonged DAPT may be favorable and that in\nwhom P2Y12 inhibitor therapy had been discontinued >1 year before enrollment in the study (42). On the basis of all studies of DAPT in post-MI patients, extended DAPT for P2Y12 inhibitor therapy in patients with SIHD.",
    "ground_truth_context": "For purposes of this focused update, patients with a history of acute coronary syndrome (ACS) >1 year prior who have since remained free of recurrent ACS are considered to have transitioned to stable ischemic heart disease (SIHD) and are addressed in the section on SIHD.",
    "is_correct": false
  },
  {
    "question": "A 30-year-old female presents to the emergency department with a generalized tonic-clonic seizure lasting 7 minutes. She has no prior history of seizures, and IV access has not yet been established. What is the most appropriate initial therapy?",
    "options": [
      "Intravenous lorazepam",
      "Intramuscular midazolam",
      "Intravenous fosphenytoin",
      "Rectal diazepam"
    ],
    "correct_answer_text": "Intramuscular midazolam",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context specifies that in children, intravenous lorazepam and intravenous diazepam are established as efficacious for stopping seizures lasting at least 5 minutes. However, it does not mention intravenous lorazepam as an option when IV access has not been established. The context implies that for situations without established IV access, alternatives like intramuscular midazolam or rectal diazepam may be more appropriate. Since the question specifies that IV access has not yet been established, the most appropriate initial therapy would be intramuscular midazolam (option B), as it is suitable for cases where IV access is not available.",
    "reasoning_ground_truth": "In adults with convulsive status epilepticus and without established IV access, **intramuscular midazolam** is the recommended first-line therapy because it is efficacious and rapidly administered. Intravenous lorazepam is preferred if IV access is established. Fosphenytoin is second-line therapy. Rectal diazepam is an alternative when the preferred options are not available.",
    "context": "or longer, or two or more GTC seizures without full recovery of consciousness. A treatment was successful if the status epilepticus stopped within 20 minutes after infusion started with no recurrence prior to 60 minutes. Overall, 570 patients were randomized to either lorazepam (n = 146), diazepam\nlorazepam in adults with convulsive status epilepticus without established intravenous access (Level A). In children, intravenous lorazepam and intravenous diazepam are established as efficacious at stopping seizures lasting at least 5 minutes (Level A) while rectal diazepam, intramuscular\nThe second-therapy phase should begin when the seizure duration reaches 20 minutes and should conclude by the 40-minute mark when response (or lack of response) to the second therapy should be apparent. Reasonable options include fosphenytoin (level U), valproic acid (level B, one class II study)\nThe algorithm starts with a stabilization phase (0\u20135 minutes), which includes standard initial first aid for seizures. The initial therapy phase should begin when the seizure duration reaches 5 minutes and should conclude by the 20-minute mark when response (or lack of response) to initial therapy\nmg/kg), diazepam (0.15 mg/kg) followed by phenytoin (18 mg/kg), phenobarbital (18 mg/kg), and phenytoin alone (18 mg/kg) in adults with either overt or subtle status epilepticus (22). Overt status epilepticus was defined as a continuous GTC seizure lasting 10 minutes or longer, or two or more GTC",
    "ground_truth_context": "In adults with convulsive status epilepticus, intramuscular midazolam, intravenous lorazepam, intravenous diazepam and intravenous phenobarbital are established as efficacious as initial therapy (Level A). Intra-muscular midazolam has superior effectiveness compared to intravenous lorazepam in adults with convulsive status epilepticus without established intravenous access (Level A).",
    "is_correct": true
  },
  {
    "question": "A 45-year-old male with a history of alcohol abuse presents with jaundice, ascites, and altered mental status. His labs indicate acute liver failure. He is hypotensive and requires volume resuscitation. What is the most appropriate fluid for volume resuscitation at this time?",
    "options": [
      "Normal saline",
      "Albumin",
      "Hypertonic saline",
      "Dextrose 5% in water"
    ],
    "correct_answer_text": "Normal saline",
    "correct_answer_idx": 0.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context discusses the management of patients with ascites due to acute liver failure and highlights the importance of assessing fluid resuscitation needs individually. It mentions that in patients with significant ascites, the presence of hypoxia may be alleviated by limited volume paracentesis, indicating that careful management of fluid status is crucial. While normal saline is a common resuscitation fluid, the context implies that albumin may be more appropriate in cases of ascites and liver failure, as it can help manage intravascular volume and oncotic pressure. Thus, albumin is the most suitable choice for volume resuscitation in this scenario.",
    "reasoning_ground_truth": "Normal saline is the appropriate first line treatment for hypotension in acute liver failure, prior to considering albumin, which should be considered as a drug rather than as a simple resuscitative solution.",
    "context": "In the cohort of patients with ascites due to subacute liver failure or acute Budd-Chiari syndrome, elevated intra-abdominal pressure may be present. This may alter response to volume loading, in addition to increasing risk of gut dysfunction and AKI, response to fluid resuscitation needs to be\nthe initial cardiac index. Drainage of some ascites may be recommended. Furthermore, hypoxic hepatitis is a secondary form of ALF and as such, the primary presenting organ failure needs to be addressed and managed to facilitate liver recovery. LTx is not indicated. The use of hydrocortisone to\nlung water may facilitate optimal management of these patients. In some patients with significant ascites, the presence of hypoxia [177], and may be alleviated by limited volume paracentesis.\nresuscitation needs to be assessed individually. In patients with elevated right sided cardiac pressures and ascites, further fluid therapy is likely to have limited or minimal improve venous return and improve cardiac index [148].\nStudies of microcirculatory resuscitation as opposed to pressures. Appropriate utilisation of VA status in patients with ALF and hypoxic hepatitis. In a few cases, there may also be evidence of a toxic liver syndrome with increased lung water and ARDS. Assessment of intra-abdominal lung water may",
    "ground_truth_context": "If used in this context, albumin should be viewed more as a drug, than as a resuscitative solution.",
    "is_correct": false
  },
  {
    "question": "A 60-year-old male with a history of primary open-angle glaucoma (POAG) has been using prescribed eye drops for the past year. During his annual ophthalmology visit, his intraocular pressure (IOP) is still elevated, and his optic nerve shows progressive damage. He reports variable adherence to his medication regimen. What is the most appropriate next step in management?",
    "options": [
      "Increase the dose of his current eye drops.",
      "Add a second medication to his current eye drops",
      "Review patient education materials and discuss adherence.",
      "Refer for surgical intervention immediately."
    ],
    "correct_answer_text": "Review patient education materials and discuss adherence.",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context emphasizes the importance of managing intraocular pressure (IOP) and preventing progressive damage in patients with primary open-angle glaucoma (POAG). Given that the patient has variable adherence to his medication regimen, reviewing patient education materials and discussing adherence is crucial to ensure he understands the importance of consistent medication use. This step is necessary before considering changes to his medication regimen or surgical options, as adherence issues can significantly impact treatment effectiveness.",
    "reasoning_ground_truth": "Patient education and adherence are crucial in the management of POAG. Before escalating therapy, it's essential to ensure the patient understands the importance of medication adherence and how to use them correctly.",
    "context": "Primary open-angle glaucoma (POAG) is a chronic, progressive optic neuropathy in adults in which\nthere is a characteristic acquired atrophy of the optic nerve and loss of retinal ganglion cells and their\naxons. This condition is associated with an open anterior chamber angle by gonioscopy. Primary\nThe diagnosis of POAG requires careful evaluation of the anterior chamber angle to exclude angle-closure glaucoma or secondary causes for IOP elevation, such as angle recession, pigment dispersion, pseudoexfoliation syndrome, peripheral anterior synechiae, angle neovascularization, and inflammatory\nThe goals of managing patients with POAG are to control IOP in a target range and to prevent progressive visual field and optic nerve/RNFL damage in order to preserve visual function and quality of life. The initial glaucoma evaluation includes all components of the comprehensive adult medical\nGuidelines for follow-up of patients with POAG are summarized in Table 7. These recommendations apply to ongoing glaucoma management and not to visits for other purposes. The purpose of follow-up examination is to evaluate IOP level, visual field status, and optic disc appearance as well as ONH,\nIf the diagnosis or management of POAG is in question, or if the condition is refractory to treatment, consultation with or referral to an ophthalmologist with special training or experience in managing glaucoma should be considered. Patients with substantial visual impairment or blindness can be",
    "ground_truth_context": "Patient education and informed participation in treatment decisions may improve adherence.",
    "is_correct": true
  },
  {
    "question": "A 50-year-old female with rheumatoid arthritis (RA) has been on methotrexate for three months. She reports improvement in joint pain, but still experiences morning stiffness and fatigue, indicating moderate disease activity. What is the most appropriate next step?",
    "options": [
      "Add a biologic DMARD to her current methotrexate.",
      "Increase the dose of methotrexate",
      "Add a short course of oral prednisone to the methotrexate.",
      "Continue methotrexate monotherapy for another 3 months"
    ],
    "correct_answer_text": "Continue methotrexate monotherapy for another 3 months",
    "correct_answer_idx": 3.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context indicates that methotrexate is conditionally recommended for patients with moderate-to-high disease activity. Since the patient is experiencing moderate disease activity despite some improvement, adding a short course of oral prednisone (Option C) would be an appropriate step to manage her symptoms while continuing methotrexate. The other options either suggest increasing the methotrexate dose or adding a biologic DMARD, which are not directly supported by the context for this specific situation.",
    "reasoning_ground_truth": "According to guidelines, initial treatment for moderate-to-high RA is with **methotrexate monotherapy** . A combination approach may be considered after a trial of methotrexate. This patient has not had an adequate trial on methotrexate as she is only 3 months into treatment and still showing moderate disease activity.",
    "context": "Methotrexate is conditionally recommended over alternative DMARDs for the treatment of inflammatory arthritis for patients with clinically diagnosed mild and stable airway or parenchymal lung disease, or incidental disease detected on imaging, who have moderate-to-high disease activity.\nrecommendation is in favor of methotrexate because of its important role as an anchor treatment in RA and the lack of alternatives with similar efficacy and/or superior long-term safety profiles.\nMethotrexate is conditionally recommended over alternative DMARDs for DMARD-naive patients with NAFLD, normal liver enzymes and liver function tests, and no evidence of advanced liver fibrosis who have moderate-to-high disease activity.\n- Does switching to non-methotrexate DMARDs improve tolerability over increasing the dose of folic acid, or using folinic acid or using split dose or subcutaneous dosing, for RA patients with side effects when taking methotrexate?\n|Methotrexate is conditionally recommended over alternative DMARDs for DMARD-naive patients with nonalcoholic fatty liver disease, normal liver enzymes and liver function tests, and no evidence of advanced liver fibrosis who have moderate-to high disease activity.|Very low|PICO 87|p. 489|",
    "ground_truth_context": "Methotrexate monotherapy is conditionally recommended over the combination of methotrexate plus a bDMARD or tsDMARD.",
    "is_correct": false
  },
  {
    "question": "A 22-year-old male presents with urethral discharge and dysuria for 3 days. A gram stain of the discharge shows gram-negative diplococci. Which of the following is the recommended treatment approach?",
    "options": [
      "Oral azithromycin monotherapy",
      "Intramuscular ceftriaxone and oral azithromycin",
      "Oral doxycycline for 7 days",
      "Oral ciprofloxacin for 3 days"
    ],
    "correct_answer_text": "Intramuscular ceftriaxone and oral azithromycin",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context indicates that adults and adolescents with treatment failure of N. gonorrhoeae should be treated with Gentamicin and azithromycin, but it does not specify the first-line treatment for uncomplicated gonococcal infections. However, it mentions the previous WHO Guidelines included ciprofloxacin as a first-line treatment, which is now outdated. The current recommended treatment for gonorrhoea typically includes a combination of ceftriaxone and azithromycin, which aligns with option B. The other options (A, C, D) do not reflect the recommended treatment for gonorrhoea as per the context provided.",
    "reasoning_ground_truth": "For gonococcal infections, the recommended treatment is **intramuscular ceftriaxone plus oral azithromycin**. This combination is used to address potential resistance and co-infection with chlamydia.",
    "context": "Uncomplicated gonococcal infection commonly manifests as urethritis in men with symptoms of urethral discharge and dysuria. On examination, the urethral discharge may range from scanty and mucoid to copious and purulent. Gonorrhoea is often asymptomatic in women; less than half of infected women\nGram-stained smears can provide a presumptive diagnosis of gonorrhoea, especially among symptomatic men with urethritis. In low-income settings, Gram stains may provide a less expensive alternative to NAATs for symptomatic men. However, only 50\u201370% of asymptomatic infections in men are positive on\nSince laboratory diagnostic tests are not available in the majority of countries, diagnosis is often made clinically, based on the presence of symptoms such as vaginal and urethral discharge. Presumptive treatment is sometimes provided to those at high risk of gonococcal infection, if indicated\n|Adults and adolescents with treatment failure of N. gonorrhoeae (genital or oropharyngeal) to cephalosporins|Gentamicin 240 mg IM + azithromycin 2 g orally x 1 Gentamicin 240 mg IM + azithromycin 1 g orally x 1 Spectinomycin 2 g IM + azithromycin 2 g orally x 1 Gemifloxacin 320 mg orally +\nthe eventual development of untreatable gonococcal infections with serious sexual and reproductive health consequences (6). The previous WHO Guidelines for the management of sexually transmitted infections, published in 2003 (7), include ciprofloxacin as a first-line treatment for gonorrhoea, even",
    "ground_truth_context": "Treatments for people with treatment failure of N. gonorrhoeae (genital or oropharyngeal). Included studies: randomized and non-randomized studies",
    "is_correct": true
  },
  {
    "question": "A 65-year-old male, recently hospitalized for an acute exacerbation of COPD, is being considered for discharge. He has been immobile for most of his hospital stay and has no other identified risk factors for VTE. Which VTE prophylaxis is recommended?",
    "options": [
      "Pharmacologic prophylaxis with subcutaneous heparin",
      "Mechanical prophylaxis with intermittent pneumatic compression devices",
      "Both pharmacologic and mechanical prophylaxis",
      "No VTE prophylaxis required due to low risk."
    ],
    "correct_answer_text": "Pharmacologic prophylaxis with subcutaneous heparin",
    "correct_answer_idx": 0.0,
    "model_answer": "A",
    "model_answer_idx": 0,
    "model_reasoning": "The context indicates that the ASH guideline panel recommends inpatient VTE prophylaxis with LMWH (low molecular weight heparin) for acutely ill hospitalized medical patients. Since the patient is being considered for discharge after being immobile during his hospital stay, pharmacologic prophylaxis with subcutaneous heparin (which is a form of LMWH) is the appropriate recommendation. The other options do not align with the specific recommendations provided in the context.",
    "reasoning_ground_truth": "According to recommendations acutely ill medical patients such as those in this case,  should receive pharmacologic prophylaxis, such as heparin.",
    "context": "Should extended-duration pharmacological VTE prophylaxis after discharge (ie, up to 30 or 40 days) vs in-hospital\u2013only pharmacological VTE prophylaxis be used in acutely ill hospitalized medical patients?\nShould any DOAC extended beyond hospital discharge vs non-DOAC VTE prophylaxis administered in hospital only be used in acutely ill medical patients?\nhospitalization, and against extending pharmacological prophylaxis after hospital discharge. Conditional recommendations included not to use VTE prophylaxis routinely in long-term care patients or outpatients with minor VTE risk factors. The panel conditionally recommended use of graduated\nIn acutely ill hospitalized medical patients, the ASH guideline panel recommends inpatient VTE prophylaxis with LMWH only, rather than inpatient and extended duration outpatient VTE prophylaxis with DOACs (strong recommendation, moderate certainty in the evidence of effects \u00c5\u00c5\u00c5\u25ef). Remark: If\nto prevent VTE in these adult in-hospital and outpatient medical populations who are not on chronic anticoagulants for other indications.",
    "ground_truth_context": "Parenteral anticoagulant vs no parenteral anticoagulant in acutely ill medical patients. Summary of the evidence. We found 17 systematic reviews that addressed this question,51-67 with 25 studies29,30,68-89",
    "is_correct": true
  },
  {
    "question": "A 70-year-old female presents with cough, fever and shortness of breath. She is diagnosed with community-acquired pneumonia (CAP) and is admitted to the hospital. Her blood cultures taken on admission come back negative. What is the most appropriate step?",
    "options": [
      "Continue antibiotics for 7 days, regardless of clinical stability",
      "Continue antibiotics until a validated measure of clinical stability is achieved and for no less than 5 days.",
      "Discontinue antibiotics immediately due to negative blood culture results.",
      "Switch antibiotics to oral therapy."
    ],
    "correct_answer_text": "Continue antibiotics until a validated measure of clinical stability is achieved and for no less than 5 days.",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context indicates that for adults with clinical and radiographic evidence of CAP, standard antibacterial treatment should be prescribed, and it is implied that treatment should continue until clinical stability is achieved. The recommendation suggests a minimum duration of 5 days of antibiotics, aligning with option B, which states to continue antibiotics until clinical stability is validated and for no less than 5 days. Options A, C, and D do not align with the recommendations provided in the context.",
    "reasoning_ground_truth": "The duration of antibiotic therapy should be guided by a validated measure of clinical stability and continued for at least 5 days. Negative blood cultures do not indicate discontinuing treatment.",
    "context": "In the Inpatient Setting, Should Patients with Suspected Aspiration Pneumonia Receive Additional Anaerobic Coverage beyond Standard Empiric Treatment for CAP?\nwho have severe CAP requiring intubation should have lower respiratory tract samples, such as endotracheal aspirates, sent for Gram stain and culture promptly after intubation, particularly as these patients may be more likely to have pneumonia due to MRSA or P. aeruginosa, and endotracheal\nIn Adults with CAP, Should a Respiratory Sample Be Tested for In\ufb02uenza Virus at the Time of Diagnosis?\nWe suggest not routinely obtaining blood cultures in adults with CAP managed in the hospital setting (conditional recommendation, very low quality of evidence).\nRecommendation. We recommend that standard antibacterial treatment be initially prescribed for adults with clinical and radiographic evidence of CAP who test positive for influenza in the inpatient and outpatient settings (strong recommendation, low quality of evidence).",
    "ground_truth_context": "Antibiotic therapy duration should be guided by a validated measure of clinical stability and should be continued until stability is achieved and for no less than 5 days.",
    "is_correct": true
  },
  {
    "question": "A 62-year-old man with a history of heavy alcohol use presents with new onset jaundice, ascites, and confusion. His labs are suggestive of acute liver failure (ALF). He is hemodynamically stable and is being admitted for ongoing care. Which of the following is the preferred approach for managing his encephalopathy?",
    "options": [
      "Start intravenous steroids to reduce cerebral edema.",
      "Initiate lactulose and rifaximin.",
      "Maintain serum osmolarity above 320 mOsmol using hypertonic saline.",
      "Monitor intracranial pressure (ICP) without intervention"
    ],
    "correct_answer_text": "Initiate lactulose and rifaximin.",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context emphasizes the importance of managing hepatic encephalopathy (HE) in patients with acute liver failure (ALF). It suggests that in cases of severe acute liver injury, intensive screening for signs of HE is crucial. While the context does not explicitly mention the use of lactulose and rifaximin, these are standard treatments for managing HE, which aligns with the need to address encephalopathy in the patient described. Other options, such as intravenous steroids or monitoring ICP without intervention, are not supported by the context provided.",
    "reasoning_ground_truth": "The preferred approach for treating hepatic encephalopathy in ALF involves **lactulose and rifaximin**, which reduce the production and absorption of neurotoxins. Steroids are not recommended for treating elevated ICP in ALF. Serum osmolarity should be maintained below 320 mOsmol. ICP should be monitored and treatment initiated as necessary using interventions such as hypertonic saline or intravenous mannitol.",
    "context": "course. In \u2018hyper-acute\u2019 liver failure the onset of hepatic encephalopathy (HE) occurs within seven days of the onset of jaundice and patients most often recover promptly with medical therapy alone or after transplantation or die soon after illness onset. Due to the short duration of illness in\nthe initial cardiac index. Drainage of some ascites may be recommended. Furthermore, hypoxic hepatitis is a secondary form of ALF and as such, the primary presenting organ failure needs to be addressed and managed to facilitate liver recovery. LTx is not indicated. The use of hydrocortisone to\nDevelopment of encephalopathy is of key prognostic importance, with onset indicating critically impaired liver function. In subacute presentations, even low grade transaminases, increasing bilirubin and INR and encephalopathy may indicate extremely poor prognosis (evidence level II-2, grade of\n- In patients with severe ALI, screen intensively for any signs of hepatic encephalopathy.\n- Exclude the presence of cirrhosis, alcohol induced liver injury or malignant infiltration of the liver.\nHypoxic hepatitis is a secondary form of ALF. Therefore, the primary presenting organ failure needs to be addressed and managed to facilitate liver recovery [36], and LTx should not normally be considered. A characteristic pattern of liver blood tests are seen, which are similar to those observed",
    "ground_truth_context": "Hypertonic saline or intravenous mannitol can be used to treat sustained surges in intracranial pressure (ICP). Steroids are not recommended for treating elevated ICP in ALF. Serum osmolarity should be maintained below 320 mOsmol with RRT as required.",
    "is_correct": true
  },
  {
    "question": "A 48-year-old female with a 10-year history of type 1 diabetes is being screened for chronic kidney disease (CKD). Which test should be used to start the screening process, given her history?",
    "options": [
      "Urine dipstick for protein",
      "Serum creatinine and calculate eGFR",
      "24-hour urine collection for albumin",
      "Kidney biopsy"
    ],
    "correct_answer_text": "Serum creatinine and calculate eGFR",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context specifies that for individuals at risk for chronic kidney disease (CKD), such as those with diabetes, testing should include both urine albumin measurement and assessment of glomerular filtration rate (GFR). Since the patient has a 10-year history of type 1 diabetes, she falls into the category of individuals recommended for screening. The most direct method to start the screening process, as indicated in the context, is to assess serum creatinine and calculate eGFR, making option B the correct choice.",
    "reasoning_ground_truth": "The initial screening test for CKD is an **eGFR calculated using serum creatinine**. While urine albumin is part of CKD evaluation, eGFR is the initial and primary test used.",
    "context": "of CKD is often already apparent at this time. For T1D, screening is recommended commencing 5 years after diagnosis. A second important group includes people with recent AKI or acute kidney disease (AKD), particularly multiple episodes of AKI, and those who have been \u201cpartially diagnosed\u201d with CKD\nPractice Point 1.1.1.1: Test people at risk for and with chronic kidney disease (CKD) using both urine albumin measurement and assessment of glomerular filtration rate (GFR).\nPractice Point 1.1.1.1: Test people at risk for and with chronic kidney disease (CKD) using both urine albumin measurement and assessment of glomerular filtration rate (GFR).\nFigure 3 | Screening algorithm for diagnosis and staging of chronic kidney disease (CKD) in adults. Risk factor conditions are listed in Table 5. *For recommended methods to estimate glomerular filtration rate (eGFR), see Section 1.2. \u2020Markers of kidney damage other than albuminuria may also be\nThe highest priority conditions for CKD detection are hypertension, diabetes, and CVD, including heart failure. For diabetes, the ADA and KDIGO recommend annual screening of people with diabetes for CKD. CKD screening should start at diagnosis of T2D because evidence of CKD is often already",
    "ground_truth_context": "As in the previous KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, the first method to evaluate GFR should be eGFRcr.",
    "is_correct": true
  },
  {
    "question": "A 78-year-old male is diagnosed with acute bacterial rhinosinusitis (ABRS). He has a known penicillin allergy. Which antibiotic is most appropriate?",
    "options": [
      "Oral amoxicillin/clavulanate",
      "Oral azithromycin",
      "Oral doxycycline",
      "Topical intranasal corticosteroids"
    ],
    "correct_answer_text": "Oral doxycycline",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context discusses the management of acute bacterial rhinosinusitis (ABRS) and mentions that clinicians should be cautious with antibiotic prescriptions, especially considering patient allergies. Given the patient's known penicillin allergy, oral amoxicillin/clavulanate (Option A) is not appropriate. While azithromycin (Option B) is an alternative, doxycycline (Option C) is often recommended for patients with penicillin allergies and is effective against the bacteria typically causing ABRS. Topical intranasal corticosteroids (Option D) are not antibiotics and would not be appropriate for treating a bacterial infection. Therefore, the most suitable choice is oral doxycycline.",
    "reasoning_ground_truth": "For patients with a penicillin allergy, **doxycycline** is a recommended alternative for treating ABRS. Azithromycin may be considered as an alternative to doxycycline. While topical intranasal corticosteroids are recommended for symptom relief, they are not an alternative to antibiotics for ABRS.",
    "context": "Clinicians should distinguish presumed acute bacterial rhinosinusitis (ABRS) from acute rhinosinusitis caused by viral upper respiratory infections and noninfectious conditions. A clinician should diagnose ABRS when (a) symptoms or signs of acute rhinosinusitis (purulent nasal drainage accompanied\n|Acute bacterial rhinosinusitis (ABRS)|Acute rhinosinusitis that is caused by, or is presumed to be caused by, bacterial infection. A clinician should diagnose ABRS when: a. symptoms or signs of acute rhinosinusitis fail to improve within 10 days or more beyond the onset of upper respiratory\nfor watchful waiting (without antibiotic therapy) as initial therapy of acute bacterial rhinosinusitis (ABRS), and 3 new recommendations for managing chronic rhinosinusitis (CRS).\nNational ambulatory care data from 2006 to 2010 revealed that rhinosinusitis accounted for more outpatient antibiotic prescriptions than any other diagnosis. Despite guidelines that encourage judicious antibiotic use for ARS, they are prescribed in about 82% of visits. From 2006 to 2010,\nmore or less from antibiotic therapy. Further, there is no conclusive evidence that increased age or allergic rhinitis predicts a prolonged or chronic course of ABRS or any evidence that older patients benefit more from antibiotic therapy.",
    "ground_truth_context": "For acute bacterial rhinosinusitis (ABRS), amoxicillin with or without clavulanate is a recommended antibiotic. If a patient is allergic to penicillin, doxycycline or a respiratory quinolone can be used.",
    "is_correct": true
  },
  {
    "question": "A 28-year-old pregnant female at 32 weeks gestation is admitted to the hospital with a first-time seizure lasting 8 minutes.  IV access has been obtained. What is the preferred initial treatment for her convulsive status epilepticus?",
    "options": [
      "Intravenous phenytoin",
      "Intramuscular midazolam",
      "Intravenous lorazepam",
      "Rectal diazepam"
    ],
    "correct_answer_text": "Intravenous lorazepam",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context indicates that intravenous lorazepam is established as an effective treatment for convulsive status epilepticus, particularly in adults with established intravenous access. Since the patient in the question has IV access and is experiencing a seizure lasting 8 minutes, intravenous lorazepam is the preferred initial treatment according to the provided information. Other options, such as phenytoin, midazolam, and rectal diazepam, are not indicated as the first-line treatment in this scenario based on the context.",
    "reasoning_ground_truth": "For a patient with convulsive status epilepticus with established IV access, **intravenous lorazepam** is the recommended initial therapy. Intramuscular midazolam is preferred when IV access has not yet been established. Phenytoin is an acceptable alternative second line medication. Rectal diazepam is considered an alternative when the preferred options are not available.",
    "context": "lorazepam in adults with convulsive status epilepticus without established intravenous access (Level A). In children, intravenous lorazepam and intravenous diazepam are established as efficacious at stopping seizures lasting at least 5 minutes (Level A) while rectal diazepam, intramuscular\nor longer, or two or more GTC seizures without full recovery of consciousness. A treatment was successful if the status epilepticus stopped within 20 minutes after infusion started with no recurrence prior to 60 minutes. Overall, 570 patients were randomized to either lorazepam (n = 146), diazepam\nmg/kg), diazepam (0.15 mg/kg) followed by phenytoin (18 mg/kg), phenobarbital (18 mg/kg), and phenytoin alone (18 mg/kg) in adults with either overt or subtle status epilepticus (22). Overt status epilepticus was defined as a continuous GTC seizure lasting 10 minutes or longer, or two or more GTC\n2. Treatment of convulsive status epilepticus. Recommendations of the Epilepsy Foundation of America\u2019s Working Group on Status Epilepticus. JAMA 1993;270:854\u2013859.\n3. Shinnar S, Berg AT, Moshe SL, Shinnar R. How long do new-onset seizures in children last? Ann Neurol 2001;49:659\u2013664.\nThe optimal pharmacologic treatment for early convulsive status epilepticus is unclear.",
    "ground_truth_context": "In adults with convulsive status epilepticus, intramuscular midazolam, intravenous lorazepam, intravenous diazepam and intravenous phenobarbital are established as efficacious as initial therapy (Level A). Intra-muscular midazolam has superior effectiveness compared to intravenous lorazepam in adults with convulsive status epilepticus without established intravenous access (Level A).",
    "is_correct": true
  },
  {
    "question": "A 52-year-old male with a history of chronic liver disease presents with worsening ascites and is being evaluated for possible liver transplant. What type of renal replacement therapy (RRT) is preferred if the patient develops acute kidney injury?",
    "options": [
      "Intermittent hemodialysis",
      "Continuous renal replacement therapy (CRRT)",
      "Peritoneal dialysis",
      "No RRT is indicated at this time"
    ],
    "correct_answer_text": "Continuous renal replacement therapy (CRRT)",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context specifies that \"Continuous RRT should always be undertaken in the critically ill patient with ALF as opposed to intermittent.\" Given that the patient has chronic liver disease and is being evaluated for a liver transplant, he may be considered critically ill, thus supporting the preference for continuous renal replacement therapy (CRRT) if acute kidney injury develops.",
    "reasoning_ground_truth": "For patients with acute liver failure and acute kidney injury, **continuous renal replacement therapy (CRRT)** is preferred over intermittent hemodialysis to avoid metabolic and hemodynamic fluctuations.",
    "context": "[211] Davenport A. Is there a role for continuous renal replacement therapies in patients with liver and renal failure? Kidney Int Suppl 1999;72:S62\u2013S66.\nEarly institution of extracorporeal support (RRT) should be considered for persistent hyperammonaemia, control of hyponatraemia and other metabolic abnormalities, fluid balance and potentially temperature control (evidence level III, grade of recommendation 1).\nContinuous RRT should always be undertaken in the critically ill patient with ALF as opposed to intermittent [222]. The role of additional supportive therapies such as tranexamic acid should also be considered in this context.\nConsider planning for preemptive kidney transplantation and/or dialysis access in adults when the GFR is <15\u201320 ml/min per 1.73 m2 or risk of KRT is >40% over 2 years.\nPractice Point 5.4.3: Consider planning for preemptive kidney transplantation and/or dialysis access in adults when the GFR is <15\u201320 ml/min per 1.73 m2 or risk of KRT is >40% over 2 years.",
    "ground_truth_context": "Continuous renal replacement therapy (RRT) is preferred over intermittent dialysis to avoid metabolic and hemodynamic fluctuations.",
    "is_correct": true
  },
  {
    "question": "A 68-year-old male with established primary open-angle glaucoma (POAG) is using a single eye drop medication. His intraocular pressure (IOP) remains elevated at his follow up appointment. What is the next step in the treatment of this patient?",
    "options": [
      "Increase the dose of his current eye drop",
      "Add a second medication to his current eye drop",
      "Consider laser trabeculoplasty",
      "Consider surgery."
    ],
    "correct_answer_text": "Add a second medication to his current eye drop",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context indicates that medical therapy is the most common initial intervention to lower IOP, and if the necessary reduction of IOP exceeds the expected efficacy of a single drug, adding a second medication is a reasonable next step. Since the patient is currently using a single eye drop medication and his IOP remains elevated, the appropriate action would be to add a second medication to enhance the IOP reduction.",
    "reasoning_ground_truth": "When a single medication is not adequate to manage POAG, adding a second medication is the preferred next step in management before considering laser trabeculoplasty or surgery.",
    "context": "|Advanced Glaucoma Intervention Study, 2000|POAG after medical therapy failure with no previous surgery: laser trabeculoplasty first vs. trabeculectomy first|591|10\u201313|\n|United Kingdom Glaucoma Treatment Study, 2014|Newly diagnosed OAG: latanoprost 0.005% vs. placebo|516|2|\npretreatment IOP by 25% or more has been shown to slow progression of POAG.70, 72-74, 81, 82 Choosing a lower target IOP can be justified if there is more severe optic nerve damage, if the damage is progressing rapidly, or if other risk factors such as family history, age, or disc hemorrhages are\nA reasonable initial treatment goal in a POAG patient is to reduce IOP 20% to 30% below baseline and to adjust up or down as indicated by disease course and severity.  \nP795\nMedical therapy is presently the most common initial intervention to lower IOP (see Table 4 for an overview of options available). Prostaglandin analogs are the most frequently prescribed eye drops for lowering IOP in patients with glaucoma because they are most efficacious and well tolerated, and\nto glaucoma treatment,347, 348 fixed combination therapy may improve patient adherence, and reduce exposure to preservatives, although it is not recommended for initial treatment in most circumstances. However, when the necessary reduction of IOP exceeds the expected efficacy of a single drug,",
    "ground_truth_context": "Patient education and informed participation in treatment decisions may improve adherence.",
    "is_correct": true
  },
  {
    "question": "A 58-year-old female with rheumatoid arthritis (RA) is currently treated with methotrexate, but is still having persistent moderate disease activity. Which of the following is the next recommended step?",
    "options": [
      "Add a targeted synthetic DMARD (tsDMARD)",
      "Increase the dose of methotrexate",
      "Add a biologic DMARD (bDMARD)",
      "Add a short course of oral prednisone"
    ],
    "correct_answer_text": "Add a biologic DMARD (bDMARD)",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context indicates that methotrexate is conditionally recommended for patients with moderate-to-high disease activity. However, for patients who have persistent disease activity despite methotrexate treatment, the implication is that additional therapies may be necessary. The context does not specify increasing the dose of methotrexate or adding a short course of oral prednisone as the next steps. Instead, it suggests that patients may prefer combination treatment for a more rapid response, which aligns with the addition of a biologic DMARD (bDMARD) as a potential next step for those with ongoing moderate disease activity.",
    "reasoning_ground_truth": "According to the guidelines, if a patient on methotrexate monotherapy continues to have moderate disease activity, the next recommended step would be to add a **biologic DMARD** or a targeted synthetic DMARD.",
    "context": "Methotrexate is conditionally recommended over alternative DMARDs for the treatment of inflammatory arthritis for patients with clinically diagnosed mild and stable airway or parenchymal lung disease, or incidental disease detected on imaging, who have moderate-to-high disease activity.\nThe recommendation is conditional because the voting panel thought that some patients who have already had persistent disease activity despite use of \u22651 csDMARD will prefer combination treatment for a more rapid response.  \nRecommendations for administration of methotrexate (Table 3)\nmonotherapy, preferably with methotrexate, for patients with both low and moderate/high disease activity, whereas this update recommends an initial trial of hydroxychloroquine or sulfasalazine for those with low disease activity. Second, the 2015 guidelines recommended DMARD tapering for patients\nrecommendation is in favor of methotrexate because of its important role as an anchor treatment in RA and the lack of alternatives with similar efficacy and/or superior long-term safety profiles.\nMethotrexate monotherapy is conditionally recommended over dual or triple csDMARD therapy for DMARD-naive patients with moderate-to-high disease activity. The recommendation favors methotrexate monotherapy because the higher burden of combination therapy (e.g., multiple medications, higher cost)",
    "ground_truth_context": "Methotrexate monotherapy is conditionally recommended over the combination of methotrexate plus a bDMARD or tsDMARD.",
    "is_correct": true
  },
  {
    "question": "A 26-year-old male is diagnosed with uncomplicated gonorrhea. He has no known drug allergies. What is the recommended treatment regimen?",
    "options": [
      "Oral azithromycin 1 gram single dose",
      "Oral doxycycline 100 mg twice daily for 7 days",
      "Intramuscular ceftriaxone 500mg and oral azithromycin 1 gram single dose",
      "Oral ciprofloxacin 500mg twice daily for 3 days"
    ],
    "correct_answer_text": "Intramuscular ceftriaxone 500mg and oral azithromycin 1 gram single dose",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context discusses treatment options for gonococcal infections, specifically mentioning the use of ceftriaxone and azithromycin as part of the treatment regimen. Although ciprofloxacin was previously included in guidelines, the current recommendation for uncomplicated gonorrhea treatment is not listed as an option. Therefore, the combination of intramuscular ceftriaxone 500mg and oral azithromycin 1 gram single dose (option C) aligns with the recommended treatment for uncomplicated gonorrhea as per the context provided.",
    "reasoning_ground_truth": "For uncomplicated gonorrhea, the current recommendation is **intramuscular ceftriaxone plus oral azithromycin**, given as a single dose.",
    "context": "the eventual development of untreatable gonococcal infections with serious sexual and reproductive health consequences (6). The previous WHO Guidelines for the management of sexually transmitted infections, published in 2003 (7), include ciprofloxacin as a first-line treatment for gonorrhoea, even\n|Adults and adolescents with treatment failure of N. gonorrhoeae (genital or oropharyngeal) to cephalosporins|Gentamicin 240 mg IM + azithromycin 2 g orally x 1 Gentamicin 240 mg IM + azithromycin 1 g orally x 1 Spectinomycin 2 g IM + azithromycin 2 g orally x 1 Gemifloxacin 320 mg orally +\nC. trachomatis, increasing the dosage of ceftriaxone to 250 mg for treatment of N. gonorrhoeae with continued monitoring of antimicrobial susceptibility, and consideration of whether azithromycin (2 g, single dose) should be recommended in early syphilis (16).\nmg orally x 1; cefixime 800 mg orally x 1; cefixime 400 mg orally x 2; or gentamicin 240 mg IM x 1|Critical: Microbiological cure, clinical cure, N. gonorrhoeae antimicrobial in vitro resistance, compliance Important: STI complications, side-effects (including allergy, toxicity), quality of life,\n- 4. Recommendations for treatment of gonococcal infections ............ 17\n- 4.1 Genital and anorectal gonococcal infections ............................ 17\n- Recommendation 1 ................................................................. 17",
    "ground_truth_context": "Treatments for people with treatment failure of N. gonorrhoeae (genital or oropharyngeal). Included studies: randomized and non-randomized studies",
    "is_correct": true
  },
  {
    "question": "A 55-year-old female is hospitalized for an acute illness. She has no prior history of venous thromboembolism (VTE). She is being considered for discharge. What should the VTE risk stratification for her take into account?",
    "options": [
      "Her age alone",
      "Her length of stay alone.",
      "Her risk factors for VTE and length of stay.",
      "Her comorbidities alone."
    ],
    "correct_answer_text": "Her risk factors for VTE and length of stay.",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context indicates that VTE risk stratification should consider various factors, including risk factors for VTE (such as recent hospitalization for acute illness) and length of stay. The mention of \"in people who are at substantially increased VTE risk\" suggests that multiple factors should be evaluated together, rather than in isolation. Therefore, option C, which includes both risk factors and length of stay, is the most comprehensive and supported by the context.",
    "reasoning_ground_truth": "VTE risk assessment considers **both risk factors for VTE and length of stay**. Age and comorbidities are risk factors that should also be considered along with the length of stay. ",
    "context": "Venous thromboembolism (VTE) is the third most common cardiovascular diagnosis, with an incidence rate of \u223c1 in 1000 annually in middle age and increasing to nearly 1% annually in nonagenarians. About 50% of all VTE events occur as a result of a current or recent hospital admission for surgery or\nVTE in hospitalized and nonhospitalized medical patients and long-distance travelers confers an important disease burden and can be fatal. About 50% of all VTE events in the community occur as a result of a current or recent hospital admission, mainly for surgery (24%) or acute medical illness\n|Elderly age (ie, .70 y)|1|\n|Heart and/or respiratory failure|1|\n|Acute myocardial infarction or ischemic stroke|1|\n|Ongoing hormonal treatment|1|\n|Obesity (body mass index .30)|1|\n|Acute infection and/or rheumatologic disorder|1|\n|IMPROVE VTE RAM: score \u20212 indicates increased VTE risk\u2020| |\nIn people who are at substantially increased VTE risk (eg, recent surgery, history of VTE, postpartum women, active malignancy, or $2 risk factors, including combinations of the above with hormone replacement therapy, obesity, or pregnancy) and in whom LMWH or graduated compression stockings is not\n|Previous VTE|3|\n|Known thrombophilia\u2021|2|\n|Lower limb paralysis\u00a7|2|\n|Active cancer|2|\n|Immobilization $7 d|1|\n|ICU/CCU stay|1|\n|Age .60 y|1|\n|IMPROVE bleeding RAM: score \u20217 indicates high bleeding risk{| |\n|Renal failure (GFR 30-59 vs $60 mL/min per m 2)|1|\n|Male vs female|1|",
    "ground_truth_context": "Parenteral anticoagulant vs no parenteral anticoagulant in acutely ill medical patients. Summary of the evidence. We found 17 systematic reviews that addressed this question,51-67 with 25 studies29,30,68-89",
    "is_correct": true
  },
  {
    "question": "A 67-year-old male with a history of COPD and recent hospitalization for pneumonia is now clinically stable and ready for discharge. What is the recommended duration for his antibiotic treatment?",
    "options": [
      "Continue antibiotics for 7 days.",
      "Continue antibiotics for 10 days.",
      "Continue antibiotics until clinical stability is achieved and for at least 5 days",
      "Discontinue antibiotics at the time of discharge."
    ],
    "correct_answer_text": "Continue antibiotics until clinical stability is achieved and for at least 5 days",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context states that antibiotic therapy should be continued until the patient achieves stability and for no less than a total of 5 days. Since the patient is clinically stable, the recommendation is to continue antibiotics for at least 5 days, which aligns with option C.",
    "reasoning_ground_truth": "Antibiotic therapy for pneumonia should be continued **until a validated measure of clinical stability has been achieved and for no less than 5 days**. Specific duration of treatment based on set number of days, without regard for stability, is not recommended, nor is discontinuing at discharge, unless at least 5 days of antibiotics have already been completed and the patient is clinically stable.",
    "context": "or proven MRSA or P. aeruginosa should be 7 days, in agreement with the recent hospital-acquired pneumonia and ventilator-associated pneumonia guidelines (166).\nand symptoms of pneumonia with radiographic confirmation) to completion of antimicrobial therapy and follow-up chest imaging.\nLonger courses of antibiotic therapy are recommended for 1) pneumonia e59\nAs recent data supporting antibiotic administration for ,5 days are scant, on a risk\u2013benefit basis we recommend treating for a minimum of 5 days, even if the patient has reached clinical stability before 5 days. As most patients will achieve clinical stability within the first 48 to 72 hours, a\nand normal mentation), and antibiotic therapy should be continued until the patient achieves stability and for no less than a total of 5 days (strong recommendation, moderate quality of evidence).",
    "ground_truth_context": "Antibiotic therapy duration should be guided by a validated measure of clinical stability and should be continued until stability is achieved and for no less than 5 days.",
    "is_correct": true
  },
  {
    "question": "A 57-year-old male with a long history of heavy alcohol use presents with worsening jaundice, ascites, and new onset confusion. He is diagnosed with acute liver failure (ALF). The patient's family is concerned about the development of intracranial pressure (ICP). What intervention should the health team implement to manage elevated ICP in this situation?",
    "options": [
      "Initiate intravenous dexamethasone",
      "Administer intravenous mannitol or hypertonic saline.",
      "Reduce the amount of IV fluids to decrease fluid overload.",
      "Administer intravenous albumin to increase intravascular volume."
    ],
    "correct_answer_text": "Administer intravenous mannitol or hypertonic saline.",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context mentions that one characteristic manifestation of acute liver failure (ALF) is the development of intracranial hypertension (ICH). While it does not specify the exact interventions for managing elevated ICP, the use of intravenous mannitol or hypertonic saline is a common approach in clinical practice for reducing intracranial pressure. The other options do not directly address the management of elevated ICP as effectively as option B does.",
    "reasoning_ground_truth": "The use of **hypertonic saline or intravenous mannitol** is recommended to treat sustained surges in ICP. Steroids are not recommended for treatment of elevated ICP in ALF. The purpose of fluid bolus in these cases is to increase stroke volume and cardiac output rather than volume resuscitation.",
    "context": "- ALF presenting with gross ascites should lead to suspicion of acute Budd-Chiari syndrome. Diagnosis of this condition is based on imaging techniques (evidence level II-3, grade of recommendation 1).\nthe initial cardiac index. Drainage of some ascites may be recommended. Furthermore, hypoxic hepatitis is a secondary form of ALF and as such, the primary presenting organ failure needs to be addressed and managed to facilitate liver recovery. LTx is not indicated. The use of hydrocortisone to\n- In patients with severe ALI, screen intensively for any signs of hepatic encephalopathy.\n- Exclude the presence of cirrhosis, alcohol induced liver injury or malignant infiltration of the liver.\nOne characteristic manifestation of ALF is the development of intracranial hypertension (ICH). These can manifest as a result of arterial hypertension, bradycardia and mydriasis in patients who have progressed to grade 3 or 4 coma.\n[280] Fortea JI, Banares R, Vaquero J. Intracranial pressure in acute liver failure: to bolt or not to bolt\u2014that is the question. Crit Care Med 2014;42:1304\u20131305.",
    "ground_truth_context": "Hypertonic saline or intravenous mannitol can be used to treat sustained surges in intracranial pressure (ICP). Steroids are not recommended for treating elevated ICP in ALF.",
    "is_correct": true
  },
  {
    "question": "A 60-year-old female with type 2 diabetes is being evaluated for chronic kidney disease (CKD). Her initial eGFR based on serum creatinine is 50 mL/min/1.73 m\u00b2. What is the next appropriate test for evaluation of her kidney function?",
    "options": [
      "Repeat serum creatinine measurement in 1 month",
      "Measure cystatin C and calculate eGFR using both creatinine and cystatin C",
      "24-hour urine collection for albumin",
      "Perform kidney biopsy"
    ],
    "correct_answer_text": "Measure cystatin C and calculate eGFR using both creatinine and cystatin C",
    "correct_answer_idx": 1.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context emphasizes the importance of testing for chronic kidney disease (CKD) using both urine albumin measurement and assessment of glomerular filtration rate (GFR). Since the patient has an initial eGFR indicating potential CKD, the next appropriate step would be to conduct a 24-hour urine collection for albumin to assess for albuminuria, which is a key indicator in the evaluation of CKD. Other options do not align with the recommended practices outlined in the context.",
    "reasoning_ground_truth": "If eGFR based on creatinine is thought to be inaccurate or a more accurate assessment of GFR is needed, the next step is to measure cystatin C and calculate the **eGFR using both creatinine and cystatin C**. 24 hour urine collection and kidney biopsy are not used as the next step but are used for other specific reasons.  ",
    "context": "Practice Point 1.1.1.1: Test people at risk for and with chronic kidney disease (CKD) using both urine albumin measurement and assessment of glomerular filtration rate (GFR).\nPractice Point 1.1.1.1: Test people at risk for and with chronic kidney disease (CKD) using both urine albumin measurement and assessment of glomerular filtration rate (GFR).\nfiltration rate (eGFR) should be monitored concurrently with serum potassium. Reproduced from Kidney Disease: Improving Global Outcomes Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022;102:S1\u2013S127.\nfiltration rate (eGFR) should be monitored concurrently with serum potassium. Reproduced from Kidney Disease: Improving Global Outcomes Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022;102:S1\u2013S127.\nand urine to detect CKD is important, with confirmatory testing if initial findings indicate the presence of abnormalities of creatinine/eGFR or albuminuria.",
    "ground_truth_context": "If eGFRcr is expected to be inaccurate, or if a more accurate assessment of GFR is needed for clinical decision-making, such as diagnosis or staging of chronic kidney disease or drug dosing, then, if available, cystatin C should be measured, and creatinine and cystatin C\u2013based estimated GFR (eGFRcr-cys) should be estimated.",
    "is_correct": false
  },
  {
    "question": "A 75-year-old male with acute bacterial rhinosinusitis (ABRS) symptoms for 10 days, including purulent nasal discharge, facial pain, and fever, reports no improvement with initial saline irrigation. He is also started on amoxicillin/clavulanate. When should the patient be reassessed?",
    "options": [
      "Reassess in 1 week if symptoms are persistent.",
      "Reassess immediately if symptoms worsen",
      "Reassess in 2 weeks, or sooner if needed.",
      "Reassess only if complications develop."
    ],
    "correct_answer_text": "Reassess in 1 week if symptoms are persistent.",
    "correct_answer_idx": 0.0,
    "model_answer": "A",
    "model_answer_idx": 0,
    "model_reasoning": "The context states that a clinician should diagnose acute bacterial rhinosinusitis (ABRS) when symptoms persist without improvement for at least 10 days. Given that the patient has had symptoms for 10 days and is being treated with amoxicillin/clavulanate, it is appropriate to reassess in 1 week if symptoms are persistent, as this aligns with the guideline for monitoring treatment effectiveness in ABRS.",
    "reasoning_ground_truth": "Patients with ABRS should be reassessed **if symptoms persist after 7 days** on initial treatment, or if there is a worsening of symptoms.",
    "context": "|Acute bacterial rhinosinusitis (ABRS)|Acute rhinosinusitis that is caused by, or is presumed to be caused by, bacterial infection. A clinician should diagnose ABRS when: a. symptoms or signs of acute rhinosinusitis fail to improve within 10 days or more beyond the onset of upper respiratory\nClinicians should distinguish presumed acute bacterial rhinosinusitis (ABRS) from acute rhinosinusitis caused by viral upper respiratory infections and noninfectious conditions. A clinician should diagnose ABRS when (a) symptoms or signs of acute rhinosinusitis (purulent nasal drainage accompanied\nABRS when (a) symptoms or signs of acute rhinosinusitis persist without evidence of improvement for at least 10 days beyond the onset of upper respiratory symptoms.\u201d\nAcute rhinosinusitis is diagnosed when a patient presents with up to 4 weeks of purulent (not clear) nasal drainage accompanied by nasal obstruction, facial pain-pressure-fullness, or both (Table 4). Nasal obstruction without purulent nasal drainage is not consistent with ARS and is beyond the scope\n|Acute rhinosinusitis (ARS)|Up to 4 weeks of purulent nasal drainage (anterior, posterior, or both) accompanied by nasal obstruction, facial pain-pressure-fullness, or both: Purulent nasal discharge is cloudy or colored, in contrast to the clear secretions that typically accompany viral upper",
    "ground_truth_context": "Define realistic expectations regarding clinical response to initial management and to articulate clearly when reassessment of the patient is warranted",
    "is_correct": true
  },
  {
    "question": "A 35-year-old male in the hospital is experiencing a seizure. The seizure has lasted for 22 minutes and intravenous access has been established. He was treated with lorazepam at 5 minutes. What is the most appropriate next step in managing his status epilepticus?",
    "options": [
      "Repeat the intravenous lorazepam dose.",
      "Administer intravenous fosphenytoin.",
      "Administer intramuscular midazolam.",
      "Start a phenobarbital infusion."
    ],
    "correct_answer_text": "Administer intravenous fosphenytoin.",
    "correct_answer_idx": 1.0,
    "model_answer": "A",
    "model_answer_idx": 0,
    "model_reasoning": "The context indicates that intravenous lorazepam is effective in stopping seizures, and it mentions that a repeat dose of lorazepam is allowed if the seizure continues after 4 minutes. Since the patient has been treated with lorazepam at 5 minutes and is still experiencing a seizure lasting 22 minutes, the most appropriate next step is to repeat the intravenous lorazepam dose. Other options do not align with the immediate management protocol outlined in the context.",
    "reasoning_ground_truth": "When a seizure continues after initial benzodiazepine therapy, the next recommended step is to administer a second line agent, such as fosphenytoin, valproic acid, or levetiracetam. Repeating the intravenous lorazepam dose is not preferred as the seizure has exceeded the initial therapy window and a second line therapy should be initiated.",
    "context": "lorazepam in adults with convulsive status epilepticus without established intravenous access (Level A). In children, intravenous lorazepam and intravenous diazepam are established as efficacious at stopping seizures lasting at least 5 minutes (Level A) while rectal diazepam, intramuscular\ncompared with IV lorazepam in adults with convulsive status epilepticus without established IV access (level A). Intravenous lorazepam is more effective than IV phenytoin in stopping seizures lasting at least 10 minutes (level A). There is no difference in efficacy between IV lorazepam followed by\nA second class I study in adults (older than 18 years) with status epilepticus was initiated outside the hospital by paramedics (23). In this 2001 study, patients were randomized to receive 2 mg IV lorazepam or 5 mg IV diazepam or IV placebo in the ambulance. The protocol allowed a repeat dose if\nallowed a repeat dose if the seizure continued after 4 minutes (for a maximum lorazepam dose of 4 mg and diazepam dose of 10 mg). For this study, status epilepticus was defined as continuous or repeated seizure for >5 minutes without recovery of consciousness. Overall, 205 patients were randomized\nor longer, or two or more GTC seizures without full recovery of consciousness. A treatment was successful if the status epilepticus stopped within 20 minutes after infusion started with no recurrence prior to 60 minutes. Overall, 570 patients were randomized to either lorazepam (n = 146), diazepam",
    "ground_truth_context": "Reasonable options for second-line therapy include fosphenytoin, valproic acid, and levetiracetam.",
    "is_correct": false
  },
  {
    "question": "A 65 year old patient with known cirrhosis and newly diagnosed hepatic encephalopathy is admitted to the hospital. She is stable and has a history of medication intolerance. Which is the preferred medication for hepatic encephalopathy?",
    "options": [
      "Lactulose",
      "Rifaximin",
      "Intravenous steroids",
      "Oral neomycin"
    ],
    "correct_answer_text": "Lactulose",
    "correct_answer_idx": 0.0,
    "model_answer": "A",
    "model_answer_idx": 0,
    "model_reasoning": "The context discusses the management of hepatic encephalopathy, specifically mentioning the treatment of patients with cirrhosis and the importance of evaluating patients with low-grade encephalopathy. While it does not explicitly state the preferred medication, lactulose is commonly recognized as a first-line treatment for hepatic encephalopathy, especially in patients with medication intolerance. The other options (rifaximin, intravenous steroids, and oral neomycin) are not indicated as first-line treatments in the context provided.",
    "reasoning_ground_truth": "The preferred first line treatment for Hepatic encephalopathy is **Lactulose**. While Rifaximin may also be used, guidelines recommend starting with Lactulose. Intravenous steroids are not indicated in the management of HE. Oral neomycin is an alternative therapy but not first line. ",
    "context": "43. Amodio P, Bemeur C, Butterworth R, Cordoba J, Kato A, Montagnese S, et al. The nutritional management of hepatic encephalopathy in patients with cirrhosis: international society for hepatic encephalopathy and nitrogen metabolism consensus. Hepatology 2013;58(1):325e36.\n6. Michel H, Bories P, Aubin JP, Pomier-Layrargues G, Bauret P, Bellet-Herman H. Treatment of acute hepatic encephalopathy in cirrhotics with a branched-chain amino acids enriched versus a conventional amino acids mixture. A controlled study of 70 patients. Liver 1985;5(5):282e9.\n[110\u201a111\u201a388\u201a410] or mental state in a highly selected group of protein intolerant LC patients with encephalopathy [386]. In the two largest trials (174 and 646 patients) oral BCAA supplementation (12 and 24 months) was useful to prevent progressive hepatic failure and to improve surrogate markers\nPatients with low grade encephalopathy should be frequently evaluated for signs of worsening encephalopathy (evidence level III, grade of recommendation 1).\n8. Strauss E. Treatment of hepatic encephalopathy: a randomized clinical trial comparing branched chain enriched amino acid solution to oral neomycin. Nutr Supp Serv 1986;6:18e21.",
    "ground_truth_context": "Continuous renal replacement therapy (RRT) is preferred over intermittent dialysis to avoid metabolic and hemodynamic fluctuations. Hypertonic saline or intravenous mannitol can be used to treat sustained surges in intracranial pressure (ICP). Steroids are not recommended for treating elevated ICP in ALF.",
    "is_correct": true
  },
  {
    "question": "A 50-year-old female with a diagnosis of primary open-angle glaucoma (POAG) has been treated with two different eye drop medications, but her intraocular pressure (IOP) is still not well controlled. What is the next step in her management?",
    "options": [
      "Consider laser trabeculoplasty",
      "Increase the dose of the current eye drops",
      "Add a third eye drop medication",
      "Refer for glaucoma surgery immediately"
    ],
    "correct_answer_text": "Consider laser trabeculoplasty",
    "correct_answer_idx": 0.0,
    "model_answer": "A",
    "model_answer_idx": 0,
    "model_reasoning": "The context states that if IOP is poorly controlled on several medications, options such as laser trabeculoplasty are available. Since the patient has already been treated with two different eye drop medications and her IOP is still not well controlled, considering laser trabeculoplasty aligns with the management strategies outlined for patients with POAG who are not achieving adequate IOP control.",
    "reasoning_ground_truth": "When medications do not adequately control IOP, **laser trabeculoplasty** is the next logical step to be considered before surgery is considered. While adding another eye drop medication is an option, it is not the preferred first step after initial treatment with two eye drop medications.",
    "context": "The goals of managing patients with POAG are to control IOP in a target range and to prevent progressive visual field and optic nerve/RNFL damage in order to preserve visual function and quality of life. The initial glaucoma evaluation includes all components of the comprehensive adult medical\n|Advanced Glaucoma Intervention Study, 2000|POAG after medical therapy failure with no previous surgery: laser trabeculoplasty first vs. trabeculectomy first|591|10\u201313|\n|United Kingdom Glaucoma Treatment Study, 2014|Newly diagnosed OAG: latanoprost 0.005% vs. placebo|516|2|\nPatients with POAG who have visually significant cataracts have a range of options available. If IOP control is at target on one or two medications, cataract surgery alone may be adequate, with the additional benefit that it may lower IOP slightly. If IOP is poorly controlled on several medications\nClinical trials have shown that lowering IOP reduces the risk of developing POAG and slows the progression of the disease. Medical, laser, and incisional surgical approaches exist to effectively lower IOP. Early diagnosis and treatment generally prevent visual disability.\nA reasonable initial treatment goal in a POAG patient is to reduce IOP 20% to 30% below baseline and to adjust up or down as indicated by disease course and severity.  \nP795",
    "ground_truth_context": "Patients should receive proper professional support and referrals when their conditions fail to respond to treatment.",
    "is_correct": true
  },
  {
    "question": "A 45-year-old male with rheumatoid arthritis (RA) is on methotrexate monotherapy, but is still having moderate disease activity. He is now being started on a biologic DMARD (bDMARD). What is the best way to approach his current methotrexate therapy?",
    "options": [
      "Discontinue methotrexate at the time of starting the bDMARD",
      "Reduce the dose of methotrexate while starting the bDMARD",
      "Continue methotrexate at the same dose when starting the bDMARD",
      "Stop methotrexate and start the bDMARD"
    ],
    "correct_answer_text": "Continue methotrexate at the same dose when starting the bDMARD",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context indicates that methotrexate monotherapy is strongly recommended for DMARD-naive patients with moderate-to-high disease activity. It also states that methotrexate monotherapy is conditionally recommended over the combination of methotrexate plus a bDMARD or tsDMARD, suggesting that continuing methotrexate at the same dose while starting the bDMARD is a valid approach. There is no indication in the context that methotrexate should be discontinued or reduced when starting a bDMARD, making option C the best choice.",
    "reasoning_ground_truth": "According to guidelines, when adding a bDMARD to methotrexate therapy, the recommendation is to **continue methotrexate at the current dose**. Discontinuation or reducing the dose of methotrexate is not recommended at this time.",
    "context": "Methotrexate monotherapy is strongly recommended over bDMARD or tsDMARD monotherapy for DMARD-naive patients with moderate-to-high disease activity. There is low-certainty evidence suggesting superiority of tocilizumab monotherapy (15) over methotrexate monotherapy and moderate-certainty evidence\nMethotrexate monotherapy is conditionally recommended over methotrexate plus a tumor necrosis factor (TNF) inhibitor for DMARD-naive patients with moderate-to-high disease activity. Methotrexate monotherapy is strongly preferred given the lack of proven benefit and additional risks and costs\nMethotrexate monotherapy is conditionally recommended over dual or triple csDMARD therapy for DMARD-naive patients with moderate-to-high disease activity. The recommendation favors methotrexate monotherapy because the higher burden of combination therapy (e.g., multiple medications, higher cost)\n|Methotrexate monotherapy is conditionally recommended over the combination of methotrexate plus a bDMARD or tsDMARD.**|Moderate/very low|PICO 6b.C1\u20134/C5\u00a7|p. 136\u201356|\nMethotrexate monotherapy is conditionally recommended over the combination of methotrexate plus a bDMARD or tsDMARD physician and patient preferences regarding the tradeoff between the increased efficacy and risks of toxicity associated with higher starting doses. This recommendation refers only to",
    "ground_truth_context": "Continuation of DMARDs at the current dose is preferred over dose reduction, which is preferred over gradual discontinuation, which is preferred over abrupt discontinuation.",
    "is_correct": true
  },
  {
    "question": "A 28-year-old male presents to the clinic with concern for possible gonorrhea. He reports a recent unprotected sexual encounter.  What is the preferred initial treatment if he is diagnosed with gonorrhea?",
    "options": [
      "Oral azithromycin 1 gram single dose",
      "Oral doxycycline 100mg twice daily for 7 days",
      "Intramuscular ceftriaxone 500 mg and oral azithromycin 1 gram single dose",
      "Oral ciprofloxacin 500 mg twice daily for 3 days"
    ],
    "correct_answer_text": "Intramuscular ceftriaxone 500 mg and oral azithromycin 1 gram single dose",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context mentions that for adults and adolescents with treatment failure of N. gonorrhoeae, the recommended treatment includes \"Gentamicin 240 mg IM + azithromycin 2 g orally x 1\" and also discusses increasing the dosage of ceftriaxone to 250 mg for treatment of N. gonorrhoeae. Although the specific dosage of ceftriaxone is not provided in the options, the mention of ceftriaxone as a treatment aligns with option C, which includes \"Intramuscular ceftriaxone 500 mg and oral azithromycin 1 gram single dose.\" This option is consistent with current treatment guidelines for gonorrhea, making it the preferred initial treatment if the patient is diagnosed with gonorrhea.",
    "reasoning_ground_truth": "The recommended initial treatment for gonorrhea is a single dose of **intramuscular ceftriaxone along with a single dose of oral azithromycin**.",
    "context": "the eventual development of untreatable gonococcal infections with serious sexual and reproductive health consequences (6). The previous WHO Guidelines for the management of sexually transmitted infections, published in 2003 (7), include ciprofloxacin as a first-line treatment for gonorrhoea, even\nanother first-line treatment for gonorrhoea, is on the rise (13). Low-level resistance to Trichomonas vaginalis has also been reported for nitroimidazoles, the only available treatment. Resistance to azithromycin has been reported in some strains of Treponema pallidum and treatment failures have\nSince laboratory diagnostic tests are not available in the majority of countries, diagnosis is often made clinically, based on the presence of symptoms such as vaginal and urethral discharge. Presumptive treatment is sometimes provided to those at high risk of gonococcal infection, if indicated\n|Adults and adolescents with treatment failure of N. gonorrhoeae (genital or oropharyngeal) to cephalosporins|Gentamicin 240 mg IM + azithromycin 2 g orally x 1 Gentamicin 240 mg IM + azithromycin 1 g orally x 1 Spectinomycin 2 g IM + azithromycin 2 g orally x 1 Gemifloxacin 320 mg orally +\nC. trachomatis, increasing the dosage of ceftriaxone to 250 mg for treatment of N. gonorrhoeae with continued monitoring of antimicrobial susceptibility, and consideration of whether azithromycin (2 g, single dose) should be recommended in early syphilis (16).",
    "ground_truth_context": "Treatments for people with treatment failure of N. gonorrhoeae (genital or oropharyngeal). Included studies: randomized and non-randomized studies",
    "is_correct": true
  },
  {
    "question": "A 70-year-old patient is admitted to the hospital for an acute medical illness. They have limited mobility during the admission. What is the preferred initial method of VTE prophylaxis?",
    "options": [
      "Mechanical prophylaxis with graduated compression stockings",
      "Mechanical prophylaxis with intermittent pneumatic compression",
      "Pharmacological prophylaxis with LMWH or UFH",
      "No prophylaxis is necessary due to limited VTE risk."
    ],
    "correct_answer_text": "Pharmacological prophylaxis with LMWH or UFH",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context states that in acutely ill hospitalized medical patients, the ASH guideline panel recommends inpatient VTE prophylaxis with LMWH (Low Molecular Weight Heparin) only. This indicates that pharmacological prophylaxis is preferred for patients like the 70-year-old with limited mobility during their hospital admission. Options A and B refer to mechanical prophylaxis methods, which are not the preferred initial method according to the guidelines provided. Option D is incorrect as it suggests no prophylaxis is necessary, which contradicts the recommendation for VTE prophylaxis in acutely ill patients.",
    "reasoning_ground_truth": "For acutely ill medical patients, guidelines recommend **pharmacologic prophylaxis with a low molecular weight heparin (LMWH) or unfractionated heparin (UFH)**. Mechanical prophylaxis can be used in certain situations, but is not the preferred initial method",
    "context": "admission for surgery or acute medical illness. Hospital-acquired VTE is preventable, with interventions including anticoagulants and mechanical measures, including compression stockings and intermittent pneumatic compression.\nIn acutely ill hospitalized medical patients, the ASH guideline panel recommends inpatient VTE prophylaxis with LMWH only, rather than inpatient and extended duration outpatient VTE prophylaxis with DOACs (strong recommendation, moderate certainty in the evidence of effects \u00c5\u00c5\u00c5\u25ef). Remark: If\nShould any DOAC extended beyond hospital discharge vs non-DOAC VTE prophylaxis administered in hospital only be used in acutely ill medical patients?\n- Chronically ill medical inpatients or nursing home residents\n- Outpatients with minor provoking VTE risk factors\n- Acutely or critically ill medical inpatients\n- Travelers\nShould extended-duration pharmacological VTE prophylaxis after discharge (ie, up to 30 or 40 days) vs in-hospital\u2013only pharmacological VTE prophylaxis be used in acutely ill hospitalized medical patients?",
    "ground_truth_context": "LMWH vs UFH in acutely ill medical patients. Summary of the evidence. We found 8 systematic reviews51,52,54,58,59,63,65,67 that addressed this question and included 11 RCTs.",
    "is_correct": true
  },
  {
    "question": "A 54 year-old male is admitted to the hospital with community-acquired pneumonia (CAP). His blood cultures are negative, and his symptoms are improving after 3 days of intravenous antibiotics. How long should he continue antibiotic therapy?",
    "options": [
      "Continue intravenous antibiotics for 7 days",
      "Switch to oral antibiotics for 7 days",
      "Continue intravenous antibiotics until clinical stability and then for 2 additional days",
      "Continue antibiotics until clinical stability is achieved and for at least 5 days"
    ],
    "correct_answer_text": "Continue antibiotics until clinical stability is achieved and for at least 5 days",
    "correct_answer_idx": 3.0,
    "model_answer": "D",
    "model_answer_idx": 3,
    "model_reasoning": "The context indicates that controlled studies are needed to establish the duration of antibiotic therapy for adults with complications of CAP and emphasizes the importance of achieving clinical stability. Although the specific duration for this scenario isn't explicitly stated, the mention of continuing antibiotics until clinical stability is achieved and for at least 5 days aligns with option D, making it the most supported choice based on the context provided.",
    "reasoning_ground_truth": "Antibiotic therapy for CAP should be continued until the patient achieves **clinical stability and for at least 5 days**. The route of administration of the antibiotic should be based on the patient\u2019s ability to tolerate oral intake.",
    "context": "Finally, routine cultures in patients empirically treated for MRSA or P. aeruginosa allow deescalation to standard CAP therapy if cultures do not reveal a drug-resistant pathogen and the patient is clinically improving at 48 hours.\nresults that lead to unnecessary antibiotic use and increased length of stay. In severe CAP, delay in covering less-common pathogens can have serious consequences. Therefore, the potential benefit of blood cultures is much larger when results can be returned within 24 to 48 hours.\nIn Outpatient and Inpatient Adults with CAP Who Are Improving, What Is the Appropriate Duration of Antibiotic Treatment?\nIn Adults with CAP Who Test Positive for In\ufb02uenza, Should the Treatment Regimen Include Antibacterial Therapy?\nControlled studies are needed to establish the duration of antibiotic therapy for adults with complications of CAP, including empyema, and adults with prolonged time to achieving clinical stability.",
    "ground_truth_context": "Antibiotic therapy duration should be guided by a validated measure of clinical stability and should be continued until stability is achieved and for no less than 5 days.",
    "is_correct": true
  },
  {
    "question": "A 45-year-old female with chronic rhinosinusitis (CRS) presents with persistent nasal congestion and facial pain despite using saline nasal irrigation and topical corticosteroids. She reports no history of allergies. What is the next most appropriate step in her management?",
    "options": [
      "Prescribe a course of oral antibiotics.",
      "Recommend allergy testing and consider immunotherapy.",
      "Perform nasal endoscopy to assess for polyps and obtain objective evidence of sinonasal inflammation.",
      "Obtain a CT scan of the sinuses to assess for anatomical abnormalities."
    ],
    "correct_answer_text": "Perform nasal endoscopy to assess for polyps and obtain objective evidence of sinonasal inflammation.",
    "correct_answer_idx": 2,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context emphasizes the importance of confirming a clinical diagnosis of chronic rhinosinusitis (CRS) with objective documentation of sinonasal inflammation, which can be achieved through nasal endoscopy. This step is crucial for assessing the presence of nasal polyps and obtaining evidence of inflammation, especially since the patient is experiencing persistent symptoms despite current treatments. Options A and B do not align with the immediate need for objective assessment, and option D, while relevant, is not the next most appropriate step as nasal endoscopy directly addresses the patient's current symptoms and management needs.",
    "reasoning_ground_truth": "The patient has persistent CRS despite initial management, it is important to obtain objective evidence of sinonasal inflammation, and evaluate for nasal polyps by nasal endoscopy. Antibiotics are not a primary treatment for CRS. Allergy testing may be considered, but an objective confirmation of CRS should be prioritized. CT scan is an option for objective documentation but nasal endoscopy is a more appropriate first-line diagnostic step.",
    "context": "Clinicians should assess the patient with chronic rhinosinusitis or recurrent acute rhinosinusitis for multiple chronic conditions that would modify management such as asthma, cystic fibrosis, immunocompromised state, and ciliary dyskinesia. Recommendation based on one systematic review and multiple\ndyskinesia; (6) confirm the presence or absence of nasal polyps in a patient with CRS; and (7) recommend saline nasal irrigation, topical intranasal corticosteroids, or both for symptom relief of CRS.\nThe clinician should confirm a clinical diagnosis of CRS with objective documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. Strong recommendation based on cross-sectional studies with a preponderance of benefit over\n|11. Topical intranasal therapy for CRS|Clinicians should recommend saline nasal irrigation, topical intranasal corticosteroids, or both for symptom relief of CRS.|\n|12. Antifungal therapy for CRS|Clinicians should not prescribe topical or systemic antifungal therapy for patients with CRS.|\nAdjunctive treatments for rhinosinusitis that may aid in symptomatic relief include analgesics, decongestants (\u03b1-adrenergic), corticosteroids, saline irrigation, and mucolytics. None of these products has been specifically approved by the FDA for use in acute rhinosinusitis (as of March 2014), and",
    "ground_truth_context": "The clinician should confirm a clinical diagnosis of CRS with objective documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. Clinicians should confirm the presence or absence of nasal polyps in a patient with CRS.",
    "is_correct": true
  },
  {
    "question": "A 52-year-old male, post-stent placement for stable ischemic heart disease (SIHD) 6 months ago, is scheduled for an elective cholecystectomy. He is currently on dual antiplatelet therapy (DAPT) with aspirin and clopidogrel. What is the most appropriate perioperative management of his antiplatelet therapy?",
    "options": [
      "Continue both aspirin and clopidogrel throughout the perioperative period.",
      "Discontinue both aspirin and clopidogrel 5 days before surgery.",
      "Continue aspirin and discontinue clopidogrel 5 days prior to surgery.",
      "Discontinue aspirin and continue clopidogrel throughout the perioperative period."
    ],
    "correct_answer_text": "Continue aspirin and discontinue clopidogrel 5 days prior to surgery.",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context indicates that in patients treated with DAPT after DES implantation, P2Y12 inhibitor therapy (clopidogrel) should be given for at least 6 months. Since the patient is 6 months post-stent placement for SIHD, it is appropriate to consider the continuation of aspirin therapy, which is recommended to be continued indefinitely in patients with coronary artery disease. However, if P2Y12 inhibitor therapy needs to be held, the continuation of aspirin is recommended. Therefore, the most appropriate perioperative management is to continue aspirin and discontinue clopidogrel 5 days prior to surgery to mitigate bleeding risk while maintaining some level of antiplatelet protection.",
    "reasoning_ground_truth": "For patients with SIHD undergoing elective surgery, it is generally recommended to continue aspirin and discontinue the P2Y12 inhibitor (in this case, clopidogrel) 5 days prior to surgery to reduce the risk of bleeding. Stopping both medications increases the risk of thrombotic events. Continuing both medications increases bleeding risk",
    "context": "|I|B-RSR|In patients with SIHD treated with DAPT after DES implantation, P2Y12 inhibitor therapy (clopidogrel) should be given for at least 6 months (17,18,21,30,96,97).|\n|I|B-NR|In patients treated with DAPT, a daily aspirin dose of 81 mg (range, 75 mg to 100 mg) is recommended (56\u201360,75\u201378).|\n|I|B-RSR|In patients with SIHD treated with DAPT after DES implantation, P2Y12 inhibitor therapy (clopidogrel) should be given for at least 6 months (17,18,21,30,96,97).|\n|I|B-NR|In patients treated with DAPT, a daily aspirin dose of 81 mg (range, 75 mg to 100 mg) is recommended (56\u201360,75\u201378).|\nDAPT is not established. Clopidogrel is the only currently used P2Y12 inhibitor studied in patients with SIHD undergoing PCI. Aspirin therapy is almost always continued indefinitely in patients with coronary artery disease. 5 High bleeding risk denotes those who have or develop a high risk of\nThe magnitude of incremental bleeding risk in patients treated with antiplatelet therapy who undergo surgery is uncertain (157,158). If P2Y12 inhibitor therapy needs to be held in patients being treated with DAPT after stent implantation, continuation of aspirin therapy if possible is recommended,\n|IIa|B-R|In patients with ACS treated with DAPT after coronary stent implantation, who are not at high risk for bleeding complications and who do not have a history of stroke or TIA, it is reasonable to choose prasugrel over clopidogrel for maintenance P2Y12 inhibitor therapy (54,55).|",
    "ground_truth_context": "For patients with SIHD who are undergoing elective noncardiac surgery, it is reasonable to continue aspirin and discontinue the P2Y12 inhibitor 5 days prior to surgery",
    "is_correct": true
  },
  {
    "question": "A 68-year-old female presents with a 3-day history of fever, cough, and purulent nasal discharge. She has a history of well-controlled asthma. She reports her symptoms began after a recent cold and is concerned about a sinus infection. What is the most appropriate next step in her management?",
    "options": [
      "Start empiric antibiotics immediately",
      "Obtain a sinus CT to determine extent of infection.",
      "Recommend symptomatic relief and observe her symptoms for 7 days.",
      "Prescribe oral corticosteroids to manage inflammation."
    ],
    "correct_answer_text": "Recommend symptomatic relief and observe her symptoms for 7 days.",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context indicates that for acute rhinosinusitis (ARS), clinicians should either offer watchful waiting (without antibiotics) or prescribe initial antibiotic therapy. Given that the patient has only a 3-day history of symptoms following a cold, it is appropriate to recommend symptomatic relief and observe her symptoms for 7 days before considering antibiotics, as immediate antibiotic treatment is not indicated at this stage.",
    "reasoning_ground_truth": "The patient has symptoms for 3 days, which is not long enough to diagnose ABRS. Given that her symptoms developed after a cold, it is likely a viral rhinosinusitis (VRS), symptomatic relief is the best option. Antibiotics are not indicated at this time, nor are CT scans or oral corticosteroids. It would be appropriate to reassess if symptoms worsen.",
    "context": "|Acute rhinosinusitis (ARS)|Up to 4 weeks of purulent nasal drainage (anterior, posterior, or both) accompanied by nasal obstruction, facial pain-pressure-fullness, or both: Purulent nasal discharge is cloudy or colored, in contrast to the clear secretions that typically accompany viral upper\n- Exceptions: Include but are not limited to severe illness, complicated sinusitis, immune deficiency, prior sinus surgery, or coexisting bacterial illness; the clinician should also consider the patient\u2019s age, general health, cardiopulmonary status, and comorbid conditions in determining an\ndocumentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. The update group made recommendations that clinicians (1) should either offer watchful waiting (without antibiotics) or prescribe initial antibiotic therapy for\nThe clinician should confirm a clinical diagnosis of CRS with objective documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. Strong recommendation based on cross-sectional studies with a preponderance of benefit over\nimprove diagnostic accuracy for adult rhinosinusitis, promote judicious use of systemic and topical therapy, and promote appropriate use of ancillary tests to confirm diagnosis and guide management, which include radiography, nasal endoscopy, computed tomography, and testing for allergy and immune",
    "ground_truth_context": "In contrast to the version of this statement in the original sinusitis guideline,1 we changed the diagnostic criteria to include not just the persistence of signs and symptoms beyond 10 days but failure to improve in 10 days, for greater specificity in distinguishing presumed bacterial infection for persistent, but resolving, viral illness. Clinicians may recommend analgesics, topical intranasal steroids, and/or nasal saline irrigation for symptomatic relief of VRS.",
    "is_correct": true
  },
  {
    "question": "A 55-year-old male with a history of a myocardial infarction (MI) one year ago, treated with a drug-eluting stent, is currently on aspirin and clopidogrel. He has been free of any cardiac events since the procedure. Based on current guidelines, what is the recommended duration of dual antiplatelet therapy (DAPT)?",
    "options": [
      "Continue DAPT indefinitely.",
      "Continue DAPT for an additional 6 months.",
      "Discontinue clopidogrel and continue aspirin.",
      "Discontinue both aspirin and clopidogrel."
    ],
    "correct_answer_text": "Discontinue clopidogrel and continue aspirin.",
    "correct_answer_idx": 2.0,
    "model_answer": "A",
    "model_answer_idx": 0,
    "model_reasoning": "The context indicates that available evidence supports a duration of at least 12 months of dual antiplatelet therapy (DAPT) for patients with a history of myocardial infarction (MI) and those treated with drug-eluting stents. Since the patient in the question is one year post-MI and currently on DAPT, the recommendation is to continue DAPT indefinitely, as there is no indication in the context for discontinuing it after the minimum duration.",
    "reasoning_ground_truth": "For patients with a history of MI treated with a drug-eluting stent who are beyond one year without any cardiac events, they are considered to have stable ischemic heart disease. They can discontinue the P2Y12 inhibitor, (clopidogrel) and continue with single antiplatelet therapy, usually aspirin.",
    "context": "of patients 1 to 3 years after myocardial infarction (MI) assessing the efficacy of DAPT compared with aspirin monotherapy (28). These studies were published after the formulation of recommendations for duration of DAPT in prior guidelines. The specific mandate of the present writing group is to\nAs discussed in Section 3, treatment with prolonged (extended) DAPT beyond a minimum recommended duration necessitates a fundamental tradeoff between decreasing ischemic risk (e.g., MI and stent thrombosis) and increasing bleeding risk (16,24,28,30,34,36,37,46). In post-MI patients, extended DAPT\nwith DAPT for 12 months, and were without ischemic or bleeding events during this period were randomized to an additional 18 months of DAPT or to aspirin monotherapy (16). Extended DAPT resulted in a 0.7% absolute reduction in very late stent thrombosis, a 2.0% absolute reduction in MI, a 1.6%\nboth in those treated with revascularization (PCI or CABG) and in those treated with medical therapy alone (51,52). Available evidence from this trial, as well as from PLATO (53,71,72) and TRITON-TIMI 38 (54,55), supports DAPT duration of at least 12 months for patients with NSTE-ACS.\nThe scope of this focused update is limited to addressing recommendations on duration of dual antiplatelet therapy (DAPT) (aspirin plus a P2Y12 inhibitor) in patients with coronary artery disease (CAD). Recommendations considered are those in 6 guidelines: \u201c2011 ACCF/AHA/SCAI Guideline for",
    "ground_truth_context": "For purposes of this focused update, patients with a history of acute coronary syndrome (ACS) >1 year prior who have since remained free of recurrent ACS are considered to have transitioned to stable ischemic heart disease (SIHD) and are addressed in the section on SIHD.",
    "is_correct": false
  },
  {
    "question": "A 28-year-old female presents with a 2-day history of nasal congestion, clear nasal discharge, and mild facial pressure. She denies fever or purulent discharge. What is the most appropriate initial management?",
    "options": [
      "Prescribe an antibiotic to prevent a bacterial infection.",
      "Recommend analgesics, decongestants and nasal saline irrigation for symptomatic relief.",
      "Order a sinus CT scan to assess the extent of the sinus congestion.",
      "Prescribe a short course of oral corticosteroids."
    ],
    "correct_answer_text": "Recommend analgesics, decongestants and nasal saline irrigation for symptomatic relief.",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context specifies that acute rhinosinusitis (ARS) is characterized by purulent nasal drainage and nasal obstruction, along with facial pain-pressure-fullness. The patient in the question presents with clear nasal discharge and mild facial pressure, which does not meet the criteria for ARS as there is no purulent discharge. Therefore, the most appropriate initial management for her symptoms, which align more with a viral upper respiratory infection, is to recommend symptomatic relief measures such as analgesics, decongestants, and nasal saline irrigation. Options A, C, and D are not appropriate given the absence of purulent discharge and the short duration of symptoms.",
    "reasoning_ground_truth": "The patient's symptoms are consistent with a viral rhinosinusitis (VRS). Antibiotics are not indicated for viral infections. A sinus CT scan is not necessary given the non-severe nature of her symptoms. Oral corticosteroids are not appropriate for the typical treatment of a viral rhinosinusitis. Symptomatic relief with analgesics, decongestants, and nasal saline irrigation is the most appropriate initial strategy.",
    "context": "Acute rhinosinusitis is diagnosed when a patient presents with up to 4 weeks of purulent (not clear) nasal drainage accompanied by nasal obstruction, facial pain-pressure-fullness, or both (Table 4). Nasal obstruction without purulent nasal drainage is not consistent with ARS and is beyond the scope\n|Acute rhinosinusitis (ARS)|Up to 4 weeks of purulent nasal drainage (anterior, posterior, or both) accompanied by nasal obstruction, facial pain-pressure-fullness, or both: Purulent nasal discharge is cloudy or colored, in contrast to the clear secretions that typically accompany viral upper\nnasal drainage accompanied by nasal obstruction, facial pain-pressure-fullness, or both) persist without\nto symptomatic therapy, especially when nasal discharge is colored or purulent. Existing educational material from the Centers for Disease Control and Prevention (CDC) Get Smart Campaign can be used by clinicians to help clarify misconceptions about viral illness and nasal discharge.\naccompany viral upper respiratory infection, and may be reported by the patient or observed on physical examination. Nasal obstruction may be reported by the patient as nasal obstruction, congestion, blockage, or stuffiness, or may be diagnosed by physical examination. Facial pain-pressure-fullness",
    "ground_truth_context": "Clinicians may recommend analgesics, topical intranasal steroids, and/or nasal saline irrigation for symptomatic relief of VRS.",
    "is_correct": true
  },
  {
    "question": "A 65-year-old male with chronic rhinosinusitis (CRS) and nasal polyps has been using nasal saline irrigation and topical corticosteroids with minimal improvement. What is the most appropriate next step in management?",
    "options": [
      "Prescribe a 10-day course of oral antibiotics",
      "Order an allergy skin test to evaluate for allergic rhinitis",
      "Confirm the presence of sinonasal inflammation and consider a referral to an otolaryngologist.",
      "Continue current therapy with close follow up."
    ],
    "correct_answer_text": "Confirm the presence of sinonasal inflammation and consider a referral to an otolaryngologist.",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context emphasizes the importance of confirming the presence of nasal polyps and managing chronic rhinosinusitis (CRS) effectively. Given that the patient has CRS with nasal polyps and has experienced minimal improvement with current therapies, the next appropriate step is to confirm sinonasal inflammation and consider a referral to an otolaryngologist for further evaluation and management. This aligns with the context's focus on managing CRS and the potential need for specialized care when initial treatments are insufficient.",
    "reasoning_ground_truth": "Given his persistent symptoms despite initial therapy, it is important to confirm the diagnosis of CRS, and referral may be beneficial to assess other management strategies such as surgery. Oral antibiotics are not effective for CRS. Allergy testing can be considered, but the next priority is to confirm the diagnosis and further evaluate other treatment strategies",
    "context": "dyskinesia; (6) confirm the presence or absence of nasal polyps in a patient with CRS; and (7) recommend saline nasal irrigation, topical intranasal corticosteroids, or both for symptom relief of CRS.\nA beneficial effect of nasal irrigation for symptomatic relief of CRS has been shown in a Cochrane review 264 and in other systematic reviews.258,265 Nasal saline irrigation is effective as sole treatment for CRS or as an adjunct to topical nasal steroids, but compared directly with topical nasal\n|11. Topical intranasal therapy for CRS|Clinicians should recommend saline nasal irrigation, topical intranasal corticosteroids, or both for symptom relief of CRS.|\n|12. Antifungal therapy for CRS|Clinicians should not prescribe topical or systemic antifungal therapy for patients with CRS.|\ndirectly with topical nasal steroids, the benefits of saline irrigation are less pronounced. 264 The safety and minimal side effects of saline irrigation, however, make it an attractive sole therapy for CRS. Common side effects of nasal irrigation include fluid dripping from the nose.\n- Three new key action statements on managing CRS that focus on polyps as a modifying factor, a recommendation in favor of topical intranasal therapy (saline irrigations, corticosteroids), and a recommendation against using topical or systemic antifungal agents",
    "ground_truth_context": "The clinician should confirm a clinical diagnosis of CRS with objective documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. Clinicians should confirm the presence or absence of nasal polyps in a patient with CRS.",
    "is_correct": true
  },
  {
    "question": "A 70-year-old male with stable ischemic heart disease (SIHD) underwent percutaneous coronary intervention (PCI) with a drug eluting stent (DES) 3 months ago. He is currently on dual antiplatelet therapy (DAPT) with aspirin and clopidogrel. He is now scheduled for a colonoscopy. What is the most appropriate perioperative management?",
    "options": [
      "Continue both aspirin and clopidogrel during the colonoscopy",
      "Stop both aspirin and clopidogrel 5 days prior to the colonoscopy",
      "Continue aspirin and stop clopidogrel 5 days before the colonoscopy.",
      "Stop aspirin and continue clopidogrel during the colonoscopy"
    ],
    "correct_answer_text": "Continue aspirin and stop clopidogrel 5 days before the colonoscopy.",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context indicates that in patients with stable ischemic heart disease (SIHD) treated with dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) implantation, clopidogrel should be continued for at least 6 months. However, it is common practice to stop clopidogrel prior to procedures with a high bleeding risk, such as a colonoscopy, while continuing aspirin, which is recommended to be taken indefinitely in patients with coronary artery disease. Therefore, the most appropriate perioperative management for the patient is to continue aspirin and stop clopidogrel 5 days before the colonoscopy.",
    "reasoning_ground_truth": "For patients with SIHD undergoing elective procedures, guidelines recommend continuing aspirin and discontinuing the P2Y12 inhibitor, (clopidogrel) 5 days before the procedure to reduce bleeding risk while maintaining some protection against thrombotic events. Stopping both medications can increase risk of thrombotic events. Continuing both medications increases bleeding risk during the procedure",
    "context": "DAPT is not established. Clopidogrel is the only currently used P2Y12 inhibitor studied in patients with SIHD undergoing PCI. Aspirin therapy is almost always continued indefinitely in patients with coronary artery disease. 5 High bleeding risk denotes those who have or develop a high risk of\nThe benefit/risk ratio of prolonged DAPT in patients treated with PCI may be more favorable for those with prior MI (or ACS) than for those with SIHD (28,41,43). Preliminary data suggest that in patients with a high DAPT score the benefit/risk ratio with prolonged DAPT may be favorable and that in\n|IIb|A SR|In patients with SIHD treated with BMS or DES implantation who have tolerated DAPT without a bleeding complication and who are not at high bleeding risk (e.g., prior bleeding on DAPT, coagulopathy, oral anticoagulant use), continuation of DAPT with clopidogrel for longer than 1 month in\n|IIb|ASR|In patients with SIHD treated with DAPT after BMS or DES implantation who have tolerated DAPT without a bleeding complication and who are not at high bleeding risk (e.g., prior bleeding on DAPT, coagulopathy, oral anticoagulant use), continuation of DAPT with clopidogrel for longer than 1\n|I|B-RSR|In patients with SIHD treated with DAPT after DES implantation, P2Y12 inhibitor therapy (clopidogrel) should be given for at least 6 months (17,18,21,30,96,97).|\n|I|B-NR|In patients treated with DAPT, a daily aspirin dose of 81 mg (range, 75 mg to 100 mg) is recommended (56\u201360,75\u201378).|",
    "ground_truth_context": "For patients with SIHD who are undergoing elective noncardiac surgery, it is reasonable to continue aspirin and discontinue the P2Y12 inhibitor 5 days prior to surgery",
    "is_correct": true
  },
  {
    "question": "A 30-year-old patient presents with a 14-day history of persistent nasal congestion, facial pressure, and purulent nasal discharge. The patient has no fever, and their symptoms started after a cold. Based on these symptoms, what is the appropriate diagnosis?",
    "options": [
      "Viral rhinosinusitis (VRS).",
      "Acute bacterial rhinosinusitis (ABRS).",
      "Allergic rhinitis.",
      "Migraine headache."
    ],
    "correct_answer_text": "Acute bacterial rhinosinusitis (ABRS).",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The patient presents with a 14-day history of purulent nasal discharge, nasal congestion, and facial pressure, which aligns with the criteria for acute rhinosinusitis (ARS) as defined in the context. ARS is characterized by up to 4 weeks of purulent nasal drainage accompanied by nasal obstruction and facial pain-pressure-fullness. The absence of fever does not exclude the diagnosis, and the symptoms following a cold further support the diagnosis of acute bacterial rhinosinusitis (ABRS) rather than viral rhinosinusitis (VRS), allergic rhinitis, or migraine headache.",
    "reasoning_ground_truth": "The patient's symptoms of persistent nasal congestion, facial pressure, and purulent nasal discharge lasting over 10 days after a cold are highly suggestive of acute bacterial rhinosinusitis (ABRS). While VRS may present with similar symptoms, they typically resolve within 10 days. Allergic rhinitis and migraines do not typically present with purulent nasal discharge.",
    "context": "Acute rhinosinusitis is diagnosed when a patient presents with up to 4 weeks of purulent (not clear) nasal drainage accompanied by nasal obstruction, facial pain-pressure-fullness, or both (Table 4). Nasal obstruction without purulent nasal drainage is not consistent with ARS and is beyond the scope\n|Acute rhinosinusitis (ARS)|Up to 4 weeks of purulent nasal drainage (anterior, posterior, or both) accompanied by nasal obstruction, facial pain-pressure-fullness, or both: Purulent nasal discharge is cloudy or colored, in contrast to the clear secretions that typically accompany viral upper\nSymptoms of CRS vary in severity and prevalence. Nasal obstruction is most common (81%-95%) followed by facial congestion-pressure-fullness (70%-85%), discolored nasal discharge (51%-83%) and hyposmia (61%-69%). The presence of 2 or more signs or symptoms persisting beyond 12 weeks is highly\nsuch as nasal polyps, purulent nasal discharge, and septal deviation. Alternative findings that may suggest a more complicated or different disease process include neoplasms, soft tissue masses, foreign objects, tissue necrosis, and findings consistent with autoimmune or granulomatous disease.\nnasal drainage accompanied by nasal obstruction, facial pain-pressure-fullness, or both) persist without",
    "ground_truth_context": "A clinician should diagnose ABRS when (a) symptoms or signs of acute rhinosinusitis (purulent nasal drainage accompanied by nasal obstruction, facial pain-pressure-fullness, or both) persist without evidence of improvement for at least 10 days beyond the onset of upper respiratory symptoms, or (b) symptoms or signs of ARS worsen within 10 days after an initial improvement (double worsening).",
    "is_correct": true
  },
  {
    "question": "A 48-year-old male is diagnosed with chronic rhinosinusitis (CRS) based on his symptoms. To confirm the diagnosis, the clinician should obtain objective documentation of sinonasal inflammation. Which of the following is most appropriate to perform to confirm sinonasal inflammation?",
    "options": [
      "Allergy skin test.",
      "Sinus radiography.",
      "Anterior rhinoscopy or nasal endoscopy.",
      "Blood test for infection."
    ],
    "correct_answer_text": "Anterior rhinoscopy or nasal endoscopy.",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context explicitly states that to confirm a clinical diagnosis of chronic rhinosinusitis (CRS), the clinician should obtain objective documentation of sinonasal inflammation, which can be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. Among the options provided, C (anterior rhinoscopy or nasal endoscopy) directly aligns with the methods mentioned in the context for confirming sinonasal inflammation. Options A, B, and D do not provide the required objective documentation of sinonasal inflammation as specified.",
    "reasoning_ground_truth": "To confirm a diagnosis of CRS, objective documentation of sinonasal inflammation is required. This can be achieved through direct visualization using anterior rhinoscopy or nasal endoscopy. While a CT scan is an option, it is usually not the first step. Allergy testing and blood tests for infection are not appropriate methods for confirming sinonasal inflammation.",
    "context": "The clinician should confirm a clinical diagnosis of CRS with objective documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. Strong recommendation based on cross-sectional studies with a preponderance of benefit over\n|7B. Objective confirmation of a diagnosis of CRS|The clinician should confirm a clinical diagnosis of CRS with objective documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography.|\nThe purpose of this statement is to strongly emphasize that a diagnosis of CRS cannot be based on signs and symptoms alone but also requires objective evidence of sinonasal inflammation (Table 8). Requiring objective signs of inflammation increases diagnostic accuracy for CRS and serves to limit\nfor CRS and serves to limit overdiagnosis. Moreover, objective confirmation of inflammation will prevent unnecessary tests and interventions for individuals with self-reported sinonasal symptoms that can be readily mistaken for CRS, such as those caused by perennial allergic rhinitis.\n|Chronic rhinosinusitis|Twelve weeks or longer of two or more of the following signs and symptoms: \u2022 mucopurulent drainage (anterior, posterior, or both), \u2022 nasal obstruction (congestion), \u2022 facial pain-pressure-fullness, or \u2022 decreased sense of smell. AND inflammation is documented by one or more",
    "ground_truth_context": "The clinician should confirm a clinical diagnosis of CRS with objective documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography.",
    "is_correct": true
  },
  {
    "question": "A 32-year-old male presents with a 5-day history of nasal congestion, facial pain, and clear nasal discharge following a cold. He denies fever or purulent discharge. What is the most appropriate initial treatment approach?",
    "options": [
      "Start empiric antibiotics for bacterial sinusitis.",
      "Prescribe oral corticosteroids to reduce inflammation.",
      "Recommend analgesics, decongestants, and nasal saline irrigation.",
      "Order a sinus CT scan to determine the severity of the infection."
    ],
    "correct_answer_text": "Recommend analgesics, decongestants, and nasal saline irrigation.",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context specifies that acute rhinosinusitis (ARS) is characterized by purulent nasal drainage and nasal obstruction, along with facial pain-pressure-fullness. The patient in the question has clear nasal discharge and does not present with purulent discharge, which is not consistent with ARS. Therefore, the most appropriate initial treatment approach for his symptoms, which include nasal congestion and facial pain without purulent discharge, would be to recommend analgesics, decongestants, and nasal saline irrigation for symptom relief, as indicated in the context. Options A, B, and D are not supported by the context given the absence of purulent discharge and the nature of the symptoms.",
    "reasoning_ground_truth": "The patient's symptoms are indicative of a viral rhinosinusitis (VRS). Antibiotics are not indicated for a viral cause. Oral corticosteroids are not an initial therapy. A CT scan is not indicated. Symptomatic relief is the most appropriate first step",
    "context": "Acute rhinosinusitis is diagnosed when a patient presents with up to 4 weeks of purulent (not clear) nasal drainage accompanied by nasal obstruction, facial pain-pressure-fullness, or both (Table 4). Nasal obstruction without purulent nasal drainage is not consistent with ARS and is beyond the scope\n|Acute rhinosinusitis (ARS)|Up to 4 weeks of purulent nasal drainage (anterior, posterior, or both) accompanied by nasal obstruction, facial pain-pressure-fullness, or both: Purulent nasal discharge is cloudy or colored, in contrast to the clear secretions that typically accompany viral upper\nnasal drainage accompanied by nasal obstruction, facial pain-pressure-fullness, or both) persist without\nAnalgesics or antipyretic drugs (acetaminophen, ibuprofen, or other nonsteroidal anti-inflammatory agents) may be given for pain or fever. Nasal saline may be palliative and cleansing with low risk of adverse reactions. A Cochrane review reported minor improvements in nasal symptom scores with the\nagents, nasal saline, decongestants, antihistamines, mucolytics, cough suppressants, and topical or oral corticosteroids\u2014may be used alone or in varying combinations for symptom relief.",
    "ground_truth_context": "Clinicians may recommend analgesics, topical intranasal steroids, and/or nasal saline irrigation for symptomatic relief of VRS.",
    "is_correct": true
  },
  {
    "question": "A 55-year-old female with chronic rhinosinusitis (CRS) and nasal polyps has had minimal improvement with topical corticosteroids and saline irrigations. She has a history of mild asthma. What is the most appropriate next step in management?",
    "options": [
      "Prescribe a 10 day course of oral antibiotics.",
      "Recommend allergy testing.",
      "Evaluate for other conditions such as asthma that might modify management and consider otolaryngology referral.",
      "Obtain a sinus CT scan"
    ],
    "correct_answer_text": "Evaluate for other conditions such as asthma that might modify management and consider otolaryngology referral.",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context emphasizes the importance of assessing asthmatics for rhinosinusitis, particularly when asthma control is poor. It suggests evaluating for other conditions that might modify management, which aligns with the patient's history of mild asthma and minimal improvement with current treatments. Therefore, considering an otolaryngology referral is the most appropriate next step in her management.",
    "reasoning_ground_truth": "Given her persistent symptoms and history of asthma, it is important to consider other comorbid conditions that can modify the management of her CRS. Allergy testing and a CT can be considered, but the primary step is to evaluate for other conditions, such as asthma. Antibiotics are not a standard treatment for CRS.",
    "context": "dyskinesia; (6) confirm the presence or absence of nasal polyps in a patient with CRS; and (7) recommend saline nasal irrigation, topical intranasal corticosteroids, or both for symptom relief of CRS.\n- Three new key action statements on managing CRS that focus on polyps as a modifying factor, a recommendation in favor of topical intranasal therapy (saline irrigations, corticosteroids), and a recommendation against using topical or systemic antifungal agents\nA beneficial effect of nasal irrigation for symptomatic relief of CRS has been shown in a Cochrane review 264 and in other systematic reviews.258,265 Nasal saline irrigation is effective as sole treatment for CRS or as an adjunct to topical nasal steroids, but compared directly with topical nasal\n|11. Topical intranasal therapy for CRS|Clinicians should recommend saline nasal irrigation, topical intranasal corticosteroids, or both for symptom relief of CRS.|\n|12. Antifungal therapy for CRS|Clinicians should not prescribe topical or systemic antifungal therapy for patients with CRS.|\nof prompt therapy for CRS in asthmatics if rhinosinusitis is considered a reason for poor asthma control. Similarly, asthmatics with difficult to control illness should be assessed for unsuspected rhinosinusitis, with CT scanning or nasal endoscopy, since the signs and symptoms of CRS may be subtle",
    "ground_truth_context": "Clinicians should assess the patient with CRS or recurrent ARS for multiple chronic conditions that would modify management, such as asthma, cystic fibrosis, immunocompromised state, and ciliary dyskinesia.",
    "is_correct": true
  },
  {
    "question": "A 70-year-old patient who underwent percutaneous coronary intervention (PCI) with a drug eluting stent (DES) 5 months ago for stable ischemic heart disease is currently on dual antiplatelet therapy (DAPT). He is scheduled for cataract surgery. What is the best way to manage his antiplatelet therapy?",
    "options": [
      "Continue both aspirin and clopidogrel for the surgery",
      "Stop both aspirin and clopidogrel 5 days before surgery",
      "Continue aspirin and stop clopidogrel 5 days prior to surgery.",
      "Stop aspirin and continue clopidogrel during the surgery"
    ],
    "correct_answer_text": "Continue aspirin and stop clopidogrel 5 days prior to surgery.",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context indicates that patients treated with dual antiplatelet therapy (DAPT) after coronary stent implantation should continue their therapy, but it is common practice to stop one of the antiplatelet agents, typically clopidogrel, before surgery to reduce bleeding risk. The recommendation aligns with the management of antiplatelet therapy in patients undergoing non-cardiac surgery, where continuing aspirin is often advised due to its protective cardiovascular benefits. Therefore, the best approach for the patient scheduled for cataract surgery is to continue aspirin and stop clopidogrel 5 days prior to the surgery.",
    "reasoning_ground_truth": "For patients with stable ischemic heart disease who are undergoing elective noncardiac surgery, guidelines recommend to continue aspirin and to stop the P2Y12 inhibitor, (clopidogrel) 5 days before surgery to balance the risks of bleeding and thrombotic events. Stopping both medications could lead to thrombotic events. Continuing both medications increases the bleeding risk.",
    "context": "monotherapy (Data Supplement 4). Based primarily on the CURE trial and PCI-CURE analyses, the prior recommendation that patients with NSTE-ACS treated with coronary stent implantation be treated with DAPT for at least 12 months is continued in this update and has been extrapolated to patients with\nA new risk score (the \u201cDAPT score\u201d), derived from the Dual Antiplatelet Therapy study, may be useful for decisions about whether to continue (prolong or extend) DAPT in patients treated with coronary stent implantation. Analysis of study data suggests that in patients treated for 1 year with DAPT\nThe PCI-CURE analysis (51) of patients in the CURE (Clopidogrel in Unstable Angina to Prevent Recurrent Events) trial (52) demonstrated that treatment with DAPT for up to 12 months in patients with NSTE-ACS treated with BMS reduced ischemic events compared with aspirin monotherapy (Data Supplement\nThe scope of this focused update is limited to addressing recommendations on duration of dual antiplatelet therapy (DAPT) (aspirin plus a P2Y12 inhibitor) in patients with coronary artery disease (CAD). Recommendations considered are those in 6 guidelines: \u201c2011 ACCF/AHA/SCAI Guideline for\n|---|---|---|---|\n|In patients treated with DAPT after coronary stent implantation who subsequently undergo CABG, P2Y12 inhibitor therapy should be resumed postoperatively so that DAPT continues until the recommended duration of therapy is completed.|I|C-EO| |",
    "ground_truth_context": "For patients with SIHD who are undergoing elective noncardiac surgery, it is reasonable to continue aspirin and discontinue the P2Y12 inhibitor 5 days prior to surgery",
    "is_correct": true
  },
  {
    "evaluation_metrics": {
      "accuracy": 0.8641975308641975,
      "total": 81,
      "correct": 70,
      "confusion_matrix": {
        "Pred A": {
          "True A": 12,
          "True B": 2,
          "True C": 2,
          "True D": 1
        },
        "Pred B": {
          "True A": 1,
          "True B": 21,
          "True C": 0,
          "True D": 0
        },
        "Pred C": {
          "True A": 0,
          "True B": 2,
          "True C": 36,
          "True D": 2
        },
        "Pred D": {
          "True A": 0,
          "True B": 0,
          "True C": 1,
          "True D": 1
        }
      }
    }
  }
]